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ABSTRACT 
The sex-dependent pituitary growth hormone (GH) secretory profiles, pulsatile in males 
and persistent in females, regulate sex-biased expression of hundreds of genes in 
mammalian liver, contributing to sex differences in hepatic metabolism and disease. The 
sex-biased GH actions in the liver are mediated by STAT5b and enhanced by a network of 
transcription factors including the male-biased BCL6 and the female-specific CUX2, 
acting in the context of sex-biased chromatin states. First, the transcriptional and 
epigenomic changes induced by continuous-GH infusion (cGH) in male mice, which 
rapidly feminizes the temporal profile of liver STAT5 activity, were examined. RNA-seq 
analysis determined that cGH repressed the majority of male-biased genes and induced 
most female-biased genes within 4-days; however, several highly female-specific genes 
showed partial feminization. Female-biased genes already in an active chromatin state in 
male liver were induced early; genes in an inactive chromatin state often responded late. 
Early cGH-responsive genes included Cux2 and Bcl6 and their targets.  DNase-seq and 
ChIP-seq were used to identify changes in sex-specific chromatin accessibility and histone 
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modifications accompanying these cGH-induced gene expression changes. H3-K27me3 is 
a key sex-biased repressive mark found preferentially at highly female-biased genes in 
male mouse liver. Consistently, induction of female-biased genes by cGH was associated 
with loss of H3-K27me3 at their gene bodies. H3K27 methylation is catalyzed by 
Polycomb Repressive Complex-2 (PRC2) through its homologous catalytic subunits EZH1 
and EZH2. An Ezh1-knockout mouse model with a hepatocyte-specific knockout of Ezh2 
(DKO) was used to further investigate the role of H3-K27me3 in repressing sex-biased 
genes in mouse liver. Loss of Ezh1/Ezh2 led to a significant decrease in sex-specific gene 
expression, with many female-biased genes induced and male-biased genes repressed. 
These gene responses were more extensive in male than female liver, as was the loss of 
H3K27me3 sites and the reciprocal increases in active histone marks.  There was 
substantial up-regulation of liver cancer and liver fibrosis-related genes in male and female 
DKO-mouse liver, with a subset of genes preferentially up-regulated in females. Thus, GH 
regulated sex-biased liver physiology is dictated by transcription factors arranged in a 
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CHAPTER 1. Introduction 
1.1 Summary 
Growth hormone regulates a broad range of physiological processes including cell growth, 
differentiation, and metabolism. GH secretion by the anterior pituitary gland is controlled by 
the hypothalamus and regulated by metabolic cues. The sexually dimorphic GH secretion 
patterns are the primary hormonal regulator of the sex-biased gene expression of hundreds of 
genes in the mammalian liver imparting sex-differences in metabolism and liver disease. The 
sex-biased actions of GH in the liver are mediated by a transcription factor network centered 
around STAT5b, and enhanced by the sex-biased transcriptional repressors CUX2 and BCL6. 
Integration of genome-wide chromatin accessibility and histone modification data from male 
and female liver has allowed for the identification of sex-biased chromatin states defining the 
context in which transcription factors bind to regulate gene expression. Tri-methylation of 
lysine 27 on histone H3 (H3K27me3), a hallmark of gene repression, is exclusively enriched 
at female-biased genes in male liver. Animal models that abolish GH secretion or perturb its 
secretion patterns, have been used to elucidate the mechanisms of GH mediated gene 
regulation.  
This introduction provides a literature review on the physiological actions of GH and the 
effects of its sex-specific secretory patterns on liver gene expression. This review will focus 
on the current knowledge on the GH-dependent transcriptional and epigenetic regulatory 
mechanisms that shape sex-differential liver gene expression. Additionally, I will present and 
review some of the concepts that are discussed in subsequent chapters.  Finally, the hypotheses 




1.2. Growth hormone  
1.2.1 Physiological actions of growth hormone 
Growth hormone (GH) is an anabolic hormone acting in various tissues, with many of its 
actions being mediated by insulin-like growth factors IGF-1 and 2 that are synthesized mainly 
in the liver (Davey et al., 2001). As implied by its name, GH is primarily involved in body 
growth and body composition; GH and IGF-1 promote longitudinal growth by acting at the 
bone growth plate and by regulating mineral acquisition (Yakar et al., 2010).  Aside from its 
growth-promoting actions, GH has an essential role in regulating metabolism. In adipose 
tissue, GH stimulates lipolysis, and it is involved in adipocyte differentiation and proliferation, 
and in skeletal muscle, GH and IGF-1 increase protein synthesis, decrease protein breakdown 
and induce free fatty acid uptake (Chia, 2014; Vijayakumar et al., 2011). GH increases liver 
and kidney glucose production via glycogenolysis and gluconeogenesis and antagonizes 
insulin action in peripheral tissues; thus, it is considered a diabetogenic hormone (Kim and 
Park, 2017). GH also regulates the synthesis and secretion of insulin in the pancreas 
(Vijayakumar et al., 2011). Thus, it plays a significant role in energy homeostasis.  
1.2.2 Growth hormone synthesis and secretion  
Growth hormone (GH) also known as somatotropin, is a 191-amino acid protein hormone. 
The human GH gene cluster includes five variants, and it is located on chromosome 17. 
Transcription of the GH gene is regulated by several transcription factors including Pit-1 and 
Sp1. (Vijayakumar et al., 2011). GH is expressed, synthesized, and stored within secretory 




secretion is under the control of two hypothalamic hormones; it is stimulated by Growth 
hormone-releasing hormone (GHRH) and inhibited by Somatostatin (Meinhardt and Ho, 
2007). Ghrelin, another hormone secreted in the gastrointestinal tract, stimulates the secretion 
of GH to increase glucose levels (Kojima et al., 1999). GH is regulated by a short feedback 
loop, and the GH-stimulated release of IGF-1 also controls the release of GH (Jaffe et al., 
1998). The secretion of GH is a dynamic process. The amplitude, frequency, regularity and 
basal levels of GH vary between individuals, sexes and physiological states (Steyn and Ngo, 
2017). Mean GH- concentrations decline with age and with increased body weight (Basu et 
al., 2018). In humans, GH release changes with the sleep-wake cycle, with maximal GH 
release occurring after the onset of slow-wave sleep (Steyn et al., 2016). In rodents, 
associations between sleep and GH secretion are not well established due to more complex 
sleep-wake patterns. However, ultradian patterns of GH release are conserved between the 
species (Steyn and Ngo, 2017). 
 
1.2.3 Sex-specific GH secretory profiles  
GH is secreted in a sexually dimorphic manner in many species, including rats, mice, and 
humans. These differences are more pronounced in the rat; in males, GH is secreted in a highly 
regular pulsatile manner with peak plasma levels of 200 ng/ml followed by periods where 
plasma GH is not detectable between pulses (Figure 1.1). In female rats, GH pulses are more 
frequent, resulting in the continuous presence of GH in circulation at an average level of 30-
60 ng/ml(Waxman and O'Connor, 2006). Early studies also found lower nadir levels in male 




sampling and deconvolution analysis in mice confirmed that females were more likely to have 
a physiologically relevant level of plasma GH than males at any given time-point, and that 
males had more prolonged trough periods (Adams et al., 2015). The mechanism responsible 
for GH pulsing in male vs. females is the interaction between GHRH and Somatostatin 
(Adams et al., 2015; Steyn and Ngo, 2017). Inhibition of GHRH ablates GH pulses in rats and 
loss of Somatostatin in male mice result in feminized GH secretory patterns (Adams et al., 
2015). These patterns of pituitary GH secretion are set during the neonatal period by exposure 
of GHRH neurons to gonadal steroids (Waxman et al., 1985).  At puberty, structural changes 
within the pituitary gland and the hypothalamus result in the onset of sex-biased GH secretion 
which persists through adulthood (Chowen et al., 2004; Jansson et al., 1985; Meinhardt and 
Ho, 2007). 
 
1.3 The sex-biased actions of GH in the liver   
1.3.1 Sex-differences in the expression of hepatic genes 
The liver is a major target of GH action, in part because it is the primary source of IGF-1, 
the main effector of GH in peripheral tissues (Davey et al., 2001). Interestingly, the sex-
specific temporal patterns of GH secretion, impart sex-differences in hepatic physiology 
and pathology with ~ 1000 genes showing significant sex differences in expression 
(Waxman and Holloway, 2009b).  Genes that are sexually dimorphic include many of the 
gene families encoding for drug, steroid, and cholesterol metabolizing enzymes. The 
Cytochrome P450 (Cyp) (Shapiro et al., 1995; Waxman and Holloway, 2009a), 




et al., 2006a) and UDP-glucuronosyltransferases (Ugt) (Albiston et al., 1995; Buckley and 
Klaassen, 2009; Klaassen et al., 1998) are differentially expressed in mouse and rat liver. 
For endogenous chemicals, these differences enable each sex to meet its particular 
metabolic requirements. However, they also impart sexual dimorphism in 
pharmacokinetics and pharmacodynamics that characterize many drugs, and contribute to 
individual differences in drug efficacy and toxicity (Waxman and Holloway, 2009b). 
For example, CYP3A4, the principal cytochrome P450 in human liver, shows higher mRNA 
levels and higher protein amounts in females, resulting in the higher clearance rates of its drug 
substrates observed in women. In contrast, the higher levels of CYP1A2 in males, results in 
higher clearance rates in men and more side effects in women for many antipsychotic drugs 
(Waxman and Holloway, 2009; Zhang et al., 2011). Specific examples of Cytochrome P450 
enzymes that are sexually dimorphic in humans and their substrates, are shown in Table 1.1.  
 
Extensive studies of individual Cyp  genes in rodents, have established that GH, activates 
two mutually exclusive patterns of liver gene expression, depending on whether it 
stimulates the target hepatocyte in a persistent manner (female liver) or intermittently (male 
liver),(Waxman and O'Connor, 2006). Furthermore, it was recently discovered that 
pulsatile GH exposure of male liver during the early postnatal period programs the male 
liver for GH pulse responsiveness later in life, and this is required for full adult expression 




1.3.2 GH regulated transcriptional networks  
GH binds with high affinity to the extracellular domain of the GH receptor (GHR) inducing a 
conformational change that leads to the activation of Janus kinase 2 (JAK2), a receptor-linked 
intracellular tyrosine kinase which phosphorylates tyrosine residues in the intracellular part of 
the GHR, promoting the activation of several signaling pathways that regulate cellular 
responses to GH (Chia and Rotwein, 2010). The central mediator of the transcriptional 
responses to GH is the transcription factor signal transducer and activator of transcription 5 
(STAT5). After being phosphorylated by JAK2, STAT5 dimerizes and translocates to the 
nucleus to bind DNA response elements and activate gene transcription (Herrington and 
Carter-Su, 2001) (Figure 1.2).  In Male liver, STAT5 is activated in direct response to each 
plasma GH pulse, in female liver STAT5 activity remains constant due to the continuous 
presence of GH in the circulation (Connerney et al., 2017). 
 
Sex-biased gene regulation by transcription factors has been elucidated by gene knockout 
studies (Clodfelter et al., 2006; Clodfelter et al., 2007; Holloway et al., 2008) and more 
recently by global mapping of transcription factor binding sites by chromatin 
immunoprecipitation paired with sequencing (ChIP-seq). (Conforto et al., 2015; Conforto et 
al., 2012; Zhang et al., 2012a). In male mouse liver, knockout of STAT5b repressed the 
expression of 90% of all male-biased genes and induced the expression of 61% of female-
biased genes. In contrast, the vast majority of the sex-biased genes were unaffected by the 
STAT5b knockout in female liver (Clodfelter et al., 2006). STAT5a was not able to 




small subset of female-biased genes in female liver (Clodfelter et al., 2007).  STAT5 (a and 
b) binds in a Sex-biased manner at > 3,000 sites in mouse liver (Zhang et al., 2012a). Further, 
Male-biased STAT5 binding is enriched at male-specific genes, and female-biased STAT5 
binding is enriched at female-specific genes (Zhang et al., 2012b). 
 
Other transcription factors (TF) that act in concert with STAT5 to enforce liver sex-
differences have been identified. BCL6 a male-biased transcriptional repressor preferentially 
binds and represses female-biased STAT5 target genes in male liver (Zhang et al., 2012b). 
CUX2, a female-specific repressor, down regulates a subset of male-biased genes and 
activates a subset of female-biased genes in female liver (Conforto et al., 2012).  The 
hepatocyte-enriched nuclear factors HNF4a and HNF6 are also GH regulated TFs that 
contribute to maintaining liver sex-differences (Conforto et al., 2015; Holloway et al., 2006b; 
Holloway et al., 2008). Liver-specific deletion of HNF4a also leads to significant loss of sex-
biased gene expression with more substantial impact in male compared to female liver 
(Holloway et al., 2008).  HNF6 shows sex-biased binding at thousands of sites in mouse liver 
and the vast majority of CUX2 binding sites are also bound by HNF6 (Conforto et al., 2015).   
The studies presented above confirm that sex-differences in liver gene expression are achieved 
by complex interactions between GH regulated TFs. However, these TFs act within or modify 
the existing chromatin landscape. Next, I will review the current knowledge on the epigenetic 






1.4 Epigenomic mechanisms of sex-biased gene regulation    
1.4.1 Chromatin accessibility  
DNase hypersensitive sites (DHS) were first discovered more than 30 years ago as 
nucleosome depleted areas that are subject to cleavage by the endonuclease DNase I. 
(Gross and Garrard, 1988).  Lately, genome-wide mapping of DNase Hypersensitive sites 
by massive parallel sequencing of the digested fragments (DNase-seq) has been widely 
used to assay chromatin accessibility (Boyle et al., 2008). DHS encompass the majority of 
the genomic regulatory elements including enhancers, promoters and insulators that are 
required for cell-type specific gene regulation (Thurman et al., 2012). 
Sex differences in gene expression have been linked to sex differences in GH-regulated 
chromatin accessibility.  In mouse liver, > 70, 000 DHS have been identified of which > 
1000 show robust sex-differences, and continuous GH infusion suppressed a subset of the 
male-biased sites and induced a subset of female-biased sites (Ling et al., 2010). Further, 
Sex-biased DHS are strongly enriched for sex-biased binding of STAT5 and other GH 
regulated transcription factors (Conforto et al., 2015; Conforto et al., 2012; Zhang et al., 
2012) Sex differences in chromatin accessibility are thus a fundamental feature of sex-
differential liver gene expression, in fact, recently we showed that chromatin opening and 
target gene transcription of male-biased genes are dynamically responsive to the 
endogenous pulses of GH in male liver (Connerney et al., 2017).  
 
 The majority of sex-biased DHS are >100 kb away from sex-biased genes (Ling et al., 




organized into self-interacting regions known as topologically associating domains (TADs) 
(Dixon et al., 2012). Current projects in our lab focus on refining the regulatory-gene 
associations by taking advantage of liver TAD and sub-TAD definitions. Further, 
chromosome conformation capture (3C) based methods (Dekker et al., 2013; Dekker et al., 
2002)  could be used to confirm looping interactions between predicted regulatory elements 
and the promoters of sex-biased genes. 
 
1.4.2 Histone modifications and chromatin states 
DHS are flanked by nucleosome that have characteristic histone tail modifications that are 
associated with different regulatory elements and orchestrate the opening or compaction of 
the chromatin. Tri-methylation of lysine 4 of histone H3 (H3K4me3) marks promoters. 
Enhancers are marked by H3K4me1 and have been classified as poised or active enhancers 
based on the absence or presence of H3K27ac respectively (Creyghton et al., 2010; Rada-
Iglesias et al., 2011).  In contrast to promoters, enhancers have a variable chromatin 
landscape that correlates with changes in gene expression. Enhancers are cell specific, they 
provide the cis-regulatory context in which transcription factors activated by 
environmental stimuli operate to modify gene expression (Heintzman et al., 2009). 
Similarly, gene repression is associated with the deposition of H3K27me3 or HK9me3 
(Ernst et al., 2011; Sugathan and Waxman, 2013). 
  
The combination of histone modifications and chromatin accessibility define distinct 




characterized chromatin environments on a global scale in both male and female mouse 
liver based on chromatin immunoprecipitation followed by high-throughput sequencing 
(ChIP-seq)(Sugathan and Waxman, 2013). Data for four activating chromatin marks, two 
repressive chromatin marks and global DHS maps were integrated. Sex differences in 
chromatin environment were seen at male-biased and female-biased DHS. For a subset of 
highly sex-biased genes, sex differences in proximal chromatin marks were identified. 
(Sugathan and Waxman, 2013).  
 
Interestingly, the study described above (Sugathan and Waxman, 2013) found  that males 
and females show different sets of regulatory mechanisms. Tri-methylation of histone H3 
at lysine 27 (H3K27me3) was identified as a sex-biased chromatin mark in mouse liver, 
where a remarkable male bias in the density of H3K27me3 marks is seen at many of the 
most highly female-biased genes in male liver, but not at male-biased genes in female liver. 
The mechanisms by which this histone modifications are deposited and maintained by GH 
to enforce liver sex-bias are still not fully understood.  
 
H3K27, is methylated by the polycomb repressive complex-2 (PRC2), a protein group 
involved in several biological processes including differentiation, cell identity and 
proliferation. PRC2 has three core components, SUZ12 (suppressor of zeste homolog), 
EED (embryonic ectoderm development) and the homologous catalytic subunits Ezh1 and 
Ezh2 (enhancer of zeste homolog 1 or 2). Ezh1 and Ezh2 both contain a SET domain, 




PRC2 is recruited to its target genes generally, and in this case, how sex-dependent plasma 
GH patterns regulates interacts with the PRC2 is poorly understood. Many long non-coding 
RNAs (lncRNAs) are physically associated with PRC2 (Aranda et al., 2015) and may 
impact the site-specificity of PRC’s actions. Several hundred liver-expressed lncRNAs 
show sex-biased expression in mouse liver, many of which are nuclear enriched and 
regulated by growth hormone (Melia et al., 2016). Further studies are required to determine 
what roles male-biased lncRNAs that interact with PRC2 may play in the recruitment of 
PRC2 to repress female-biased genes in male liver. 
 
1.5 Models for the study of liver sex-biased gene expression  
Early studies in this field focused on the involvement of gonadal steroids on the sex-biased 
expression of liver genes (Kramer et al., 1978) However, it was later found that the regulation 
by testosterone and estrogen only occurred through an intact pituitary gland (Gustafsson and 
Stenberg, 1974). Later studies implicated GH and its sex-biased secretion pattern as the main 
hormonal regulator of sex-biased genes in the liver (Wilson and Bass, 1973). Ablation of 
circulating GH by surgical removal of the pituitary gland (hypophysectomy) abolishes 
~90% of liver sexual dimorphism, and exogenous GH given in pulses or continuously, 
restores the sex-biased gene expression (Connerney et al., 2017; Wauthier et al., 2010; 
Wauthier and Waxman, 2008). Two distinct classes of sex-biased genes can be identified 
based on their response to hypophysectomy.  Class I male-biased genes require the male 
plasma GH pattern for full expression and thus, show decreased expression in male liver 




profile and, consequently, they are strongly de-repressed in female liver following 
hypophysectomy. The corresponding classes are identified for female-biased genes; that 
is, genes that require the continuous GH female pattern and whose expression in female 
liver decreases after hypophysectomy (class I), and genes whose expression is repressed 
by the male pituitary profile and consequently show strong de- repression in 
hypophysectomized male liver (class II) (Connerney et al., 2017; Wauthier et al., 2010). 
 
The use of osmotic pumps to infuse GH continuously, thereby overriding the endogenous 
male pulsatile pattern is a useful way to feminize liver gene expression (Holloway et al., 2006; 
Mode et al., 1981). Continuous GH (cGH) infusion of male mice abolishes the male 
specific, pulsatile pattern of liver STAT5 activity (Zhang et al., 2012). cGH infusion also 
closes male-biased DHS and opens female-biased DHS in male liver (Ling et al., 2010)  in 
accordance with the induction of female-biased genes and the repression of male-biased 
genes. In Chapters 2 and 3, I used the cGH infusion model to carry out a global gene 
expression time course study to elucidate the transcriptional events that lead to 
feminization of male mouse liver. Further, I explored the changes in chromatin 
accessibility and enhancer associated histone modifications that accompany the time-
dependent induction of female-biased genes and the repression of male-biased genes.  
 
1.6 Liver zonation and its impact on sex-biased liver gene expression   
The liver is thought to be a homogeneous organ since parenchymal cells (hepatocytes) 




the portal vein (periportal) differ in metabolic functions from the ones near the central vein 
(pericentral, or centrilobular). Functional zonation is directed by the zonated pattern of 
expression of several genes. Many of these differentially expressed genes code for enzymes 
involved in metabolism such as the CYP450 family, which are typically expressed in the 
pericentral zone (Oinonen and Lindros, 1998; Torre et al., 2011).  Studies have shown that 
in hypophysectomized rats, there is high expression of CYP2B and CYP3A in the 
periportal region, and that the normal pericentral pattern is restored by GH infusion 
suggesting that GH and other pituitary hormones normally repress the expression of a 
subset of CYP genes in the periportal region (Oinonen et al., 2000). Furthermore, a recent 
study used laser-capture microdissection to isolate periportal and pericentral hepatocytes 
from male and female mice detected differences in zonation of gene expression between 
males and females (Saito et al., 2013). It is clear by the studies above, that periportal and 
pericentral cells are exposed to different concentrations of endogenous or infused growth 
hormone. In Chapter 2, I investigated if zonation of gene expression constitutes a constraint 
for GH responsiveness. 
 
1.7 Translational significance 
Males and females exhibit differences in drug pharmacokinetics and pharmacodynamics 
resulting in many known differences in drug efficacy and toxicity between the sexes. 
Enzymes active in the metabolism of drugs, steroids, fatty acids and chemicals, including 
cytochrome P450 (CYP450), sulfotransferases and glutathione transferases, have shown to 




differential patterns of GH (Waxman and Holloway, 2009). Moreover, genes that 
participate in or regulate lipid metabolism and have been associated with dyslipidemia and 
cardiovascular disease, show sex-biased expression in human liver (Zhang et al., 2011).  
Liver diseases show sex differences in their incidence and progression (Yokoyama et al., 
2005). Liver fibrosis and cirrhosis result from chronic liver stressors, including viral 
hepatitis, alcoholic liver disease and non-alcoholic steatohepatitis (Marcellin and Kutala, 
2018). Fibrosis progression is more rapid in males than in females, which are protected 
against chemically induced cirrhosis (Poynard et al., 1997). Further, the incidence of 
Hepatocellular carcinoma (HCC) is three times higher in males (Clocchiatti et al., 2016; 
El-Serag, 2012). Disruption of the GH-STAT5 axis also leads to liver fibrosis and liver 
cancer. Loss of STAT5 in hepatocytes in a mouse model of cholestatic liver disease (Blaas 
et al., 2010) or in mice treated with Carbon tetrachloride (CCl4) results in severe liver 
fibrosis (Hosui et al., 2009), and experimental data suggests GH as a potential treatment 
for non-alcoholic fatty liver disease and liver fibrosis (Takahashi, 2017). This suggests that 
the sex-biased gene targets of GH action contribute to the observed differences between 
males and females, and in fact, some female-biased genes such as Trim24 (Herquel et al., 
2011b; Jiang et al., 2015) and Hao2 (Mattu et al., 2016) have been identified as tumor 
suppressors in HCC. The findings in this dissertation contribute to the understanding on 
how the temporal GH pattern dictates the differential expression of sex-biased genes 




1.8 Thesis hypotheses and goals 
Continuous GH treatment of intact male mice, which overrides the endogenous male, 
pulsatile plasma GH pattern, down-regulates male specific genes and up-regulates female 
specific genes (Mode et al., 1981). Previous studies in our lab have shown that feminization 
of liver gene expression is a sequential process with genes responding early; by 10 hours 
of GH infusion, while other genes respond as late as 7 to 14 days of GH treatment 
(Holloway et al., 2006). These findings lead to the hypothesis that there is a hierarchical 
and functional order to the observed changes in gene expression in response to growth 
hormone, where early responding genes mediate changes in later responding genes. In the 
second chapter of this dissertation, I used the cGH infusion model to carry out a global 
gene expression time course study to elucidate the transcriptional events that lead to 
feminization of male mouse liver. The third chapter, expands on the findings revealed in 
chapter 2 by integrating global DNase-seq and ChIP-seq data with the observed changes in 
gene expression.  
The polycomb-repressive complex (PRC2) mediates the methylation of Histone H3 lysine 
27 (H3K27), through its catalytic subunit Ezh2 (Enhancer of Zeste Homolog). H3K27me3, 
is a major sex-biased repressive mark present at highly female-biased, but not at highly 
male-biased genes (Sugathan and Waxman, 2013). In the fourth chapter of this dissertation 
I used an Ezh1-knockout mouse model with a hepatocyte-specific knockout of Ezh2 to 
investigate the role of H3K27me3 in repressing sex-biased genes in mouse liver and the 




Figure 1.1. Sex specific growth hormone secretion patterns in the rat, mouse and 
human males and females.    
In the three-species presented, GH secretion in the male is pulsatile with prolonged periods 
of undetectable GH between pulses. GH pulses in the female are more frequent and there 
is a near continuous presence of GH in circulation. Thus, the conserved interpeak period 
in the males is determinant factor for dimorphic gene expression. Figures obtained from 














volution-estimated GH secretory patterns are plotted in the
bottom panel and the GH concentrations derived from these
secretion estimates are overlaid on the measured concentra-




SE) GH concentrations for the
eight men and eight women are given in Fig. 2. The 24-h pro-
files in men were characterized by the presence of a dominant
nocturnal pulse with much smaller pulses at other times of the
day. In contrast, GH secretion in women was more continuous,
with pulses of similar amplitude throughout the 24 h.
Several methods were used to quantify the differences in
the pattern of GH secretion in men and women (Table I). As a
measure of uniformity of pulse amplitude, a SD for each sub-
ject’s GH pulse amplitudes during the baseline study was cal-
culated. GH pulse amplitudes were logarithmically trans-
formed before analysis. This estimate of variation was greater













similar analysis was performed after logarithmic transforma-
tion of the 145 daily GH concentrations. A higher SD for daily












 0.04). Fig. 3
shows a histogram of GH concentrations in these two groups.
GH concentrations were either equal to or above the assay de-
tection limit 98% of the time in men and 100% of the time in
women. Although there was no difference between men and
women in terms of absolute GH nadir, there was a difference
in the frequency of biologically low GH concentrations. Reu-
tens et al. (22) recently reported that subjects with severe or-









g/liter during 24-h sampling. Using this value as





4% of the spontaneous plasma GH measurements in
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Deconvolution was used to determine differences in GH
secretion that would account for gender-specific GH concen-




) shows the BPF for men and
women calculated as the deconvolution estimated pulse fre-
Figure 2. Composite picture of plasma GH con-
centration profiles (mean6SE) in eight men (top) 
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Table 1.1 Sexually dimorphic Cytochrome P450 enzymes  
Examples of human Cytochrome P450 genes that show sexual-dimorphism in humans, 
their substrates and the effects in males and females. Adapted from (Zhang et al., 2011)  
  
SEXUALLY DIMORPHIC CYTOCHROME P450 ENZYMES (HUMAN) 








Males Rapid clearance rates in 
males, more side effects in 
females 
CYP7A1 Cholesterol  Females  More favorable lipid profile 
in females  
CYP2D6 Propranolol,  
Metoprolol 
Dextromethorphan 




Figure 1.2. Growth hormone signaling pathway.  
GH signals through the JAK-STAT pathway to regulate transcription of target genes 






Figure 1.3. Model for regulation of sex-biased genes in male and female liver.  
In male liver, BCL6 represses female-biased genes. In female liver CUX2 represses male-
biased genes. Both transcriptional regulators are repressed by the pattern of STAT5 activity 









by positive-acting endogenous factors. One such factor is the tran-
scriptional activator Onecut1/HNF6, whose motif is very similar
to that of CUX2 and which likely competes with CUX2 for DNA
binding. Other possibilities include the absence in male liver of a
cofactor or a posttranslational modification required for efficient
repression by CUX2 of its male-specific gene targets and the re-
quirement of high levels of CUX2 to overcome the positive, stim-
ulatory effects of male chromatin structure on male-specific gene
expression.
Many fewer sex-specific genes responded to CUX2 overexpres-
sion in female liver than in male liver. This likely reflects the com-
paratively high endogenous female level of CUX2, which may be
sufficient to maximally repress many male-biased genes, e.g.,
those whose basal expression is low. Indeed, genes repressed by
adeno-CUX2 in both male and female liver tend to be more highly
expressed in untreated female liver than genes repressed by adeno-
CUX2 in male liver only (see Fig. S4 in the supplemental material).
While most genes responding to CUX2 overexpression in both
male and female liver showed the same response in each sex, sex-
dependent responses were seen in some cases. This may reflect a
differential availability of transcriptional cofactors of CUX2, lead-
ing to the observed sex-differential regulation of these genes,
FIG 8 Genes responsive to CUX2 overexpression are enriched for genes show-
ing developmental changes from 3 to 8 weeks. A comparison of male-biased
(A), female-biased (B), and stringent sex-independent (C) genes altered by
adeno-CUX2 treatment (5 days) to genes showing developmental changes
between 3 weeks and 8 weeks in male (left) and female (right) mouse liver is
shown. The developmental changes considered were upregulation, downregu-
lation, and no change in expression from 3 weeks to 8 weeks at !fold change! "
1.5 and P # 0.0001, based on microarray studies reported elsewhere (6). Sta-
tistical analysis (two-tailed Fisher exact test): ***, ES P # 10$5 for genes show-
ing developmental upregulation from 3 to 8 weeks; %%%, ES P # 10$5 for
genes showing development downregulation from 3 to 8 weeks.
FIG 9 Model for regulation of sex-specific liver gene expression by CUX2. (A)
Model for regulation of sex-biased genes in male and female liver. Differences
in plasma GH secretion between males (pulsatile GH) and females (near-
continuous GH) lead to sex-differential activation of STAT5 (pulsatile activa-
tion in male liver and persistent activation in female liver) and to male-biased
expression of BCL6 and female-specific expression of CUX2 in mouse liver, as
shown. BCL6 preferentially represses female-biased genes in male liver (54). In
female liver, CUX2 represses 35% of male-biased genes, primarily through a
direct binding mechanism. CUX2 also induces 36% of female-biased genes,
acting through both direct and indirect mechanisms, with the direct CUX2
targets Tox and Trim24 potentially mediating these indirect effects. (B) Model
for direct repression by CUX2 of male-biased genes in adult female liver.
CUX2 binding sites in adult female liver are enriched at sites that are more
open in male than in female liver (male-biased DNase hypersensitivity sites)
that are also male-enriched STAT5 biding sites. CUX2 binding and recruit-
ment of chromatin remodeling proteins, such as histone deacetylases
(HDACs) and/or histone lysine methyltransferases (HKMTs), are proposed to
alter chromatin accessibility and repress STAT5-dependent expression of
male-biased target genes in female liver.
Conforto et al.
4624 mcb.asm.org Molecular and Cellular Biology
 on O












CHAPTER 2. Time-dependent Epigenetic Regulation of Continuous Growth 
Hormone-Responsive Sex-Biased Genes in Male Mouse Liver 
 
2.1 Abstract 
Sex-dependent pituitary GH secretory profiles–pulsatile in males and persistent in 
females–regulate sex-biased, STAT5-dependent expression of hundreds of genes in mouse 
liver, imparting sex differences in hepatic drug/lipid metabolism and disease risk. Here we 
examine transcriptional and epigenetic changes induced by continuous-GH infusion (cGH) 
in male mice, which rapidly feminizes the temporal profile of liver STAT5 activity. cGH 
repressed 86% of male-biased genes and induced 68% of female-biased genes within 4-
days; however, several highly female-specific genes showed weak or no feminization, even 
after 14-days cGH. Female-biased genes already in an active chromatin state in male liver 
generally showed early cGH responses; genes in an inactive chromatin state often 
responded late. Early cGH-responsive genes included those encoding two GH/STAT5-
regulated transcriptional repressors: male-biased BCL6, which was repressed, and female-
specific CUX2, which was induced. Male-biased genes activated by STAT5 and/or 
repressed by CUX2 were enriched for early cGH repression. Female-biased BCL6 targets 
were enriched for early cGH de-repression. Changes in sex-specific chromatin accessibility 
and histone modifications accompanied these cGH-induced sex-biased gene expression 
changes. Thus, the temporal, sex-biased gene responses to persistent GH stimulation are 
dictated by GH/STAT5-regulated transcription factors arranged in a hierarchical network 





Sexual dimorphism is a characteristic of liver physiology and pathology (Yokoyama et al., 
2005). Males and females exhibit differences in hepatic drug and lipid metabolism, which 
impact cholesterol sensing and transport (Lorbek et al., 2013), as well as pharmacokinetics 
and pharmacodynamics linked to sex differences in drug efficacy, drug toxicity, and liver 
disease susceptibility (Buzzetti et al., 2017; Waxman and Holloway, 2009). Females are 
more susceptible to acute liver failure, autoimmune hepatitis, and toxin-mediated 
hepatotoxicity (Guy and Peters, 2013), while males are more susceptible to liver fibrosis 
progression (Poynard et al., 1997) and hepatocellular carcinoma (Clocchiatti et al., 2016; 
El-Serag, 2012; Ruggieri et al., 2010). Underlying these phenotypic sex differences are sex 
differences in expression of an unexpectedly large number of genes, as shown in mouse, 
rat and human liver (Clodfelter et al., 2006; Kwekel et al., 2010; Rinn et al., 2004; Zhang 
et al., 2011), including genes involved in lipid metabolism associated with dyslipidemia 
and cardiovascular disease risk in humans (Zhang et al., 2011).  
Growth hormone (GH), acting through its sex-specific plasma profiles and cell surface 
receptor (Waters, 2016), is the major hormonal determinant of sex differences in adult 
liver. GH secretion by the anterior pituitary gland is controlled by the hypothalamus and 
regulated by metabolic cues (Meinhardt and Ho, 2007) and shows sexual dimorphism in 
many species, including rodents and humans (Jansson et al., 1985; Shapiro et al., 1995; 
Waxman and O'Connor, 2006). In the rat and mouse, pituitary GH secretion is intermittent 
in males, whereas in females, GH is secreted more frequently, and consequently, target 




Steyn et al., 2011). GH secretion patterns are set by gonadal steroids during the neonatal 
period, are first manifested at puberty, and continue into adulthood (Chowen et al., 2004; 
Meinhardt and Ho, 2007). Ablation of circulating GH by hypophysectomy abolishes ~90% 
of liver sex differences, and exogenous GH given either in pulses (male pattern) or 
continuously (female-like pattern) restores the corresponding sex-biased patterns of liver 
gene expression (Holloway et al., 2006; Wauthier et al., 2010; Wauthier and Waxman, 
2008) 
The transcription factor STAT5b is a major essential mediator of the sex-dependent 
transcriptional responses of the liver to GH, as seen in mouse knockout models (Clodfelter 
et al., 2006; Holloway et al., 2007). Liver STAT5 activity directly correlates with the 
occurrence of a plasma GH pulse in male rats (Choi and Waxman, 2000; Tannenbaum et 
al., 2001), whereas in female rats, liver STAT5 activity persists due to the more persistent 
stimulation of hepatocytes by GH (Choi and Waxman, 1999). Comparison of the sex-
differential, GH-induced liver STAT5 activation patterns between rats (Choi and Waxman, 
2000) and mice (Xu et al., 2012) indicates that the key sex difference is the occurrence of 
a sustained period of time when STAT5 is inactive in male liver. The sex-specific 
transcriptional actions of GH-activated STAT5 are enhanced by several GH/STAT5-
regulated transcription factors, including BCL6 (Huang and Melnick, 2015), a male-biased 
transcriptional repressor (Meyer et al., 2009) that preferentially represses female-biased 
genes in male liver (Xu et al., 2012), and CUX2 (Gingras et al., 2005), a female-specific 
repressor (Laz et al., 2007) that down regulates a subset of male-biased genes in female 




Information on chromatin accessibility, histone modification and transcription factor 
binding can be integrated to elucidate complex patterns of transcriptional regulation. 
Genomic sites hypersensitive to cleavage by DNase I (DNase hypersensitive sites; DHS) 
correspond to accessible (open) chromatin regions, which encompass key regulatory 
elements, including enhancers, promoters, insulators and silencers, and are often flanked 
by specific histone modifications (Thurman et al., 2012). Genome-wide DHS mapping in 
mouse liver has established a close relationship between sex differences in chromatin 
accessibility and sex differences in gene expression (Ling et al., 2010; Sugathan and 
Waxman, 2013). Sex-biased STAT5 binding to liver chromatin is strongly enriched at sex-
biased DHS, and correlates positively with sex-biased activating histone marks and 
negatively with repressive marks (Sugathan and Waxman, 2013; Xu et al., 2012).  
Differences in the epigenetic regulatory mechanisms utilized in male and female liver are 
apparent, with many of the most highly female-biased genes specifically subject to H3-
K27me3-based repression in male liver (Sugathan and Waxman, 2013).  
GH regulation of sex-biased gene expression thus involves complex interactions between 
transcriptional networks, genomic regulatory elements and epigenetic features. 
Fundamental questions remain regarding the mechanisms by which GH establishes and 
maintains the sex-biased chromatin states that determine the sex-biased expression of many 
GH target genes (Sugathan and Waxman, 2013). Continuous GH (cGH) infusion of male 
mice overrides the endogenous male, pulsatile GH pattern, thereby abolishing the male-
specific, pulsatile pattern of liver STAT5 activity (Xu et al., 2012). cGH infusion also 




2010) while down regulating several male-biased genes and up regulating female-biased 
genes (Holloway et al., 2006). Here we utilize the cGH infusion model to carry out a global 
gene expression time course study to elucidate the transcriptional events that lead to 
feminization of male mouse liver. Our findings reveal that cGH infusion induces distinct, 
time-dependent waves of male-biased gene repression and female-biased gene de-
repression associated with changes in the sex-biased liver chromatin environment and 
initiated by a hierarchical transcriptional network comprised of several sex-biased 
transcription factors.  
 
2.3 Materials and Methods 
2.3.1 Animal treatments 
Male and female CD1 mice (Crl:CD(ICR); strain code 022), 8–9 weeks of age, were 
purchased from Charles River Laboratories (Kingston, NY). Mice were housed in a 
temperature and humidity controlled environment with a 12-h light, 12-h dark cycle, fed 
with standard rodent chow and supplied with tap water. Alzet osmotic pumps (model 
1007D, Durect Corp., Cupertino, CA) were filled with recombinant rat GH (purchased 
from Dr. Arieh Gertler, Protein Laboratories Rehovot Ltd, Rehovot, Israel) dissolved in 30 
mM NaHCO3 and 0.15 M NaCl containing 0.1 mg/ml rat albumin (Sigma-Aldrich, Cat. 
#A6414). Pumps were implanted subcutaneously under ketamine and xylazine anesthesia. 
GH was infused at a rate of 25 ng/g body weight/h for periods ranging from 10 h to 14 d. 




implantation, initiation of GH delivery for the 10 h to 7-day time points was delayed for a 
period of 96 h. This delay was achieved as suggested by the manufacturer, by attaching to 
each pump a coiled polyethylene catheter (PE-60, Durect Corporation, Cupertino, CA, Cat. 
# 0007750, lot # PE00008) filled with saline buffer whose length and flow rate correspond 
to the 96-h delay period, as follows. The measured rate of saline flow through a coiled 
catheter was used to calculate a catheter length (0.99 mm/h x 96 h). An extra 4 mm length 
was added to the calculated catheter length to adjust for the 4-mm length required to attach 
the catheter to the pump’s flow moderator. This 96 h delay was not introduced for the 14-
day GH infusion time point, as preliminary studies showed that stress-induced gene 
expression changes (e.g., induction of acute phase genes Cxcl1 and Saa3) (Zhou et al., 
2016) dissipated within a few days. However, to ensure a full 14-day exposure to bioactive 
GH, Alzet pumps were removed 7 days after initiating cGH infusion (i.e., 96 h + 7 days 
after pump implantation) and replaced with a new Alzet minipump delivering fresh GH for 
an additional 7 days. Untreated female and sham-treated male mice (i.e., Alzet pumps filled 
with buffer) were used as controls. Mice were euthanized by cervical dislocation. All 
animal procedures were approved by the Boston University Institutional Animal Care and 
Use Committee.1 
 
2.3.2 Nuclear extraction and chromatin cross-linking.  
Fresh liver tissue was excised from individual mice and homogenized on ice in a Potter-
Elvehjem tissue grinder using 12 ml of homogenization buffer [10 mM HEPES (pH 7.6), 
																																																								




25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM Na orthovanadate, 10 mM 
NaF, 1 mM EDTA, 2 M sucrose, and 10% glycerol] with complete protease inhibitor 
cocktail (1 tablet/25 ml, Sigma-Aldrich Cat. # 11697498001). The homogenate was loaded 
onto a 3-ml cushion of homogenization buffer on Ultra-Clear ultracentrifugation tubes 
(Beckman Cat. #344059) and centrifuged in a Sorvall Pro ultracentrifuge in a SW41 Ti 
rotor at 4°C at 25,000 rpm for 30 min. The pelleted nuclei obtained from ~30-35% of the 
liver homogenate were resuspended in 400 μl of nuclei storage buffer [20 mM Tris-HCl 
(pH 8.0), 75 mM NaCl, 0.5 mM EDTA, 50% glycerol, 0.85 mM DTT, 0.125 mM PMSF] 
using a 0.5 ml Dounce homogenizer. Samples were snap frozen and stored at -80°C until 
further use for DNase hypersensitivity analysis. The pelleted nuclei from the remaining 
two thirds of each liver were resuspended in 1 ml of cross-linking buffer [10 mM HEPES 
(pH 7.6), 25 mM KCl, 0.34 M sucrose, 0.15 mM 2-mercaptoethanol, 2 mM MgCl2] and 
incubated with 0.8% formaldehyde (final concentration) for 9 min in a 30°C water bath 
with periodic shaking. Cross-linking was halted by addition of a 1 M glycine (pH 8.0) 
solution (final concentration, 0.1 M), followed by incubation for 5 min at room 
temperature. Samples were placed on ice, layered on a 3-ml cushion of homogenization 
buffer, and centrifuged at 4°C at 25,000 rpm for 30 min. The cross-linked nuclear pellet 
was resuspended in 1 ml of 1X radioimmunoprecipitation assay (RIPA) buffer [50 mM 
Tris Cl (pH 8.1), 150 mM NaCl, 1% IGEPAL CA-630 (Sigma-Aldrich, Cat. #I8896) 0.5% 
sodium deoxycholate] containing 0.5% SDS and complete protease inhibitor cocktail. 
Samples were sonicated in borosilicate glass tubes (Kimble Chase 73500-1275, Rim Top, 




for 15 s ON and 45 s OFF, for 30 cycles) or using a Diagenode Bioruptor UCD-400 Twin 
in 15 ml polystyrene tubes (BD Falcon Cat # 352095) for 75-80 cycles (30 s ON and 30 s 
OFF, high intensity). A 15 μl aliquot of the sonicated chromatin was reverse cross-linked, 
treated with RNase A and proteinase K, and electrophoresed on a 1% agarose gel to size 
the fragments. The majority of DNA fragments ranged from 100 to 300 bp. The remaining 
sonicated chromatin was snap-frozen in liquid nitrogen and stored at -80°C until further 
use for chromatin immunoprecipitation. 
 
2.3.3 Chromatin immunoprecipitation (ChIP) and DNase hypersensitivity assay.  
ChIP was performed as reported previously (Xu et al., 2012) using the following ChIP-
validated antibodies: H3K27me3 (Abcam Cat # ab6002, 2 μg antibody per 10 μg of 
sonicated chromatin), and normal rabbit IgG (Santa Cruz, Cat # sc-2027, 3 μg antibody per 
15 μg of sonicated chromatin). ChIP DNA was quantified using a Quant-iT PicoGreen 
assay kit (Invitrogen) and analyzed by quantitative PCR (qPCR) to interrogate genomic 
regions selected as positive controls or as negative controls for H3K27me3, generally based 
on published ChIP-seq data (Sugathan and Waxman, 2013). DNase I digestion of liver 
nuclei (Ling et al., 2010) was performed as previously described(Connerney et al., 2017). 
Briefly, 25 x 106 liver nuclei per sample were incubated with 32 U of RQ1 RNase-free 
DNase I (1 U/μl; Promega) for 2 min at 37°C. Samples were extracted with 
phenol/chloroform and then loaded on a sucrose gradient and centrifuged at 25,000 rpm 
for 24 h at 25°C. Individual fractions were collected and analyzed on a SYBR green-stained 




fragments between 100 bp and 1 kb in size (median size 300 bp) were pooled. Fragments 
125-400 bp long were isolated using a dual SPRI size selection with Agencourt AMPure 
XP beads (Beckman Coulter, Cat# A63881). DNA was quantified using a Quant-iT 
PicoGreen assay kit (Invitrogen) and qualified by qPCR using primers that amplify 
genomic sequences previously identified as liver DHS (Ling et al., 2010)2.  
 
2.3.4 RNA isolation and sequencing.  
Approximately 10% of each individual liver was snap frozen in liquid nitrogen and used 
for RNA extraction with TRIzol reagent (Invitrogen Life Technologies Inc., Carlsbad, CA) 
following the manufacturer’s instructions. Total liver RNA was isolated from livers of 
cGH-infused or sham-treated male mice. Two or three sequencing libraries (biological 
replicates) were prepared for each time point of cGH treatment (i.e., 10 h, 1 d, 4 d, 7 d, and 
14 d GH infusion). For the 1, 4 and 7-day cGH time points, each sequencing library was 
prepared from a single mouse liver. For the 14-day time point and for the sham-treated 
males, each sequencing library corresponded to a pool of n=2-3 individuals. We observed 
high individual variability in gene responses after 10 h of GH infusion, therefore, we 
expanded the number of individual mouse livers at that time-point to give a pool of n=9-
10 individual livers for each of two sequencing libraries. Sequencing libraries were 
prepared using the Illumina TruSeq RNA library preparation kit (Illumina, cat# RS-122-
2001). Total liver RNA was also isolated from a large number of control (untreated) male 
and female mouse livers, from which we prepared three RNA pools per sex, each 
																																																								




comprised of RNA from n=12-17 individual livers. In addition, total RNA isolated from 
livers of sham-treated males, control females, and from mice given cGH infusion for 10 h 
or 1 day were used to prepare 3 pools per condition, using n=2-4 livers per pool. The latter 
RNA samples were treated with DNase and then depleted of ribosomal RNA using the 
NEBNext Ribosomal RNA (rRNA) depletion kit (NEB, Cat# E6310). Sequencing libraries 
were prepared using NEBNext Ultra Directional RNA Library Prep kit for Illumina (NEB, 
Cat# E7420) following the manufacturer’s instructions. NEBNext Multiplex Oligos for 
Illumina (NEB, Cat# E7335) were used for multiplexing. The Agencourt AMPure XP 
system (Beckman Coulter, Cat# A63880) was used for sample and library purification. 
Library quality and size distribution were assessed using the Agilent Bioanalyzer DNA 
high sensitivity kit (Agilent Technologies, Cat# 5067-4627). Sequencing on an Illumina 
HiSeq2000 or HiSeq2500 instrument was carried out at the New York Genome Center 
(New York, NY) or at the Boston University Dept. of Computational Biomedicine (Boston, 
MA), generating either 100 nt or 125 nt paired-end sequence reads. 
 
2.3.5 RNA-seq and identification of sex-biased and GH-responsive genes.  
RNA-seq data were analyzed using a custom pipeline developed in our lab and recently 
described (Connerney et al., 2017). Briefly, sequence reads were aligned to mouse genome 
build mm9 (NCBI 37) using Tophat (version 2.0.13) (Trapnell et al., 2012), and 
FeatureCounts (Liao et al., 2014) was used to count sequence reads mapping to three 
different sets of genomic regions: collapsed exon (the union of the exonic regions in all 




that overlap an intron in any of the isoforms), and intronic-only (the union of the intronic 
regions in all isoforms of a given gene, excluding those intronic sequences that overlap an 
exon in any of the isoforms). Differential expression analysis was conducted using the 
Bioconductor package EdgeR (Robinson et al., 2010). We identified 9,709 liver-expressed 
genes based on Fragments Per Kilobase length of transcript per Million mapped reads 
(FPKM) values >1 in either male or female liver. 983 sex-biased genes were identified 
based on thresholds of EdgeR adjusted p-value < 0.01 and FPKM >1, which empirically 
corresponded to a >1.2-fold sex-difference in expression (see gene listing in Table S1).  
A stringent set of 255 sex-biased genes was defined based on an adjusted p-value <0.01 
and showing a > 2-fold sex-difference when comparing adult male to adult female liver; 
this list excludes four Y-chromosome genes (Table S2, Table S3). These genes also show 
a > 2-fold ratio when comparing the FPKM values of the sham-treated males to those of 
control females. For each sex-biased gene, a percent feminization value was calculated 
based on responses to cGH infusion, as follows: % Feminization = 100% x [FPKM (cGH-
infused male) – FPKM (sham-treated male)] / [FPKM (control female) – FPKM (sham-
treated male)]. A gene was considered responsive to cGH infusion if its differential 
expression analysis met the threshold of adjusted p-value < 0.05 and if the gene showed > 
20% feminization at a given time-point. All raw and processed RNA-seq data are available 
under accession number GSE98586 at Gene Expression Omnibus 
(https://www.ncbi.nlm.nih.gov/gds/). A set of 7,225 stringent sex-independent genes was 
defined based on an EdgeR adjusted p-value > 0.1, and fold-change for sex-difference < 




more time points, and only 14 of the 62 genes were consistently induced or consistently 
repressed by cGH and showed > 4-fold maximal response, while 11 genes show significant 
responses only after 14 days of cGH infusion (Table S4, Table S5).  
 
2.3.6 Clustering of cGH-responsive genes.  
STEM (Short Time-series Expression Miner) (Ernst and Bar-Joseph, 2006; Ernst et al., 
2005) was used for initial analysis of the patterns of response to cGH infusion. STEM 
defines a set of model response profiles independent of the data. Each gene was assigned 
to the pre-defined STEM profile that most closely resembled its time-dependent response 
to cGH infusion, and STEM profiles with a minimum correlation value were clustered 
together. STEM clustering of the set of 255 sex-biased genes (EdgeR, padj < 0.01, fold-
change >2, (Table S2, Table S3)) was carried out using the percent feminization values 
(described above) for each gene at each cGH treatment time point. The maximum number 
of model STEM profiles was set to 8, the maximum unit change in model profiles between 
time points was set to 10, the minimum correlation to cluster profiles was set to 0.7 and 
significance values represent the FDR. After excluding 22 unresponsive genes (genes that 
did not meet the EdgeR p-value threshold), STEM analysis revealed that 198 of the 233 
cGH-responsive sex-biased genes (85%) showed a time-dependent increase in 
feminization represented by STEM profile 4 (FDR 7.0E-147). These 198 genes were 
comprised of male-biased and female-biased genes with a progressive, time-dependent 
pattern of feminization (Table S2, Table S3). 16 other cGH-responsive genes with the 




biased, but either responded to cGH only after 14 days, or were highly induced by cGH, 
but nevertheless, the maximal extent of feminization was < 20%. For example, Sult2a2, 
with a female to male expression ratio of >4,000, was 919-fold induced by cGH at 14 days 
(padj 1.49E-17) (Table S1), but this corresponds to only 12% feminization. These two gene 
lists (i.e., the 198 + 16 = 214 sex-biased genes) were further clustered based on the cGH 
time course, as follows. Heatmap generation and hierarchical clustering were conducted 
using Morpheus (https://software.broadinstitute.org/morpheus/). Complete-linkage 
hierarchical clustering of the feminization values at each time point was implemented, and 
led to our identification of five clusters of cGH-responsive male-biased genes, designated 
M1 to M5, and five clusters of cGH-responsive female-biased genes, designated F1 to F5. 
One gene (Igsf23) was filtered out by this clustering and the remaining 213 sex-biased were 
used for all downstream analyses. Functional annotation analysis was performed using 
DAVID (Huang et al., 2007).  
 
2.3.7 Mapping binding sites to genes and enrichment for sex-biased gene targets.  
Male-enriched, female-enriched and sex-independent STAT5 binding sites (1,765, 1,791 
and 11,538 sites, respectively, and defined in (Xu et al., 2012)), BCL6 binding sites in male 
liver (6,432 sites), and CUX2 binding sites in female liver (1,471 sites) were obtained from 
our published ChIP-seq data (Conforto et al., 2012) (GEO accessions GSE31578, 
GSE35985). Male-biased (n=2,800), female-biased (n=1,379) and sex independent DHS 
(n=68,682) were also obtained from our published data (Ling et al., 2010) (GEO accession 




GREAT (Genomic Regions Enrichment of Annotations Tool; (McLean et al., 2010)) using 
the following parameters. Each RefSeq gene was assigned a basal regulatory domain 
extending from 5 kb upstream to 1 kb downstream of the transcription start site (TSS), and 
the regulatory domain was extended in both directions to the nearest gene’s basal 
regulatory domain up to a maximum of 1000 kb in one direction (McLean et al., 2010). 
Enrichment results obtained using this mapping method were similar to those obtained 
when transcription factor binding sites were mapped to the nearest gene within 10 kb, as 
was done previously (Conforto et al., 2012; Xu et al., 2014) (Data not shown). For STAT5 
and for DHS, the gene targets of male-enriched sites were filtered to remove any genes that 
were also identified as a target of a female-enriched site, and correspondingly for the gene 
targets of female-enriched sites. Gene targets of sex-independent STAT5 binding sites or 
DHS were defined as those identified by GREAT as a target of one or more sex-
independent sites but that did not map to any male-enriched or female-enriched 
transcription factor binding site. The enrichment of sex-biased genes in each set of 
transcription factor targets was calculated as compared to the set of stringent sex-
independent genes (Table S5). The enrichment of the transcription factor targets for 
belonging to each of the 5 cGH response clusters in each sex (designated M1 to M5 and 
F1 to F5; see Table 1, below) was calculated compared to all GH responsive male-biased 





2.3.8 Enrichment for liver chromatin states.  
We previously clustered all liver-expressed genes by the read densities of 7 chromatin 
features across a 2 kb window centered at the TSS and a 2 kb window centered at the 
transcript end site (TES) (Sugathan and Waxman, 2013). Clusters of genes were defined 
as either active (clusters 1, 2 and 3 of Fig. S5 of (Sugathan and Waxman, 2013)), poised 
(clusters 4 and 5 of Fig. S5 of (Sugathan and Waxman, 2013)) or inactive (cluster 6 of Fig. 
S5 of (Sugathan and Waxman, 2013)) based on the relative density of DNase 
hypersensitivity, activating chromatin marks (H3-K27ac, H3-K4me1, H3-K4me3, H3-
K36me3) and repressive chromatin marks (H3-K27me3 and H3-K9me3). 158 of the 213 
sex-biased genes grouped into clusters M1-M5 and F1-F5, as described above, were 
available for analysis of enrichment for liver chromatin states after removal of 38 genes <5 
kb in length (to exclude genes whose TSS-proximal sequences overlap the TES-associated 
region) and after removing 17 genes for which the earlier chromatin state analysis 
(Sugathan and Waxman, 2013) was not performed. Genes from this list of 158 genes found 
in each of the 5 cGH response clusters in each sex were tested for their being enriched in 
active, poised or inactive chromatin states, when compared to all cGH-responsive female 
or male biased genes, respectively. Statistical significance was calculated using Fisher’s 
exact test. Clustering and enrichments were carried out separately in male and female liver. 
For example, of the 53 female-biased genes in clusters F1 and F2 (Table S3), 29 are in an 
active chromatin state in male liver, compared to 10/46 genes in the other clusters (F3-F5). 
An enrichment score of 4.35 (Fig. 2.5B, below) was calculated as follows: [29 (F1+F2) 




state] / [36 (F3-F4-F5) genes not in active state]). A significant p-value = 0.00098 was 
obtained by Fisher’s exact test. 
 
2.3.9 qPCR analysis.  
Liver total RNA (1μg) was used for reverse transcription (RT) using the Applied 
Biosystems High-Capacity cDNA Reverse Transcription Kit (Fisher, Cat#43-688-14). 
qPCR was performed using Power SYBR green PCR master mix and processed on an ABS 
7900HT sequence detection system (Applied Biosystems) or the CFX384 Touch Real-
Time PCR detection system (Bio-Rad). For RT-qPCR, raw Ct values were analyzed using 
the comparative Ct method with normalization to the 18S RNA content in each sample. 
Raw Ct values for DHS samples were normalized to the DHS level in each sample at a 
prominent, sex-independent DHS near Tram2 (mm9 genomic coordinates: chr1: 
21,049,167-21,050,218). Raw Ct values for H3-K27me3 ChIP-qPCR were normalized to 
the H3-K27me3 level in the Hoxb gene region (mm9 genomic coordinates: chr11: 
96,135,000-96,145,000, 2.1 Kb upstream of Hoxb8). qPCR primers were designed using 
Primer Express software (Thermo Fisher Scientific, Inc.). Primers were specific for their 
target sequences as verified using the BLAT function of the UCSC browser after extending 
the sequence to include 3 to 10 nt of flanking sequence on each end, as 
described(Connerney et al., 2017). Primary RNA transcripts (hnRNA) were quantified 
using a primer pair spanning an exon-intron junction. Primers used to quantify mature 
(spliced) mRNAs were targeted to adjacent exons separated by an intron >1 kb in length 




of having contaminating genomic DNA contribute to the qPCR signal. Primer sequences 
are shown in Table S6. 
 
2.3.10 Analysis of liver zonation of cGH responsive sex-biased genes.  
We used liver zonation data reported in a recent study (Bahar Halpern et al., 2017) that 
combined single-molecule fluorescence in situ hybridization (smFISH) and single-cell 
RNAseq data to establish the zonation profiles of all liver expressed genes in adult male 
liver. Zonation layers in the liver lobule were numbered from zone 1 (closest to central 
vein) to zone 9 (most periportal) and the expression values in each zone were determined 
for every liver expressed gene. We obtained the zonation profiles for 229 sex biased genes 
sex-biased genes and for 6,672 stringent sex-independent genes. Genes were defined as 
being significantly zonated if they met a q value <0.2 for differential zonation according to 
(Bahar Halpern et al., 2017).  For each of the significantly zonated genes, a zonation bias 
ratio was calculated: Zonation bias = [Expression in zone 1 (closest to central vein) - 
Expression in zone 9 (most periportal)] / (mean expression in all 9 zones)]. Zonation ratios 
were compared for sex-biased genes vs. sex-independent genes, and for Clusters 1 + 2 
(early) vs. Clusters 3-5 (not-early) cGH-responsive female-biased genes, and separately, 
male-biased genes. P-values were obtained by Wilcoxon rank-sum tests.  
 
2.3.11 Statistical analysis.  
Graphical and statistical analyses were performed using GraphPad Prism 7 software. RNA, 




(SEM) for n=6-10 individual mouse livers per group, as specified in each figure legend. 
One-way analysis of variance (ANOVA) with a Dunnett post-test was used to compare 
each treatment group to its sham-treated control group, and is indicated by the symbol *. 
Statistical significance reached by a t-test but not ANOVA is indicated by ^. A single 
symbol (*, or ^) indicates significance at P <0.05, a double symbol indicates significance 
at P <0.01, and a triple symbol indicates significance at P<0.001. Statistical significance of 
all the enrichment or depletion calculations was evaluated using Fisher’s exact test.  
 
2.4 Results 
2.4.1 Continuous GH-responsive sex-biased genes in mouse liver 
Adult male mice were treated with GH given as a continuous infusion (cGH) for times 
ranging from 10 h to 14 days, to override the male pulsatile GH secretion pattern. RNA-
seq analysis of liver mRNA identified 983 liver-expressed, sex-biased genes (Table S2.1), 
of which 74% showed feminized expression, i.e. suppression of male-biased genes and 
induction of female-biased genes, following cGH infusion. Moreover, 69% of the cGH-
responsive genes were fully feminized at their maximal response time point (Fig. 2.1 A). 
Of the 255 sex-biased genes with a sex ratio >2 (142 female-biased genes and 113 male-
biased genes, excluding 4 Y-chromosome genes), 233 (91%) were cGH-responsive (Table 
S2.2, Table S2.3). The majority of these stringent sex-biased genes responded within 4-
days (86% of male-biased genes and 68% of female-biased genes with feminization > 
20%). In contrast, only 62 (0.9%) of 7,225 stringently sex-independent genes responded to 




Hierarchical clustering of a set of 214 sex biased genes selected for consistent patterns of 
GH responsiveness using STEM (Ernst and Bar-Joseph, 2006) (see Methods) identified 
five clusters of female-biased genes (F1-F5), and five other clusters of male-biased genes 
(M1-M5) (Fig. 2.1B, Table 2.1). cGH response patterns were validated for select genes by 
RT-qPCR. Cux2, a cluster F1 female-biased gene, was significantly induced after 10 h cGH 
infusion and was fully feminized (>100% intact female expression level) within 1 day; in 
contrast, Cyp2b9, in cluster F2, was not significantly induced by cGH until day 4 (Fig. 
2.2A). Several highly female-biased Sult and Cyp genes in clusters F4 and F5 (Fig. 2.1A, 
Table 2.1) were only partially feminized after 14 days cGH treatment, as shown for Sult3a1 
(Fig. 2.2A). Elovl3, a male-biased gene in cluster M1, reached > 90% feminization by 4 
days of cGH infusion (Fig. 2.2B). Similarly, Nox4, in cluster M2, was significantly down 
regulated by 1 day cGH but required longer time for full feminization. C9, in cluster M3, 
showed partial responses at the early time points and was completely feminized (i.e., 
repressed) after 4 days. Genes in cluster M4 showed no response at the early time points 
but were completely feminized by 4 days cGH or later (Fig. 2.1B). Genes in cluster M5 
were only partially repressed after 14 days cGH infusion (Table 2.1). KEGG pathway 
analysis of the genes in each cluster revealed enrichment for metabolism gene pathways in 
all of the clusters (Table S2.7).  
 
2.4.2 Early transcriptional changes indicated by intronic sequence reads 
As RNA abundance measured by RNA-seq is a function of both RNA synthesis and 




the time required for those mRNAs to decline following cGH infusion. Intronic sequence 
reads assayed by RNA-seq primarily correspond to unprocessed transcripts whose 
abundance reflects the nascent transcription rate; they can therefore be compared to exonic 
sequence reads to distinguish transcriptional from post-transcriptional regulation (Ameur 
et al., 2011; Gaidatzis et al., 2015). Accordingly, we quantified cGH-induced gene 
expression changes separately for exonic reads and intronic reads extracted from our 
polyA-liver RNA-seq dataset (see Methods). Similar overall cGH response patterns were 
apparent when comparing exonic and intronic reads (Fig. S2.1), consistent with the effects 
of cGH largely being transcriptional, and as anticipated, more rapid decline in expression 
was apparent for some of the male-biased genes when monitored using intronic reads. To 
better assess changes in nascent transcription rates, we obtained ribosomal RNA-depleted 
RNA-seq data for the 10 h and 1 day cGH-treated male livers, and from sham-treated male 
and control female livers, removing the bias toward spliced RNA that polyA selection can 
introduce (Table S2.8). The cGH-induced changes in expression were strongly correlated 
between exonic and intronic read data at both time points (r = 0.82 at 10 h cGH; r = 0.76 
at 1 day cGH; Fig. 2.3A). Furthermore, the overall response patterns were very similar 
(Fig. 2.3B). Only two male-biased genes, Ces2b and Ugt2b38, showed a significant, >2-
fold difference in response between intronic and exonic reads after 10 h cGH treatment 
(Fig. 2.3C). These two male-biased genes are direct targets of STAT5, and their 
transcription is rapidly induced by each successive GH pulse in male liver (Connerney et 
al., 2017). Further, the primary transcript levels (i.e., hnRNA) of these two genes peak 




(Connerney et al., 2017). Accordingly, these male-biased genes are particularly sensitive 
to the loss of pulsatile STAT5 activity secondary to cGH infusion (Xu et al., 2012), and 
consequently, their primary transcripts, measured by intronic read counts, are expected to 
show the earlier down regulation compared to the mature RNAs (exonic sequence reads) 
seen in Fig. 2.3C. Two other STAT5 target genes that are also induced by GH pulse-
activated STAT5, Igf1 and Cish (Chia, 2014; Connerney et al., 2017), were not repressed 
by cGH infusion. Igf1 and Cish can apparently be induced by either pulsatile or persistent 
STAT5 stimulation, consistent with their being expressed at similar levels in male and 
female liver (Connerney et al., 2017). 
 
2.4.3 Time-dependent regulation by cGH-responsive transcription factors 
Next, we examined the impact of cGH infusion on all sex-biased genes that are direct 
targets of STAT5, to obtain a global view of the impact of the change from pulsatile to 
persistent liver STAT5 activity with cGH treatment. Liver STAT5 binding sites identified 
by ChIP-seq, including binding sites significantly stronger in males or in females (male-
enriched and female-enriched STAT5 binding sites, respectively) (Xu et al., 2012) were 
mapped to their putative target genes using GREAT (McLean et al., 2010) (see Methods). 
Sex-biased STAT5 binding was observed nearby 44% of all sex-biased genes, with gene 
targets of male-enriched STAT5 binding significantly enriched for male-biased genes (ES 
= 4.6, P = 2.98E-12) and gene targets of female-enriched STAT5 binding significantly 
enriched for female-biased genes (ES = 4.9, P = 2.2E-16) (Fig. 2.4A), consistent with our 




enriched STAT5 binding sites were repressed by cGH infusion, and 96% of the female-
biased gene targets of female-enriched STAT5 binding sites were induced by cGH 
infusion. Given these significant responses, we investigated whether the sex-biased STAT5 
target genes show a preferential distribution across the defined clusters of time 
responsiveness to cGH infusion (Fig. 2.1B). Male-biased genes targeted by male-biased 
STAT5 binding sites were enriched in gene cluster M2 (ES = 2.58, P = 6.06E-4), whose 
genes are significantly repressed 1 day after liver STAT5 pulsation is abolished by cGH 
infusion. Of note, 81% (18/22) of the male-biased STAT5 targets in cluster M2 are 
repressed in male liver following hypophysectomy (type-I gene response;(Connerney et 
al., 2017)), and 68% of these genes are down regulated in STAT5b-deficient male liver, as 
determined by microarray analysis (Clodfelter et al., 2006), indicating these genes are 
positively regulated by GH pulse-activated STAT5. Conversely, the genes targeted by 
female-biased STAT5 binding sites did not show significant preferential enrichment in any 
of the cGH response clusters (Fig. 2.4B, right).  
 
Two other sex-biased, GH-regulated transcription factors work together with STAT5 to 
enforce the sex-specific effects of GH in the liver. BCL6, a GH/STAT5-regulated, male-
biased transcriptional repressor, preferentially binds to and represses female-biased genes 
in male liver, in part by competing for STAT5 binding (Xu et al., 2012); and CUX2, a 
GH/STAT5-regulated female-specific repressor, both represses a subset of male-biased 
genes and activates a subset of female-biased genes in female liver (Conforto et al., 2012). 




well as Trim24, a female-biased CUX2 target gene that may in part mediate CUX2’s 
downstream effects (Conforto et al., 2012); and 2) significant down regulation of Bcl6 
(Table 2). A third female-biased transcription factor gene, Sall1, which is also a target of 
CUX2 binding (Conforto et al., 2012), was also induced at this time (Table 2).  
 
We hypothesize that the cGH-induced changes in expression seen for many sex-biased 
genes are secondary to the induction or repression of these early GH-responsive sex-biased 
transcriptional regulators. To test this hypothesis, we investigated the cGH time-
responsiveness of the gene targets of CUX2 (Conforto et al., 2012) and BCL6 (Xu et al., 
2012), as follows. 1,471 CUX2 binding sites identified in female liver (Conforto et al., 
2012) were mapped to their target genes, which were significantly enriched for both male-
biased and female-biased genes (ES = 3.2, P = 2.19E-07 and ES = 5.7, P < 2.2E-16, 
respectively) compared to sex-independent genes (Fig. 2.4C). Importantly, the male-biased 
CUX2 target genes were enriched in the gene set showing early repression by cGH (cluster 
M2; ES = 3.0, P = 0.02; Fig. 2.3D). Further, we determined that 65% of the male-biased 
CUX2 targets repressed by cGH are also repressed when Cux2 is over-expressed (Conforto 
et al., 2012) in male liver (Table S2). Thus, the early induction of Cux2 by cGH infusion 
is associated with the direct (Conforto et al., 2012) and rapid repression of male-biased 
genes. CUX2 gene targets are also enriched in the subset of late cGH-responding female-
biased genes (cluster F5; ES = 5.15, P =0.04), and 50% of these genes are induced in male 





To investigate the effects of cGH on BCL6 targets, 6,432 BCL6 binding sites previously 
identified in male liver (Zhang et al., 2012) were mapped to gene targets. These BCL6 
target genes showed strong enrichment for both male-biased and female-biased genes (ES 
= 5.8, P < 2.2E-16, and ES = 7.7, < 2.2E-16, respectively; Fig. 2.4C). Importantly, the 
female-biased BCL6 target genes are strongly enriched for early cGH-inducible genes 
(cluster F1; ES = 5.43, P = 0.004) and are depleted of late cGH-inducible genes (cluster 
F4; ES = 0.23, P = 0.0022; Fig. 2.4E), consistent with our earlier finding that BCL6 
preferentially represses female-biased genes in male liver (Zhang et al., 2012). Together, 
these findings indicate that the early induction of Cux2 and the early repression of Bcl6 by 
cGH infusion both contribute to the subsequent repression of male-biased genes and 
induction of female-biased genes in male liver. 
 
2.4.4 Continuous GH-induced epigenetic changes at sex-biased genes 
Genome-wide mapping of open chromatin sites (DHS) has shown that sex differences in 
gene expression are closely associated to sex differences in chromatin accessibility in adult 
mouse liver (Ling et al., 2010; Sugathan and Waxman, 2013). Further, cGH infusion closes 
82% of male-biased DHS and open 26% of female-biased DHS after 7 days (Ling et al., 
2010). Liver DHs that are male-biased (n=2,800), female-biased (n=1,379) and sex-
independent (n=68,682) were mapped to their target genes using GREAT and their time 
responsiveness to cGH was examined. Male-biased DHS gene targets were significantly 
enriched in male-biased genes (ES = 6.5, P < 2.2E-16) and female-biased DHS gene targets 




consistent with our earlier findings (Ling et al., 2010; Sugathan and Waxman, 2013). 
Further, 100% of the male-biased gene targets of the male-biased DHS were repressed by 
cGH infusion and 97% of the female-biased gene targets of female-biased DHS were 
induced by cGH. However, the sex-biased DHS target genes did not show enrichment 
favoring any particular cGH response cluster (data not shown).  
  
Next, we examined whether the basal chromatin state (local chromatin environment at the 
TSS and TES) in male liver impacts the time responsiveness to cGH infusion. These 
analyses used chromatin state designations that we previously developed for mouse liver 
based on DHS activity and a panel of six chromatin marks, enabling us to classify 
individual liver-expressed genes as being in an active, poised or repressed chromatin state 
(Sugathan and Waxman, 2013). High levels of DHS and activating histone marks (H3-
K27ac, H3-K4me1) characterize genes in the active chromatin state, genes in the poised 
state have both activating marks (H3-K4me1) and repressive marks (H3-K27me3) but are 
missing enhancer marks (H3-K27ac), and genes in the inactive state have high read 
densities of the repressive mark H3-K27me3. Utilizing these designations, we found that 
cGH-responsive female-biased genes already in an active chromatin state in male liver are 
enriched for early cGH responses (clusters F1+F2; ES = 4.3, P = 9.76E-04) and depleted 
from the set of late response genes (cluster F4; ES = 0.26, P = 0.02). In contrast, genes in 
an inactive chromatin state in male liver are strongly enriched for late cGH responses 
(cluster F5; ES = 10.85, P = 0.001) and depleted from the early gene response set (ES = 




state in male liver are more rapidly induced by cGH treatment. No corresponding 
chromatin state enrichments were seen for the male-biased gene clusters (data not shown). 
Overall, 38 (38%) of the 99 female-biased genes considered here are in a more active state 
in female than male liver, most commonly in a poised state in male liver and in an active 
state in female liver (Fig. 2.5C), and likely need to change to the more active chromatin 
state for cGH to induce their expression in male liver. The sex differential chromatin state 
of these 38 genes is associated with a greater sex bias in expression as compared to the 
other 61 female-biased genes, whose local chromatin state is the same in both sexes (Fig. 
2.5D). 
 
To investigate whether sex-biased genes, do, in fact, undergo a change in chromatin state 
following cGH infusion, we performed DHS analysis to identify accessible chromatin 
regions, as well as ChIP for H3-K27me3, a major sex-biased repressive mark that is found 
across gene bodies and flanking sequences of many highly female-biased genes in male 
liver but not at highly male-biased genes in female liver (Sugathan and Waxman, 2013). 
We used qPCR to assess the cGH time responsiveness of these epigenetic marks and their 
correlation to the transcriptional response for select sex-biased genes. Cux2, a highly 
female-biased gene in cluster F1, is significantly induced after 10 h of cGH infusion and is 
fully feminized after 1 day (Fig. 2.6A). Chromatin accessibility at a DHS in intron 2 of 
Cux2 increased parallel to the induction of gene expression. The male-biased pattern of 
H3-K27me3 repressive marks along the Cux2 gene body declined with cGH treatment, but 




of Cyp3a16, a highly female-biased gene in cluster F3, was significantly delayed compared 
to Cux2, first reaching full female levels after 7 days cGH infusion (Fig. 2.6B). Chromatin 
accessibility at a DHS 47 kb downstream of Cyp3a16 increased parallel to the increases in 
gene expression. In contrast, there was a significant, but partial, decrease of H3-K27me3 
along the Cyp3a16 gene body beginning after 4 days cGH infusion (Fig. 2.6B). Two other 
female-biased genes, A1bg and Cyp2b9, showed a cGH-induced decline in H3-K27me3 
marks that coincided with the observed de-repression of gene expression (Fig. 2.7A, Fig. 
2.7B). Of note, A1bg and Cyp2b9 show larger sex differences in H3-K27me3 abundance 
across the gene body than Cux2 and Cyp3a16 (Fig. S2.2).  These results are consistent with 
the expected changes in chromatin state following cGH infusion: Cyp2b9 is already in the 
poised state in male liver, such that loss of H3-K27me3-mediated repression may be 
sufficient for gene induction in cGH-treated male liver, whereas Cyp3a16 is in the inactive 
state in male liver and may require acquisition of activating marks in addition to loss of 
repressive marks for full feminization. Finally, Gstp1, a male-biased gene in cluster M3, 
showed a significant decrease in mRNA levels after a 4-day GH infusion (Fig. 2.7C). To 
better assess the impact of cGH infusion on Gstp1 transcription, we quantified the levels 
of Gstp1 hnRNA using primers that span an exon-intron junction. Gstp1 hnRNA levels 
decreased significantly after 10 h GH infusion, reaching the lower level of control female 
liver after 4 days cGH treatment. Chromatin accessibility at a DHS 13 kb downstream of 
Gstp1 decreased significantly after 10 h cGH infusion, coinciding with the apparent 





2.4.5 cGH responsiveness of liver zonated sex-biased genes  
The liver shows a zonated pattern of gene expression, which imparts to hepatocytes near 
the portal vein (periportal cells) differences in metabolic and other functions compared to 
hepatocytes near the central vein (pericentral cells) (Oinonen and Lindros, 1998; Torre et 
al., 2011). Genes showing a zonated pattern of expression in the liver (Halpern et al., 2017; 
Saito et al., 2013) might therefore have distinct sensitivities to a change in circulating GH 
patterns. We used genome-wide zonation profile data for male mouse liver (Bahar Halpern 
et al., 2017) to investigate whether differences in hormonal environment between periportal 
and pericentral hepatocytes contribute to the differential time course of cGH 
responsiveness, and/or to the partial responsiveness to cGH-induced feminization that 
characterizes some sex-biased genes. We examined zonation profiles for 229 sex-biased 
genes, 54% of which showed significant zonation in their expression (q-value <0.2); this 
proportion is comparable to the ~50% of all liver-expressed genes that show non-random 
zonation (Bahar Halpern et al., 2017). The rapid GH pulse-responsive (but sex-
independent) genes Igf1 and Cish showed significant periportal bias in expression. In 
contrast, some of the female-biased genes that were partially feminized by cGH infusion 
(clusters F4 and F5) showed strong pericentral bias (Cyp2c40, Tgtp2, Cyp3c37). To 
investigate global patterns of zonation, we compared the zonation bias of significantly 
zonated sex-biased genes (125 genes) (Fig. 2.8) to that of significantly zonated stringent 
sex-independent genes (2,678 genes). No significant difference in zonation was seen 
between the two gene sets (Wilcoxon rank-sum p=0.16). Furthermore, for sex-biased 




genes (clusters 1 + 2) and genes responding to cGH later (clusters 3-5) (Wilcoxon rank-
sum p=0.66 for female-biased and p=0.07 for male-biased genes) (Fig. 2.8). A caveat of 
this analysis is that many of the most highly female-biased genes show little or no 
expression in the male liver dataset used to define liver zonation (Bahar Halpern et al., 
2017), and were therefore necessarily excluded from this analysis. 
 
2.5 Discussion 
cGH infusion overrides the male, pulsatile pattern of plasma GH stimulation and feminizes 
liver gene expression, with female-biased genes induced and male-biased genes repressed, 
as seen in rats (Ahluwalia et al., 2004; Laz et al., 2004) and in mice (Holloway et al., 2006). 
Differences in the time responsiveness to cGH were reported for a small number of sex-
biased genes (Holloway et al., 2006; Pampori et al., 2001), but a global analysis was not 
previously carried out, and the mechanisms responsible for the temporal differences in 
responsiveness were poorly understood. Here, we used the cGH infusion mouse liver 
model to identify and characterize early, intermediate and late cGH-responding sex-biased 
genes. Early cGH responding genes identified include several GH-regulated transcription 
factors that enforce liver sex differences, most notably the female-specific repressor CUX2 
(Conforto et al., 2015; Conforto and Waxman, 2012; Conforto et al., 2012; Laz et al., 2007) 
and the male-biased repressor BCL6 (Meyer et al., 2009; Xu et al., 2012). Sex-biased 
targets of STAT5, whose temporal activation profile is directly feminized by cGH 
treatment (Xu et al., 2012), as well as sex-biased targets of these two repressors, are 




STAT5 activation and for CUX2 repression, and female cluster F1 genes are enriched for 
BCL6 repression. STAT5, CUX2 and BCL6 are thus part of a hierarchical transcriptional 
network controlling cGH-induced changes in sex-biased liver gene expression (Fig. 2.9). 
Further, the time responsiveness to cGH infusion is linked to the basal chromatin 
environment in male liver, with female-biased genes already in an active chromatin state 
in male liver enriched for early cGH responses, and genes in an inactive chromatin state 
enriched for late cGH responses (Fig. 2.10). Finally, as we illustrate for select sex-biased 
genes, corresponding time-dependent changes in sex-dependent local chromatin 
accessibility and histone modifications accompany these transcriptional responses to cGH. 
 
cGH treatment of adult male mice substantially feminizes the liver, but the time required 
for feminization showed an unexpectedly large variation between genes. The earliest 
female-biased gene responses were seen for CUX2 and certain other genes, whose 
expression in cGH-treated male liver was induced within 10 h and was fully feminized 
within 24 h of initiating cGH infusion. Many male-biased genes were also down-regulated 
over this time period, while others required 4 days for down regulation (Fig. 2.1C). In 
contrast, cGH induction of many other female-biased genes was delayed for times ranging 
from 4 to 14 days, while other female-biased genes were resistant to the feminizing effects 
cGH, even after days (e.g., Cyp2b13 and four Sult2a genes in cluster F5). In stark contrast, 
< 1% of stringent sex-independent genes showed a consistent response to cGH treatment. 
 




feminization of sex-biased genes. First, STAT5, CUX2 and BCL6 were implicated in a 
hierarchical transcriptional network that controls the time dependence of liver feminization 
(Fig. 2.9). The earliest event, in which liver STAT5 activity is feminized by its switch from 
a pulsatile to a persistent activity pattern (Xu et al., 2012), is a direct response to persistent 
GH stimulation, which overrides the male pulsatile plasma GH pattern and its pulsatile 
activation of liver nuclear STAT5 (Choi and Waxman, 2000; Tannenbaum et al., 2001). 
This loss of pulsatile STAT5 activity leads directly to the down regulation of male-biased 
genes whose transcription is dependent on intermittent STAT5 stimulation. These genes 
include Ces2b and Ugt2b38, whose transcription in adult male liver is intermittent and 
directly induced by each pulse of nuclear STAT5 activity (Connerney et al., 2017), as well 
as many other male-biased genes, whose transcriptional activation by STAT5 cannot be 
directly induced by a single pulse of STAT5 activity (Connerney et al., 2017), but 
nevertheless requires GH pulse-activated STAT5, as evidenced by their down regulation 
in STAT5 knockout mice (Clodfelter et al., 2006; Holloway et al., 2007) and following 
pituitary hormone ablation(Connerney et al., 2017). Consistent with this proposal, 48% of 
male-biased mRNAs were significantly down regulated within 1 day of cGH treatment 
(genes in clusters M1 and M2), and 78% were >80% feminized by day 4. The precise time 
required to down regulate individual male-biased RNAs likely is affected by the half-life 
of each individual mRNA.  
 
Secondary events in the hierarchical transcriptional network activated by cGH infusion 




biased genes (Zhang et al., 2012) and transcriptional activation of Cux2, a highly female-
specific transcription factor that directly represses a large fraction (~35%) of male-biased 
genes (Conforto et al., 2012). The early down regulation of Bcl6 by cGH is expected to 
contribute to the observed de-repression of many female-biased genes, while the induction 
of Cux2, which constitutes the strongest early response to cGH in our dataset (17-fold 
increase after 10 h), is expected to lead to repression of many male-biased genes. ChIP-seq 
binding studies indicate that Cux2 is a target for repression by BCL6 (Xu et al., 2012) and 
that Bcl6 is a target for repression by CUX2 (Conforto et al., 2012), highlighting the 
potential for mutual inhibitory cross-talk between these two transcriptional repressors. 
CUX2 also induces ~35% of female-biased genes by an indirect mechanism, one that does 
not involve direct binding by CUX2 but is proposed to be mediated by the female-biased 
factor TRIM24 (Laz et al., 2007) (Fig. 2.9). Trim24 itself is a direct target of CUX2 
(Conforto et al., 2012) and was induced by cGH infusion soon after Cux2. CUX2 also 
directly binds to and induces certain highly female-biased genes (Conforto et al., 2012), 
which we show here are significantly enriched in the late cGH-responding gene cluster F5. 
Cux2 induction (which occurs early) is thus not a determinant of the unusually slow 
feminization of cluster F5 genes. Taken together, these findings support a multistep 
hierarchical network, whereby early repression of a male-biased repressor of female-biased 
genes (Bcl6) and early induction of a female-biased activator of female-biased genes and 
repressor of male-biased genes (Cux2) contribute to the feminization of many downstream 





We identified SALL1 as a female-biased transcriptional regulator (Table 2) and CUX2 
target (Conforto and Waxman, 2012; Conforto et al., 2012) that may also contribute to 
transcriptional responses downstream of CUX2 (Fig. 2.9). Notably, SALL1 is a 
transcriptional repressor that interacts with the nucleosome remodeling and deacetylase 
complex NuRD (Karantzali et al., 2011) and could contribute to CUX2 repression of male-
biased genes in female liver. Similar to Trim24, Sall1 is a direct target of CUX2 binding, 
is down-regulated following Cux2 knockdown in female liver (Conforto et al., 2012), and 
acquires its female specificity in mouse liver at 4 weeks postnatal age, i.e., prior to most 
sex-biased genes (Conforto and Waxman, 2012). Further study is needed to determine the 
precise role of SALL1 in the transcriptional hierarchy controlling sex-biased liver gene 
expression.  
 
A second, complementary mechanism that impacts the time course for cGH feminization 
of male liver relates to the sex-specific effects of GH on liver chromatin states. The liver 
epigenome is characterized by extensive GH-dependent sex-differences in open chromatin 
regions (DHS) (Ling et al., 2010) and their chromatin states, as well as sex differences in 
local chromatin marks at a subset of sex-biased genes (Sugathan and Waxman, 2013). We 
found that female-biased genes already in an active chromatin state tend to be more rapidly 
induced by cGH than genes whose induction requires extensive chromatin remodeling (Fig. 
2.10). Examples of the changes in chromatin states induced by cGH infusion were provided 
by our examination of changes in sex-biased DHS and repressive chromatin marks 




of male-biased open chromatin proximal to the male-biased Gstp1 that parallels its 
repression, and cGH induced chromatin opening and a loss of a key repressive mark (H3-
K27me3) with the induction of several female-biased genes. The mechanism whereby 
these epigenetic changes are induced by the switch from a male to female plasma GH 
profile is unknown, but is expected to be complex. Factors likely contributing to the 
changes in chromatin accessibility and chromatin states induced by cGH infusion include 
hormone-responsive chromatin remodeling enzymes (Grontved et al., 2015; Nacht et al., 
2017) and GH-regulated epigenetic regulators, including sex-biased long non-coding 
RNAs (Melia et al., 2016), working in combination with the GH-responsive transcriptional 
activators and repressors discussed above.  
 
While a large majority of sex-biased genes were fully feminized by cGH infusion, many 
genes were only partially feminized, even after 14 days cGH treatment. Examples include 
several highly female-specific Sult and Cyp genes (Fig. 2.1A). In contrast, cGH infusion 
of hypophysectomized or pituitary GH secretion-deficient (little) female mice is sufficient 
to fully recapitulate female-biased expression of some of the same sulfotransferase 
(Sult2a1, Sult2a2) genes (Alnouti and Klaassen, 2011). The partial feminization seen here, 
where cGH was infused in intact male mice, suggests intact male liver may be intrinsically 
less responsive to cGH than intact female mouse liver. Consistent with this proposal, male 
and female livers show intrinsic differences in responsiveness when plasma GH pulses are 
given to hypophysectomized mice(Wauthier et al., 2010), and primary female rat 




(Thangavel et al., 2004). In the rat model, pulsatile GH exposure of male liver during the 
early postnatal period apparently programs the male liver for GH pulse responsiveness later 
in life, and this is required for full adult expression of sex-biased genes (Das et al., 2017). 
Accordingly, cGH infusion in adult male mice, as in the present study, may not be sufficient 
to abolish the imprinting effects of neonatal GH pulse exposure, and consequently, cGH 
exposure of adult males may not fully reverse the male chromatin state. Supporting this 
idea, male mice with a knockout of Somatostatin, which feminizes plasma GH profiles by 
abolishing the hormone-free trough period between plasma GH pulses, induces Sult genes 
to the level of the intact female (Adams et al., 2015). Presumably, Somatostatin deficiency 
during early male development is sufficient to abolish any programming effect of neonatal 
GH pulse exposure, and thus eliminates any intrinsic sex difference in the liver’s 
responsiveness to the female plasma GH profile. Further study is needed to determine the 
role of these, presumably epigenetic mechanisms in cGH responses. 
 
GH regulates gene expression primarily at the level of transcription initiation, as evidenced 
by run-on transcription assays and by the analysis of hnRNA for several individual genes 
(Connerney et al., 2017; Sundseth et al., 1992). Our global analysis of cGH-responsive 
genes using RNA-seq intronic reads provides further evidence for transcriptional 
regulation of liver sex differences by GH, as the nascent transcripts represented by these 
intronic reads (Gaidatzis et al., 2015; Madsen et al., 2015) showed cGH response patterns 
indistinguishable in many cases from those of mature mRNAs. Two early cGH-responding 




regulation responses at the intronic read (primary transcript) level (Fig. 2.3C). 
Transcription of these genes responds rapidly and dynamically to endogenous GH pulses 
(Connerney et al., 2017), and consequently, these male-biased genes are expected to be 
uniquely sensitive to the loss of pulsatile STAT5 activation secondary to cGH infusion.  
 
Hepatocytes near the portal vein show substantial differences in metabolic and other 
functions as compared to hepatocytes near the central vein (Oinonen and Lindros, 1998; 
Torre et al., 2011), and may be exposed to different concentrations of GH (Oinonen and 
Lindros, 1998). Indeed, many Cyp genes show a pericentral bias in expression that can be 
regulated by GH, with liver zonation abolished for a subset of rat Cyp genes by 
hypophysectomy and restored by cGH infusion (Oinonen and Lindros, 1998; Oinonen et 
al., 2000). We used liver zonation profiles recently reported (Bahar Halpern et al., 2017) 
to examine whether genes showing a zonated pattern of expression (Halpern et al., 2017; 
Saito et al., 2013) show different kinetics of response to cGH, or show a difference in 
sensitivity to a change in circulating GH that may account for the partial feminization of 
some sex-biased genes by cGH. However, although half of the 229 sex-biased genes we 
examined showed significant differential zonated distribution of expression between 
periportal and pericentral hepatocytes (Fig. 2.8), we saw no significant differences in 
zonation bias between early and late cGH-responding genes. 
 
cGH infusion alters the expression of several genes involved in hepatocellular carcinoma 




suppressor for hepatocellular carcinoma (Herquel et al., 2011b) that is induced by cGH 
within 10 h, and Nox4, a cGH-repressed male-biased gene involved in liver oxidative stress 
and stellate cell activation (Lan et al., 2015). Further studies are required to elucidate the 
responses of cGH-responsive distal regulatory elements and their interactions with 
proximal promoters and regulatory elements centered at sex-biased genes.  
 
The present model of cGH infusion in adult male mice uses a cGH dose and regimen that 
produces normal female physiological plasma GH levels in a rat model (Waxman et al., 
1991) and overrides the male, pulsatile pattern of mouse liver STAT5 activation (Xu et al., 
2012). The persistence of plasma GH achieved in these studies is markedly different from 
the pathological states of elevated GH exposure that accompany GH resistance and 
acromegaly, where circulating GH levels are elevated but in contrast to the cGH infusion 
model, plasma GH pulsatility is retained (Roelfsema et al., 2014). Importantly, whereas 
Igf1 production shows major dysregulation in both GH resistance (IGF1 suppression) and 
acromegaly (IGF1 induction), cGH treatment did not significantly alter liver Igf1 
expression, consistent with the similar levels of liver IGF1 production between the sexes 
and with cGH infusion being a physiological, and not pathophysiological model. 
 
In conclusion, the time-dependent patterns of repression of male-biased genes and de-
repression of female biased genes by cGH infusion are dictated by hierarchical 




These networks and their associated epigenetic control mechanisms are likely to impact 





Figure 2.1. cGH responsive genes in male liver.  
(A) MA plot showing the log2 sex ratio compared to gene expression level, in log2 FPKM 
units, for 983 sex-biased genes (EdgeR padj <0.01, FPKM>1). Genes are colored based on 
the maximum percent feminization after cGH infusion (Red dots, > 80% feminization; 
Green dots, 20-80% feminization; Black dots, significant induction but <20% feminization; 
Grey dots, no response). (B) Hierarchical clustering was applied to 213 cGH-responsive 
sex-biased genes based on the feminization values at each time-point. Heatmaps showing 
120 female-biased genes (≥ 2-fold sex bias) in 5 clusters (F1-F5) and 93 male-biased genes 
(≥ 2-fold sex bias) in 5 clusters (M1-M5). For female-biased genes, the female gene 
feminization level is set to 1, and for male-biased genes the male gene feminization level 
is set to 0. (C, D) Gene expression log2 sex ratios for cGH responsive, female-biased (C), 
and male-biased genes (D), for each of the cGH response clusters. Significance values by 
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Table 2.1. Hierarchical clustering of sex-biased genes  
Hierarchical clustering of cGH responsive sex-biased genes identified five clusters of male-
biased genes (M1-M5) and five clusters of female-biased genes (F1-F5).  
  
Male biased genes 
Male  
Cluster 
Mean feminization of cluster (%) 
# Genes Examples 
10 hours 1 day 4 days 7 days 14 days 
M1 61 88 100 100 100 15 Cyp7b1, Elovl3, Mup16 
M2 6 60 100 98 100 39 Nox4, Ugt2b38, Cyp4a12 
M3 40 41 100 100 100 19 Mup20, Gstp1, Selenbp2 
M4 0 0 90 89 100 13 Mup14, Mup17, Alas2 
M5 0 0 65 60 79 7 Serpina1d, Slc17a8, Dpy19l3 
No response         10 Mir293, Gm4841, Gm4956 
         103  
Female biased genes 
Female 
Cluster 
Mean feminization of cluster (%) 
# Genes Examples 
10 hours 1 day 4 days 7 days 14 days 
F1 39 >100 >100 >100 >100 26 Trim24, Sall1, Cux2 
F2 13 22 >100 >100 >100 37 Cyp2a4, Cyp2b9, Pnpla3 
F3 8 14 35 82 >100 18 Cyp3a16, Ugt2b37, Acot2 
F4 8 9 26 30 64 26 Fmo3, Sult3a1, Tox 
F5 3 0 3 2 14 13 Sult2a1, Sult2a5, Cyp2b13 
No response         12 Ankrd55, Raet1e, Xist 
            132   
Table 1. Hierarchical clustering of sex-biased genes Hierarchical clustering of cGH 
responsive sex-biased genes identified five clusters of Male-biased genes (M1-M5) and five 




Figure 2.2 qPCR expression of cGH responsive sex-biased genes.  
RT-qPCR analysis of total liver RNA using gene specific mRNA primers for the indicated 
sex-biased genes in gene clusters F1, F2 and F4 (A) and in gene clusters M1, M2 and M3 
(B) identified in Fig. 2.1B. Data shown are mean ± SEM values based on n = 6-10 livers 
per group. Significance values by ANOVA are indicated in each figure as follows: *P, 
0.05; **P, 0.01; ***P, 0.001. The symbol ^ indicates that statistical significance was 
reached only by t test and not ANOVA, at ^P , 0.05, ^^P , 0.01, and ^^^P , 0.001. Primers 
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Figure 2.3 Analysis of intronic reads from rRNA-depleted RNA-seq.  
(A) Pearson correlation of exonic read to intronic read ratios after 10 h and 1 day cGH 
infusion. Analysis is based on the set of 226 genes with >2-fold sex-bias and having 
sufficient intronic reads per transcript for reliable quantification. (B) Heatmap of the 
relative expression values at each time point comparing intronic and exonic read counts, 
scaled based on maximum FPKM value for each gene. (C) Ces2b and Ugt2b38 show a >2-
fold difference in fold change in primary transcript levels. Data are based on intronic and 
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Figure 2.4 Regulation by sex-biased transcription factors.  
(A) Male-enriched (1,765 sites), female-enriched (1,790 sites) and sex-independent 
(11,531) STAT5 binding sites were mapped to their target genes using GREAT. 
Enrichment for male-biased (blue) and female-biased (red) gene targets was computed 
compared to a set of 7,225 stringent sex independent genes. (B) Enrichment of the male-
biased target genes of male-enriched STAT5 binding sites in each of the cGH-responsive 
male gene clusters (M1 to M5), and enrichment of female-biased target genes of the 
female-enriched STAT5 binding sites in each of the cGH-responsive female gene clusters 
(F1 to F5). (C) CUX2 and BCL6 binding sites (1,471 and 6,432 respectively) were mapped 
to their target genes and enrichment for both male-biased and female-biased genes was 
computed compared to stringent sex-independent genes. (D) CUX2 female-biased and 
male-biased gene target enrichment in each cGH response clusters, as described in B. (E) 
BCL6 female-biased and male-biased gene target enrichment in each cGH response cluster, 
as described in B. The enrichment of STAT5, CUX2, and BCL6 targets for being enriched 
in each of the gene sets examined was compared to that of all cGH-responsive genes. 
Significant enrichment or depletion by Fisher’s exact test is indicated by black or red 
asterisks, respectively, and by *, P< 0.05; **, P<0.01; and ***, P<0.001. Similar results 
were obtained for STAT5 and BCL6 target enrichment when the target genes of each factor 
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CUX2/BCL6 ChIP-seq peaks - Enrichment for sex biased genes 
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Table 2.2. Sex-biased transcriptional regulators  
Shown are four sex-biased transcriptional regulators that are significantly induced or 
repressed by 1 day of cGH infusion. Onset of sex specificity in weeks according to 
(Conforto and Waxman, 2012), response to Cux2 Knockdown or over-expression 
according to (Conforto et al., 2012) and response to hypophysectomy (hypox) according to 
(Connerney et al., 2017)  
  
Gene Sex specificity M/F ratio  
 Feminization 










Bcl6 Male -1.9 94 4 wk *   (1.5 fold) up Up Down 
Sall1 Female -2.9 187 4 wk Down Down No change 
Trim24 Female -3.3 141 4 wk Down Down Up 
Cux2 Female -30.3 100 4 wk Down Down Up 
Table 2. Sex biased transcriptional regulators Shown are four sex-biased transcriptional 
regulators that are significantly induced or repressed by 1 day of cGH infusion. Onset of sex 
specificity in weeks according to (57), Response to Cux2 knockdown or over-expression 




Figure 2.5   Epigenetic regulation of cGH-responsive sex-biased genes.  
(A) Male-biased (n=2,800), female-biased (n=1,379) and sex-independent liver DHS 
(n=68,682) were mapped to their target genes using GREAT. DHS target enrichment for 
male-biased and female-biased genes was calculated compared to stringent sex-
independent genes. (B) Female-biased grouped by their chromatin state in male liver as 
described in the text. The enrichment of genes in active, poised or inactive chromatin states 
(as defined by (Sugathan and Waxman, 2013)for being early (Clusters F1 and F2), 
intermediate (Cluster F3) or late responding to cGH (Clusters F4 and F5) was tested 
compared to all cGH-responsive female-biased genes. Significant enrichment or depletion 
by Fisher’s exact test is indicated by black or red asterisks, respectively: *, P< 0.05; **, 
P<0.01; ***, P<0.001. (C) Proportion of female specific genes that are in a different local 
chromatin state in male compared to female liver. (D) Genes that are in a different 
chromatin state in male vs. female liver, are in a more active state in female liver and show 
greater female specificity, as shown in the boxplot of the distribution of female specificity 
(Log2 M/F expression) for female-biased genes in the same chromatin state in male and 
female liver (61 genes) and those in a different chromatin state (38 genes). Significance by 
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Figure 2.6 Effects of cGH infusion on expression, chromatin accessibility, and H3-
K27me3 marks for the female-biased genes Cux2 (A) and Cyp3a16 (B).  
Shown at top are RNA-seq analysis of liver total RNA isolated from intact female and 
sham-treated males and from male mice infused with cGH for 10 h, or for 1, 4, 7 or 14 
days. Gene expression data are expressed as FPKM. Shown in the middle are qPCR 
analysis of genomic DNA fragments released from DNase I–digested liver nuclei isolated 
from individual mice from the same treatment groups shown in the top panel. qPCR was 
carried out using primers that target a female-biased open chromatin region nearby Cux2. 
or Cyp3a16. DHS qPCR data were normalized to a DHS site nearby Tram2. Shown at the 
bottom are qPCR analysis of genomic DNA fragments immunoprecipitated with anti-
H3K37me3 from individual mice from the same treatment groups shown the top and 
middle panels. Data were normalized to a H3K27me3-enriched site at the Hoxb gene 
region. Data shown are mean ± SEM values based on n = 6-10 livers per group. 
Significance values by ANOVA are indicated in each figure as follows: *, P, 0.05; **, P, 
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Figure 2.7 Effects of cGH infusion on chromatin accessibility and H3-K27me3 
Effects of cGH infusion on expression and chromatin accessibility or H3-K27me3 marks, 
as indicated, for the female-biased genes A1bg (A) and Cyp2b9 (B), and for the male-biased 
gene Gstp1 (C).  Gene expression, H3-K27me3, and DHS data were obtained for the same 
samples as described in Fig. 2.6. (C) also compares Gstp1 expression measured by RT-
qPCR analysis using primers designed to specifically amplify either mature, spliced mRNA 
(top) or the primary unspliced transcript (middle). DHS data normalization and significance 
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Figure 2.8 Liver zonation and response to cGH infusion.  
Shown are heatmaps of the relative gene expression values in each liver zone, numbered 
from the central vein (PC, pericentral) to the portal tract (PP, periportal) according to 
(Bahar Halpern et al., 2017). Shown are separate heatmaps for cGH responsive male-biased 
and female-biased genes that show significant spatial zonation (q <0.2) as defined in (Bahar 
Halpern et al., 2017). (A) Female-biased genes, Early responding (clusters F1 and F2) 
compared to Not early responding (Clusters F3-F5). (B) Male-biased genes, Early 
responding (clusters M1 and M2) compared to Not early responding (Clusters M3-M5). 
Yellow, high expression; Blue, low expression. Genes are sorted by the PC/PP ratio 
(average of layers 1-3/average of layers 7-9). Statistical significance was determined by 
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Figure 2.9 The role of GH-regulated transcription factors in the hierarchical 
regulation of se-biased genes  
Model for role of GH-regulated transcription factors STAT5, BCL6 and CUX2 in 
hierarchical regulation of sex-biased genes. In untreated male liver (left), STAT5 is 
intermittently activated by plasma GH pulses, which enables STAT5 to activate many 
male-biased genes in male mouse liver, including the male-biased repressor BCL6. BCL6 
represses many female biased genes, including the female-specific repressor CUX2. Cux2 
expression is de-repressed in STAT5-deficient male liver, indicating GH pulse-activated 
STAT5 has a role (either direct or indirect) in the repression of CUX2 expression in male 
liver. The absence of CUX2 in male liver is permissive for expression of many male biased 
genes (dashed arrow). cGH infusion abolishes the intermittent activity of STAT5, which 
leads to early down regulation of BCL6, followed by early de-repression of many female-
biased targets of BCL6, including Cux2. The expression of CUX2 in cGH-treated male 
liver, in turn, represses many male-biased genes and both directly and indirectly induces 
other female-biased genes. The indirect stimulatory effects of CUX2 on many female-
biased genes are proposed to be mediated by the transcription factors TRIM24 and/or 






























Figure 2.10 Model for the impact of chromatin state in male liver on time 
responsiveness of female-biased genes to cGH infusion.  
Female-biased genes that are already in an active chromatin state in male liver are enriched 
for early responses to cGH (genes in clusters F1 and F2), whereas genes in an inactive state 
in male liver are enriched for late responses to cGH (cluster F5 genes). Female-biased 
genes in a poised chromatin state in male liver showed varied cGH time responsiveness 
(Fig. 2.5B); these genes are most commonly in an active chromatin state in female liver, 
and are therefore presumed to transition from a poised to an active chromatin state in 
response to cGH infusion. cGH induction of female-biased genes is proposed to involve 
opening of distal DHS and loss of repressive chromatin marks, as shown for several 
individual female-biased genes in Fig. 2.6 and Fig. 2.7. cGH induction likely also involves 
acquisition of activating marks. cGH repression of male-biased genes is proposed to 





























Figure S2.1. Analysis of intronic sequence reads from PolyA+ selected RNA-seq 
(A)Percentage of intronic reads in PolyA+ RNA-seq compared to Total (rRNA depleted) 
RNA-seq. Shown are the values for the same Male and Female liver samples. (B) Heatmaps 
showing the Log2 ratios of the expression values for the control females and the cGH 
treated males at each time point over the expression values of the sham-treated males, 
obtained from exonic and intronic read counts from PolyA+ RNA-seq for the 113 male-

















































































































Figure S2.2. H3K27me3 abundance on female-biased genes  
UCSC genome browser screenshots from K27me3 ChIP-seq data for male and female 
mouse liver (29) on the following female-biased genes (A) Cux2, (B) Cyp3a16, (C) A1bg 
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CHAPTER 3- Genome-wide characterization of histone modification changes in 
livers of male mice treated with continuous growth hormone 
 
3.1 Abstract 
The sex-specific patterns of growth hormone (GH) secretion; pulsatile in males, continuous 
in females, regulate the expression of hundreds of sex-biased genes in mammalian liver.  
Infusion of male mice with the female-like continuous GH pattern (cGH), feminizes liver 
gene expression. Previous studies demonstrated for a few highly sex-biased genes, that 
changes in gene expression in cGH-treated male mouse livers are associated with changes 
in chromatin accessibility and histone modifications. Here, we used DNase-I digestion and 
chromatin immunoprecipitation followed by high throughput sequencing to discover, 
genome-wide, epigenetic changes associated with the feminization of liver gene expression 
in response to continuous GH infusion. We identified time-dependent changes in chromatin 
accessibility and enhancer-associated histone modifications that preceded or coincided 
with the changes in gene expression. Differential DHS analysis identified large numbers 
of continuous GH-responsive regulatory sites: induced DHS were strongly enriched for 
being near female-biased genes, and repressed DHS were strongly enriched nearby male-
biased genes, indicating their functional roles in sex-biased gene regulation. Transcription 
factor binding enriched at both early- and late-responding DHS identified transcriptional 
regulators that are proposed to contribute to the temporal changes in sex-specific gene 
expression induced by continuous GH treatment. Thus, overriding the endogenous pulsatile 
male GH pattern by continuous GH infusion results in time-dependent epigenomic changes 




3.2 Introduction  
The sex-specific patterns of growth hormone (GH) secretion; pulsatile in males, continuous 
in females, regulate the expression of hundreds of sex-biased genes in mammalian liver.  
Infusion of male mice with the female-like continuous GH pattern (cGH), feminizes liver 
gene expression (Holloway et al., 2006; Lau-Corona et al., 2017).  In Chapter 2, we 
demonstrated that cGH infusion induces female-biased genes and represses male-biased 
genes in distinct time-dependent waves. These time-dependent changes in gene expression 
are determined by the underlying chromatin environment; female-biased genes already in 
an active chromatin state tend to be induced earlier by cGH than genes in inactive states 
and whose induction may require extensive chromatin remodeling (Lau-Corona et al., 
2017).  For a subset of highly female-biased genes, changes in gene expression were, in 
fact, accompanied by changes in chromatin accessibility as demonstrated by interrogating 
DNase Hypersensitive Sites (DHS) proximal to the genes by qPCR. Additionally, H3-
K27me3 at female-biased genes significantly decreased in response to cGH. These results 
showed an unexpectedly significant variation between genes in the time required to be 
induced or repressed by cGH, and in the responsiveness of the associated regulatory 
elements. Thus, the relationship between the time responsiveness of a given sex-biased 
gene and the response of its nearby and distal regulatory elements has yet to be established.  
DNase-I digestion of nuclei followed by parallel sequencing (DNase-Seq) in combination 
with chromatin immunoprecipitation and sequencing (ChIP-seq) for different histone 
modifications has been used to identify functional cis-regulatory elements genome-wide 




elements including enhancers, which can be identified as regions of open chromatin 
flanked by histones with post-translational modifications of histone H3 by lysine 4 mono-
methylation (H3-K4me1) and by lysine 27 acetylation (H3-K27ac) (Shlyueva et al., 2014).  
Enhancers are classified as active, poised or latent, based on the presence or absence of 
H3K27ac (Ostuni et al., 2013). Enhancers are cell-specific and dynamic, thus, providing a 
unique cis-regulatory environment in which transcription factors can function to modify 
gene expression (Rada-Iglesias et al., 2011; Thurman et al., 2012).  
In mouse liver, genome-wide DHS and chromatin mark data has been used to identify sex 
differences in GH-regulated chromatin states. Sex differences in chromatin environment 
were seen at male-biased and female-biased DHS. The most highly sex-biased genes are 
enriched for association with sex-biased DHS having a sex-biased H3K27ac (Sugathan and 
Waxman, 2013). Further, sex-biased DHS that have sex-biased enhancer marks are highly 
enriched for being GH responsive (Ling et al., 2010; Sugathan and Waxman, 2013). The 
vast majority of transcription factors binding sites are found at DHS  (Ling et al., 2010; 
Thurman et al., 2012; Yue et al., 2014). Moreover, sex-biased STAT5 binding correlates 
with open chromatin and the presence of activating histone marks, and inversely correlates 
with the presence of repressive marks (Zhang et al., 2012). 
Sex-biased epigenetic mechanisms play an essential role in the GH dependent regulation 
of sex-biased gene expression in the liver, however the mechanisms by which these states 
are established and maintained by GH is not fully understood. For a subset of highly sex-




chromatin accessibility and histone modification, however, the relationship between the 
time-responsiveness of the sites and the time-responsiveness of the genes has yet to be 
determined.  
Here, we used genome-wide DHS mapping and chromatin immunoprecipitation for H3-
K27me3 and the enhancer-associated marks, H3-K4me1 and H3-K27ac, to globally 
analyze the epigenetic changes that result in feminization of liver gene expression in male 
mice infused with GH continuously. We found that induction of female-biased genes is 
associated with chromatin opening, activation of enhancers, and loss of H3-K27me3 
marks. Thus, the epigenetic landscape responds to a change from male to female plasma 
GH stimulation in distinct time-dependent waves that help to explain the time-dependent 
hierarchical responses of sex-biased gene expression.  
 
3.3 Materials and Methods 
3.3.1 Animal Treatments Adult male mice were housed and treated as outlined in Chapter 
2 and reported in (Lau-Corona et al., 2017). Alzet osmotic pumps filled with recombinant 
rat GH were implanted subcutaneously under ketamine and xylazine anesthesia. GH was 
infused at a rate of 25 ng/g body weight/h for periods ranging from 10 h to 14 d.  Untreated 
female and sham-treated male mice (i.e., Alzet pumps filled with buffer) were used as 
controls. Mice were euthanized by cervical dislocation. All animal procedures were 
approved by the Boston University Institutional Animal Care and Use Committee. 
3.3.2 Nuclear extraction and chromatin cross-linking. Fresh liver tissue was excised from 




2 and (Lau-Corona et al., 2017). The pelleted nuclei obtained from ~30-35% of the liver 
homogenate were used for DNase hypersensitivity analysis. The pelleted nuclei from the 
remaining two thirds of each liver were cross-linked and re-suspended in 1 ml of 1X RIPA 
buffer containing 0.5% SDS and complete protease inhibitor cocktail. Samples were 
sonicated in a Branson 250D Sonifier (35% amplitude for 15 s ON and 45 s OFF, for 30 
cycles) or using a Diagenode Bioruptor UCD-400 Twin for 75-80 cycles (30 s ON and 30 
s OFF, high intensity). A 15 μl aliquot of the sonicated chromatin was reverse cross-linked, 
treated with RNase A and proteinase K, and electrophoresed on a 1% agarose gel to size 
the fragments. The majority of DNA fragments ranged from 100 to 300 bp. The remaining 
sonicated chromatin was snap-frozen in liquid nitrogen and stored at -80°C until further 
use for chromatin immunoprecipitation (Further details are provided in Chapter 2 and in 
(Lau-Corona et al., 2017). 
 
3.3.3 Chromatin immunoprecipitation (ChIP). ChIP was carried out using the following 
ChIP-validated antibodies: H3K27ac (Abcam Cat # ab4729, 3 μg antibody per 15 μg of 
sonicated chromatin), H3K4me1 (Abcam Cat # ab8895, 1.2 μg antibody per 15 μg of 
sonicated chromatin), H3K27me3 (Abcam Cat # ab6002, 2 μg antibody per 10 μg of 
sonicated chromatin), and normal rabbit IgG (Santa Cruz, Cat # sc-2027, 3 μg antibody per 
15 μg of sonicated chromatin). All steps were performed at 4°C unless indicated otherwise. 
10-15 ul of Protein A-Dynabeads (Invitrogen #1002D) were preincubated for 3 hours with 
the antibodies diluted in PBS containing 0.5% bovine serum albumin (BSA). The antibody-




Sonicated cross-linked chromatin resuspended in RIPA buffer containing 0.5% SDS was 
diluted with RIPA buffer containing complete protease inhibitor cocktail (1 tablet/25 ml, 
Sigma-Aldrich Cat. # 11697498001) to reduce the final SDS concentration to 0.1%. Two 
50-ul aliquots were removed from each sample and set aside as input controls. The diluted 
chromatin was added to the tubes containing the bead pre-incubated with the antibodies and 
incubated overnight at 4°C rotating on a HulaMixer, (Invitrogen). The samples were 
centrifuged (2000 rpm 2 min at 4°C) and the supernatant was aspirated. The beads were 
washed twice with RIPA buffer containing 0.1% SDS, three times with RIPA buffer 
containing 0.1% SDS and 0.5 M NaCl, and once with TE buffer. The Dynabeads were 
incubated in elution buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% SDS) for 35 min 
at 65°C with periodic vortexing. The supernatants were collected and incubated for 6 hours 
at 65°C in the presence of 0.2 M NaCl to reverse cross-linking, followed by successive 
treatments with 0.12 mg/ml RNaseA (Novagen, Gibbstown, NJ) for 30 min at 37°C and 
0.39 mg/ml proteinase K for 2 hours at 56°C. DNA purification was performed with a 
QIAquick gel extraction kit (Qiagen #28706) using the manufacturer’s protocol. Input 
control samples were reverse crosslinked, and treated with RNase and proteinase K,  
extracted with phenol-chloroform-isoamyl alcohol and precipitated overnight at -20°C with 
ethanol in the presence of glycogen (Ambion, Austin, TX). The pellets were washed with 
95% ethanol, dissolved in 50 ul of water, and stored at -20°C. For qPCR analysis, the input 
samples were diluted 50-fold in water. ChIP DNA was quantified using a Quant-iT 
PicoGreen assay kit (Invitrogen) and analyzed by quantitative PCR (qPCR) to interrogate 




generally based on published ChIP-seq data (Sugathan and Waxman, 2013).  
 
3.3.4 DNase hypersensitivity assay DNase I digestion of liver nuclei (Ling et al., 2010) was 
performed as previously described in chapter 2 and(Connerney et al., 2017). Briefly, liver 
nuclei were incubated with RNase-free DNase I (1 U/μl; Promega) for 2 min at 37°C. 
Samples were extracted with phenol/chloroform and then loaded on a sucrose gradient and 
ultra-centrifuged. Individual fractions were collected and analyzed on a SYBR green-
stained agarose gel to determine the fragment size distribution. Fractions enriched in DNA 
fragments between 100 bp and 1 kb in size (median size 300 bp) were pooled. Fragments 
125-400 bp long were isolated using a dual SPRI size selection with Agencourt AMPure 
XP beads (Beckman Coulter, Cat# A63881). DNA was quantified using a Quant-iT 
PicoGreen assay kit (Invitrogen) and qualified by qPCR using primers that amplify 
genomic sequences previously identified as liver DHS (Ling et al., 2010).3 
 
3.3.5 DNAse-seq and ChIP-seq library preparation and sequencing For ChIP-seq, two to 
three sequencing libraries per treatment group composed of 2-5 individual samples each 
(Details on Supplemental Table 1), were prepared from 5-100 ng of immunoprecipitated 
DNA. To improve the yield, samples were size selected using the Agencourt AMPure XP 
system (Beckman Coulter, catalog no. A63880) prior to library preparation.  Sequencing 
libraries were prepared using NEBNext Ultra DNA Library Prep Kit for Illumina (NEB, 
catalog no. E7370) according to the manufacturer’s instructions. NEBNext Multiplex 
																																																								




Oligos for Illumina (NEB, Set 1; catalog no. E7335, NEB, Set 2; catalog no. E7500) were 
used for multiplexing. The Agencourt AMPure XP system was used for sample and library 
purification. For H3K27ac ChIP samples, sequencing was carried out on an Illumina 
HiSeq2000 instrument at the MIT BioMicro Center (Cambridge, MA) generating 40 or 45 
single-end reads. Sequencing of the H3K27me3 and H3K4me1 ChIP samples was carried 
out on an Illumina HiSeq2500 instrument at the New York Genome Center (New York, 
NY), generating 50-nucleotide paired-end sequence reads.  For DNase-seq two to three 
sequencing libraries per treatment group (details are in Supplemental Table 1) were 
prepared using the SPRIworks automated system (Beckman Coulter) with Illumina 
adaptors and sequenced on an Illumina HiSeq2000 instrument at the MIT BioMicro Center 
(Cambridge, MA) generating 50 or 51 single-end reads. 
 
3.3.6 Sequencing analysis  
ChIP-seq and DNase-seq analysis was performed using a custom pipeline developed in the 
Waxman Lab starting from FASTQ files (Lodato, 2018). Sequence reads were mapped to 
the mm9 mouse genome assembly, using Bowtie 2 (version 2.3.2) (Langmead and 
Salzberg, 2012) with default parameters. Uniquely mapped reads were used for subsequent 
analyses and were further filtered using a mapping quality cutoff of q>30.  
 
3.3.6.1 Identification of differential H3-K27me3 sites H3K27me3 regions were identified 
using SICER (version 1.1, window size 400 bp and gap size 2400 bp) (Xu et al., 2014). 




a chromatin mark showed a significant difference in intensity between groups that differ in 
sex or genotype (‘differential sites’). These analyses were based on pairwise comparisons 
of each of the time-points (10h, 1d, 4d, 7d, 14d) to sham-treated males. Similarly, control 
females were compared to the sham-treated males. Differential windows were discovered 
using the nsd broad option of diffReps using each of these three window sizes: 1 kb, 5 kb, 
and 10 kb, where the step size was set to 1/10 of the window size. The default statistical 
testing parameters were used (negative binomial test with a p-value cutoff of < 0.0001 for 
significant windows). H3K27me3 differential windows discovered with two or more of the 
window size settings were consolidated and assigned the ID and information for the largest 
window size setting and retained; differential windows that were uniquely discovered by 
any of the window size settings were also retained. 
 
3.3.6.2 Identification of differential DHS and H3K27ac and H3K4me1 peaks 
 H3K4me1 peaks were discovered in males, females and cGH treated males from 5 
different time-points (10 h, 1,4,7 and 14 days) using MACS2 (version 2.1.1) (Zhang et al., 
2008) with default parameters. Regions of DNase hypersensitivity (DHS) were discovered 
in male, female and cGH treated males from 4 time-points (10h, 1, 4 and 7 days). Peaks 
were identified by MACS2 (v2.1.0.20150731) (Zhang et al. 2008) run using options (--
nomodel --shift -100 -- extsize 200) to inhibit read shifting, and options (--keep-dup) to 
retain all reads that contribute to a peak signal. Peaks were discovered on all samples as 
well as on pools of biological replicates. A pool of Input controls from multiple 




option -p 0.1) was applied to include noisy peaks in the list, as required for downstream 
analysis of the irreproducible discovery rate (IDR) (Li Q., 2011). The reproducibility of 
replicates was assessed using the IDR framework applied to individual replicates and 
pseudo-replicates as described in the ENCODE guidelines (Landt et al., 2012) using a 
script available for IDR2. Reproducible peaks were identified as the subset of peaks 
discovered using MACS2 when applied to pooled biological replicates followed by 
filtering to retain peaks that meet an IDR cutoff of 0.05 for DHS samples, and an IDR 
cutoff of 0.02 for histone marks. The cutoff for DHS was relaxed to increase the number 
of peaks since a previous study (Sugathan and Waxman, 2013) yielded many more good 
quality peaks. Given that the relaxed p-value cutoff supplied to MACS2 resulted in wider 
peaks than those obtained with default parameters, the set of reproducible peaks obtained 
with the relaxed p-value cutoff and IDR filter was intersected with the set of peaks obtained 
using default MACS2 parameters (narrow peaks), effectively resulted in narrow versions 
of the reproducible peaks. To facilitate the analysis of peaks across biological conditions, 
and to reduce the impact of changes resulting from technical artifacts, a reference set of 
peaks was defined by merging IDR-filtered peaks discovered in the male and female liver 
samples; this was done separately for DHS and for each of the histone marks. Peaks with 
differential intensities along the time-course of continuous GH treatment were identified 
by normalizing datasets against the male sample using MAnorm (Shao et al., 2012). To 
facilitate the analysis of changes across many time points, MAnorm was modified to use a 
reference set of peaks, instead of the two peak lists corresponding to each condition that 




discovery of any changes at the set of all the reference peaks, across all time points, even 
if a genomic site failed to meet the peak-discovery criteria at any condition. MAnorm was 
further modified to use a specified list of peaks to perform robust regression, instead of the 
list of common peaks that is calculated by the default version of MAnorm. This 
modification allowed the use of sets of peaks that are invariant across treatment, with 
different stringencies. To avoid the detection of differential peaks due to differences in 
sequencing depth, reads were counted in the reference set of merged peaks, separately for 
DHS, and for each histone mark, for each time point. The read files were then down-
sampled to match the lowest number of reads in peaks observed individually for DHS and 
for each of the histone marks. Counts obtained from these down-sampled read files were 
used to perform MAnorm normalization and obtain sequence-read fold-changes and 
normalized read counts for each genomic site. For each biological condition, peaks with 
log2 sequence-read-ratios (M-value) >=1 and p-value < 0.001 were considered to be 
enriched (or induced) in that condition, and peaks with M-value <= -1 and p-value < 0.001 
were considered to be depleted (or suppressed) in that condition compared to male.  
Normalized read counts obtained by MAnorm normalization were used to build a matrix, 
with each row representing a genomic location, and each column representing a time point 
of treatment by continuous GH. This matrix of normalized read counts was used as input 
to STEM [6]. STEM analysis was performed using the "normalize data" option, and a 
maximum number of model profiles of 50, to filter out genomic sites that did not show a 
consistent response to cGH treatment. Sites that show a consistent pattern of induction 




(Supplemental Fig. 1), and were retained for downstream analyses. Feminization values 
were calculated for each site using normalized read counts in linear space along the time 
course of treatment, as follows. Feminization values were presented on a scale of 0 to 1, 
where 0 represents the normalized read count, rc, in male liver, and 1 represents the 
normalized read count in female liver. These values were calculated for each time point, t, 
using the formula: 
Ft = (2rct - 2rcmale) / (2rcfemale) – (2rcmale) 
Responsive genomic sites were clustered by their feminization values along the time 
course, using k-means clustering, with k=5. Clusters were labeled "early" if the mean 
feminization value for that cluster at 10 hours of cGH treatment is ³ 0.5 or. The remaining 
clusters were labeled "middle" if the mean feminization value for that cluster is ³ 0.5 at 
four days, and "late" if the mean feminization value is < 0.5 at four days.  
 
3.3.6.3 Settings for visualization of histone marks and DHS For ChIP-seq and DNase-seq 
peak visualization in the UCSC genome browser (https://genome.ucsc.edu/), peaks were 
normalized using reads in peak per million mapped sequence reads (RiPPM) as a scaling 
factor. Peak calls from all samples were concatenated into a single file. BEDtools merge 
(Quinlan and Hall, 2010) was then used to generate a single peak list (Peak Union). The 
fraction of reads in the peak union list for each sample was then calculated to obtain a 
scaling factor. Raw read counts were divided by the per-million scaling factor to get the 
RiPPM normalized read counts.  deepTools (Ramirez et al., 2016) was used to visualize 




DHS midpoint.  
3.3.7 Association of DHS with histone marks and transcription factor binding sites4  
Since chromatin accessibility is a result of nucleosome displacement, the presence of 
histone marks is expected at regions flanking DHS, but not necessarily directly overlapping 
DHS. Therefore, DHS peaks were associated with peaks obtained for the K27ac and 
K4me1 histone marks if they overlap a 2 kb region defined around the DHS summit, by 
extending 1 kb in each direction. Overlaps were identified using the bedtools intersect 
command (Quinlan and Hall, 2010).  
Male-enriched, female-enriched and sex-independent STAT5 binding sites (1,765, 1,790, 
and 11,531 sites, respectively as defined in (Zhang et al., 2012). BCL6 binding sites in 
male liver (6,432 sites), CUX2 binding sites in female liver (1,471 sites) and HNF6 binding 
sites in male and female liver, were obtained from our published ChIP-seq data (Conforto 
et al., 2015; Conforto et al., 2012; Zhang et al., 2012) (GEO accession numbers GSE31578, 
GSE35985 and GSE60014). Publicly available ChIP-seq datasets for the following 
transcription factors were obtained from GEO; FOXA1 and FOXA2 in male and female 
liver (Li et al., 2012), PPARA, LXR, RXR in female liver (Boergesen et al., 2012), GR, 
CEBPβ (Everett et al., 2013), CTCF, CEBPα, HNF4α (Aldridge et al., 2013), mTOR, 
ERRα (Chaveroux et al., 2013) and HDAC3 (You et al., 2013) in male liver. 
Overlaps of TF binding sites with DHS were identified using the bedtools intersect 
command (Quinlan and Hall, 2010).  
																																																								




3.3.8 Association of GH responsive DHS with GH responsive genes.  
DHS belonging to each of the response clusters were mapped to their putative gene targets 
using GREAT (McLean et al., 2010) using to the following parameters. Each RefSeq gene 
was assigned a basal regulatory domain extending from 5 kb upstream to 1 kb downstream 
of the TSS, and the regulatory domain was extended in both directions to the nearest gene’s 
basal regulatory domain up to a maximum of 1,000 kb in one direction.  
 
3.3.9 Enrichments 
The enrichment of sex-biased DHS in each set of transcription factor targets was calculated 
compared to that of a background set of sex-independent DHS. The enrichment of the 
transcription factor targets or sex-biased histone mark peaks for belonging to each of the 
five cGH response clusters in each sex (designated MI to MV and FI to FV) was calculated 
compared to the set of corresponding GH-responsive sex-biased DHS that are not in that 
cluster. Statistical significance was evaluated by using Fisher’s exact test. 
 
3.3.10 Statistical analysis 
Graphical and statistical analyses were performed using GraphPad Prism 7 software. 
Statistical significance of all the enrichment or depletion calculations was evaluated by 






3.4.1 Time-dependent epigenetic changes in response to cGH 
Adult male mice were given a continuous infusion of GH (cGH), which overrides the male 
endogenous pulsatile GH secretion pattern  (Lau-Corona et al., 2017). Livers were 
collected at time-points ranging from 10 hours to 14 days, and nuclei were purified and 
subject to DNase I digestion to identify open chromatin regions as DNase hypersensitive 
sites (DHS). Liver chromatin from each time-point was analyzed by chromatin 
immunoprecipitation (ChIP) for the enhancer marks H3-K4me1 and H3-K27ac and for the 
repressive mark H3-K27me3. Data were analyzed to assess globally the epigenetic changes 
that occur in response to cGH infusion in samples from mice treated for 10 hours, 1, 4, 7 
and 14 days and male and female controls. Genome-wide sequencing identified a total of 
46,931 DHS, 42,168 H3-K27ac sites and 47,725 H3-K4me1 sites across all of the samples. 
Sites responding to cGH infusion were identified by comparing the intact female and each 
of the treatment time-points to the sham-treated male controls using MAnorm (Shao et al., 
2012) (see Methods; log2 sequence-read-ratios (M-value) >=1 and p-value < 0.001). The 
number of cGH-responsive sites increased progressively with time for all the marks 
interrogated, with comparable numbers of up-regulated and down-regulated sites (Fig. 3.1). 
For H3-K27me3, we identified 3,241 sites genome-wide (excluding the X-chromosome), 
and diffReps analysis (Shen et al., 2013) identified differential sites between the untreated 
females and between cGH-treated males and sham-treated male controls.  As expected, 
there was a higher number of male-biased sites (503 sites) compared to the female-biased 




3.4.2 cGH treatment dynamically changes chromatin accessibility  
Differential analysis of DNase-seq data revealed that chromatin accessibility changes 
gradually upon cGH infusion. K-means clustering of a set of 1,884 sex-biased DHS (1,111 
male-biased, 773 female-biased) selected for consistent patterns of GH responsiveness 
using STEM (Ernst and Bar-Joseph, 2006) (Profiles 8, 39 and 44 in Supplemental Fig. 3.1), 
identified five clusters of female-biased DHS (FI-FV; Fig. 3.2A) and correspondingly, five 
clusters of male-biased DHS (MI-MV; Fig 3.2B).  Female-biased DHS clusters were 
progressively induced by cGH. In contrast, male-biased DHS were gradually repressed. 
DHS in “Early” clusters (I, II) responded rapidly to cGH and reached the female state by 
10 hours or 1 day of cGH infusion, whereas sites in "Late" (V) clusters were only partially 
feminized after seven days of cGH infusion (Fig. 3.2C). 
 
3.4.3 Responsive DHS overlap with transcription factor binding sites  
DHS in mouse liver encompass a large percentage of transcription binding sites (Ling et 
al., 2010). We used published ChIP-seq data for several transcription factors (TF) in male 
and female liver to determine the percentage of binding sites encompassed by DHS and to 
discover sex-differences in TF binding. In this study, 15- 80% of the ChIP-seq determined 
binding sites for 21 liver-expressed TFs overlapped a DHS (see Methods for details) (Fig 
3.3A). A majority of DHS (> 60%) were bound by one or more or the 21 TFs (Fig 3.3B).  
These results validate the set of DHS identified as functional regulatory elements.  
 




liver, while in female liver, STAT5 activity persists due to the continuous presence of GH 
in the circulation. Further, cGH infusion changes the liver STAT5 activity profile from 
pulsatile to persistent (Connerney et al., 2017; Zhang et al., 2012). We analyzed the overlap 
between male-enriched (1,765 sites), female-enriched (1,790 sites), and sex-independent 
(11,531 sites) liver STAT5 binding sites with the sets of male-biased and female-biased 
DHS whose activity was altered by cGH treatment. Consistent with the effects of cGH 
treatment on sex-biased gene expression presented in chapter 2, male-enriched STAT5 
binding was strongly enriched at male-biased DHS repressed by cGH in male liver (ES = 
28.08, p-value < 2.2E-16) and female-enriched STAT5 binding was strongly enriched at 
female-biased DHS induced by cGH in male liver (ES = 6.55, p-value < 2.2E-16) (Fig 
3.3C). The sex-biased TFs CUX2 (Conforto et al., 2012) and BCL6 (Zhang et al., 2012) 
collaborate with STAT5b to regulate sex-biased genes. CUX2, a female-biased 
transcriptional repressor that represses male-biased genes and induces female-biased genes 
in female liver (Conforto et al., 2012), binds at repressed male-biased DHS and at induced 
female-biased DHS. In contrast, BCL6, a male-biased transcriptional repressor, 
preferentially represses female-biased genes in male liver (Zhang et al., 2012) and binds at 
induced female-biased DHS. (Fig.3.3D). Since female-biased DHS associate with female-
biased genes and male-biased genes are enriched for male-biased genes (Lau-Corona et al., 
2017), these results confirm what was observed in chapter 2: early induction of Cux2 by 
cGH contributes to the induction of female-biased genes and repression of male-biased 
genes and early repression of Bcl6 contributes to the de-repression of female-biased genes. 




responsiveness to cGH, we examined the distribution of TF binding sites among the DHS 
cGH response clusters. Male enriched STAT5 sites show modest enrichment for binding 
at the late responsive male-biased DHS (cluster MV) and depletion at early responsive 
clusters (MII). Female-enriched STAT5 sites are enriched at intermediate and late 
responsive female-biased DHS (Clusters FIII and FV) and depletion in the early responsive 
clusters (FI and FII) (Fig 3.3E). CUX2 binding sites are enriched in the intermediate 
responsive male-biased DHS (MIII) (Figure 3.3F). Finally, BCL6 sites show modest 
enrichment for late responsive sites (Fig. 3.3G). These results seem to contradict what was 
observed for the sex-biased genes in chapter 2. Perhaps, the results presented for the genes 
reflect TF binding at promoter DHS, and the classification of cGH responsive DHS needs 
to be further refined based on their overlap with histone modifications to understand what 
type of regulatory elements are responding to cGH. 
3.4.4 Regulation of cGH-responsive sex-biased genes by cGH responsive sex-biased DHS  
To understand the relationship between cGH responsive DHS and cGH responsive genes, 
the responsive DHS were mapped to their putative target genes using GREAT (McLean et 
al., 2010) (see Methods). Further, the cGH responsiveness of the sex-biased genes was 
obtained from the classification performed in Chapter 2. 41% of the sex-biased cGH-
responsive genes (clusters M1-M5 and F1-F5) were associated with one or more sex-biased 
cGH-responsive DHS. The vast majority were associated with 1 or 2 sites; however, some 
male-biased and female-biased cGH-responsive genes were associated with 6 or more cGH 
responsive DHS (Fig 3.4A). Previous studies have shown that male-biased DHS are 




female-biased genes (Chapter 2, Fig.2.5) (Ling et al., 2010; Sugathan and Waxman, 2013). 
Here, male-biased DHS that were repressed by cGH at any given time-point, are enriched 
for cGH repressed male-biased genes (ES = 14.7, p = 2.95E-13), and induced female-biased 
DHS are strongly enriched for cGH induced female-biased genes (ES = 46.6, p = 8.41E-
11) (Fig. 3.4B), suggesting a functional role of these regulatory elements in liver 
feminization by cGH. To establish the time-dependent relationship between the cGH 
responsive DHS and the cGH responsive genes, we investigated the distribution of the 
associated cGH responsive genes in clusters M1-M5 and F1-F5 (Chapter 2) among the 
DHS responsive clusters (MI-MV and FI-FV) (Table 3.1). There is no clear pattern of 
association between the time-responsiveness of the DHS and the genes. The majority of 
the repressed male-biased DHS associate with early repressed male-biased genes (cluster 
M2) and the majority of the induced female-biased DHS also associate with early 
responsive genes (clusters F1 and F2).  Thus, the responses of these DHS regulatory 
elements, generally precedes or coincides with the response of the genes.  
 
3.4.5 Responsive DHS overlap enhancer-associated histone marks  
DHS encompass a variety of regulatory elements including enhancers, promoters, and 
insulators (Thurman et al., 2012). In contrast to promoters, enhancers have been shown to 
respond dynamically to external stimuli in close relationship with changes in gene 
expression (Ostuni et al., 2013). To refine the characterization of the responsive DHS and 




enhancer-associated histone modifications, H3-K4me1 and H3-K27ac. Genome-wide, we 
identified 42,168 H3-K27ac peaks and 47,725 H3-K4me1 peaks. Using MAnorm (see 
Methods), we identified 670 sex-biased H3-K27ac sites and 694 sex-biased H3K4me1 
sites. As observed for DHS, there was a time-dependent increase in the number of 
responsive sites with continuous GH treatment (Fig. 3.1). Further, Male-biased H3-K4me1 
and H3-K27ac sites are repressed by cGH, in contrast, Female-biased sites are induced by 
cGH (Fig. 3.5A). 
 
DHS are by definition depleted of nucleosomes, so to calculate the overlap between the 
DHS and the histone marks, we extended the DHS by 1 kb in each direction from the 
summit. Male-biased H3K27ac peaks were enriched at responsive male-biased DHS, and 
female-biased H3K27ac peaks were strongly enriched at responsive female-biased DHS. 
Interestingly, for female-biased H3-K27ac peaks, the enrichment was only seen at 
intermediate and late responsive DHS (Fig. 3.5A). Similar results were observed for H3-
K4me1 (Fig. 3.5B). To further confirm these observations, Deeptools (Ramirez et al., 
2016) was used to visualize the histone mark changes around the responsive DHS at each 
time-point of cGH treatment (Fig 3.6 A-D).  H3-K4me1 showed a modest increase in signal 
at cGH induced female-biased DHS.  There was no apparent loss of signal at repressed 
male-biased DHS (Fig. 3.6 A, B). However, there are evident time-dependent increases in 
H3-K27ac signal around female-biased induced DHS and time-dependent losses of 
H3K27ac signal around male-biased DHS (Fig. 3.6 C, D). H3-K27ac sites that are more 




responses observed for the DHS.  These results suggest that cGH leads to activation of 
poised enhancers.  
 
3.4.6 Loss of H3K27me3 de-represses female-biased genes 
H3-K27me3 has been recognized as a sex-biased regulatory mechanism found 
preferentially at highly female-biased genes in male liver (Sugathan and Waxman, 2013). 
In Chapter 2, I showed for 4 highly female-biased genes, that gene induction by cGH 
infusion is associated with loss of H3-K27me3 (Lau-Corona et al., 2017). I therefore, 
performed genome-wide profiling of H3-K27me3 by ChIP-seq to determine the extent of 
cGH infusion impact on H3-K27me3 repression.  
 
We identified 285 sex-biased sites of H3-K27me3 (DiffReps M/F p adj <0.05) that were 
cGH responsive at any time-point.  Consistent with previous results, cGH responsive sex-
biased sites were mostly male-biased and progressively down-regulated with cGH 
infusion. By 14 days of treatment, most of the male-biased sites (%) were significantly 
downregulated (Fig 3.7A). 41.7% of the H3-K27me3 sites were localized at gene bodies 
or gene promoters or within 3 kb of a gene promoter, half of these sites overlap a DHS. 
Interestingly, 16% of all gene-body H3-K27me3 sites overlap a sex-biased DHS (Fig. 
3.7B).  Among the 100 unique genes that have a sex-biased H3-K27me3 site on their gene 
bodies, we identified 35 sex-biased genes (26 female-biased, 9 male-biased), 18 of which 




41.4% of the sex-biased H3-K27me3 sites are intergenic and 53% of the intergenic sites 
overlap a DHS.  (Fig.3.7B; DiffReps mapping (see Methods)). Similarly, half of the sites 
that map to a gene desert, overlap a DHS. About a third (35%) of the DHS overlapping an 
intergenic or gene desert H3-K27me3 site, are sex-biased DHS. Indeed, there was a strong 
enrichment (ES = 3.4 p ) for a responsive H3-K27me3 site to overlap a sex-biased 
responsive DHS compared to all DHS sites (Fig. 3.8A). To investigate their role in the 
repression of female-biased genes, we calculated the overlap between male-biased and 
female-biased H3-K27me3 sites with the cGH responsive male and female-biased DHS.  
Intermediate and late responsive female-biased DHS (FIII-V) were strongly enriched for 
male-biased H3-K27me3 (Fig 3.8B).   
 
 
3.5 Discussion and future directions  
cGH infusion overrides the male, pulsatile pattern of plasma GH and feminizes liver gene 
expression in distinct time-dependent waves of male-biased gene repression and female-
biased gene de-repression. The underlying chromatin state in male liver heavily influences 
the differences in time-responsiveness of female-biased genes; cGH infusion more rapidly 
induces genes already in an active chromatin state. For a few genes, we demonstrated that 
the changes in gene expression are accompanied by time-dependent changes in chromatin 
accessibility and histone modifications (Lau-Corona et al., 2017).  However, a genome-
wide analysis of changes in chromatin states in cGH treated mice was not previously 
performed, and the correlation between the time-dependent changes in expression and the 




Here, DNase-seq and ChIP-seq analysis revealed that changes in gene expression are 
associated with global changes in chromatin accessibility. Female-biased sites are induced 
and are strongly enriched for female-biased genes, and male-biased sites are repressed and 
strongly associated with male-biased genes. Responsive DHS are characterized by sex-
biased transcription factor binding, indicating their functional roles in sex-biased gene 
regulation. Similar to what was found for responsive sex-biased genes, we identified early, 
intermediate and late sex-biased DHS that were responsive to cGH and are enriched in sex-
biased, enhancer-associated histone marks. Finally, loss of male-biased H3-K27me3 marks 
at female-biased DHS was associated with de-repression of many female-biased genes in 
response to cGH treatment.  
 
Global DNase-seq mapping identified a large number of sex-biased cGH responsive DHS. 
The involvement of these sites in the regulation of sex-biased genes was confirmed by the 
substantial overlap with binding sites for several GH-regulated transcription factors, 
namely, STAT5, CUX2, and BCL6. These factors have been found to control the time 
dependence of liver feminization. Overriding the pulsatile-male pattern of GH secretion by 
cGH infusion results in the persistent activation of STAT5 (Zhang et al., 2012), which in 
turn leads to the direct down-regulation of male-biased genes including Bcl6 and to the 
induction of Cux2 and other female-biased genes (Lau-Corona et al., 2017). Early 
responses of these two transcription factors lead to the secondary induction and repression 
of later responsive genes. In Chapter 2 we reported that gene targets of these transcription 




However, for responsive DHS, the enrichment was seen for intermediate and late 
responsive sites. Global ChIP-seq analysis for the enhancer associated histone 
modifications (H3-K4me1 and H3-K27ac) revealed that enhancers dynamically and 
progressively change in response to cGH.  Our results indicate that activation or repression 
of enhancers (gain or loss of  H3-K27ac) precedes changes in H3-K4me1 correlating with 
the observed changes in gene expression (Fig S3.2).  
 
This chapter confirmed and expanded the findings revealed in chapter 2; transcriptional 
changes are associated with changes in chromatin accessibility and histone modification. 
The primary goal of this study was to answer the following questions: Do DNase 
hypersensitive sites and enhancers predicted to regulate early and late responding genes 
show the same time-responsiveness as their associated responsive genes?  Do proximal 
DHS show different time-responsiveness to cGH as distal DHS? Here, we discovered that 
DHS also respond to cGH in time-dependent waves and we were able to cluster sex-biased 
DHS into early, intermediate and late responding clusters. However, the relationship 
between the time-responsiveness of the regulatory elements and the time responsiveness 
of the genes is apparently complex, and further analyses are required to elucidate the 
sequence of events leading to gene feminization. 
 
First, an improvement on the identification and clustering of responsive DHS may be made 
by selecting functional DHS based on TF binding or the presence of histone modifications. 




enhancers that become activated or de-activated by cGH can be refined so that it is not 
based solely on changes in chromatin opening. Further, motif discovery on the regulated 
DHS comparing those flanked by specific histone modifications would help elucidate if 
differential histone modifications are involved in the recruitment of TF’s to specific sites. 
 
Next, the association of regulatory elements to their gene targets has mainly been carried 
out based on the assumption that proximity and similar sex-specificity are useful surrogates 
for more sophisticated mapping methods. Many studies have shown that the assumption 
made by GREAT (McLean et al., 2010) and similar approaches to map promoter-enhancer 
interactions, that regulatory elements regulate the nearest genes is often wrong, insofar of 
regulatory elements communicate with their target genes through chromatin looping 
(Sanyal et al., 2012). Indeed, we have shown that many sex-biased genes lack sex 
differences in local chromatin marks, and that the majority of sex-biased DHS are >100 kb 
away from sex-biased genes (Ling et al., 2010; Sugathan and Waxman, 2013). More 
recently, mammalian genomes were shown to be organized into self-interacting regions 
known as topologically associating domains (TADs) (Dixon et al., 2012), Thus identifying 
regulatory elements within the same TAD or the same intra-TAD DNA loop (subTAD 
loops), as the responsive gene would be a refinement to our current approach (preliminary 
H3-K27ac site –gene associations shown in Figure S3.3). Furthermore, considering the 
distance of the regulatory elements to their target genes would provide greater insight into 
the differences between proximal and distal sites. Finally, chromosome conformation 




confirm looping interactions between predicted regulatory elements and the promoters of 
select early and late responsive genes.  
 
In chapter 2 and in this study, the measure of responsiveness that we used was the percent 
feminization. For genes, this measure seems to accurately define the clusters of 
responsiveness as they are correlated with differences in transcription factor binding and 
chromatin environment. However, this measure of response may not be adequate for DHS. 
Further studies are required to determine the critical changes or degree of response required 
to activate or repress sex-biased genes. 
 
The analyses presented in chapters 2 and 3 are based on data from adult male mice treated 
with a continuous GH infusion. Future studies could explore if the infusion of male mice 
in the pre-pubertal stage results in more effective feminization of partially responsive 
genes. Further, we could explore the reversibility of the changes induced by continuous 
GH by the analysis of samples after suspending the cGH infusion.  
 
In conclusion, we used genome-wide DNase hypersensitivity and histone modification data 
to determine the chromatin dynamics that dictate liver feminization in response to cGH. 
We identified numerous functional regulatory sites that respond dynamically and follow 
differential, time-dependent patterns of induction or repression. Further analyses are 




Figure 3.1. Differential DHS and histone marks  
Differential sites were discovered as described in methods for intact females and males 
treated with continuous GH for 10 hours, 1, 4, 7 or 14 days compared to sham treated male 
controls. (A) Numbers of differential DHS (B) Numbers of differential H3K27ac peaks (C) 
Number of differential H3K4me1 peaks (D) Number of differential H3K27me3 sites. M; 
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Figure 3.2. Time-dependent chromatin accessibility changes in response to cGH  
K-means clustering was applied to 1,884 Sex-biased DHS selected for consistent response 
to cGH based on the feminization values at each time-point. (A) Heatmap for 1,111 Male-
biased DHS in five clusters (MI-MV), male feminization level is set to 0. (B) Heatmap for 
773 Female-biased DHS in five clusters (FI-FV), female feminization level is set to 1. (C) 
Cumulative plots for the feminization values of female-biased sites in cluster FI (early) and 












































Figure 3.3 Transcription factor binding at responsive DHS  
(A) Percentage overlap of transcription factor binding sites in male and female liver with 
the DHS discovered in all the samples (B) Percentage of DHS bound by different numbers 
of transcription factors (C) Male-enriched (1,765 sites), female-enriched (1,790 sites), and 
sex-independent (11,531 sites) STAT5 binding sites were overlapped with cGH responsive 
male and female-biased DHS.  Enrichment for male-biased (blue) and female-biased (red) 
DHS was computed compared to a background set of 68,682 sex-independent DHS. (D) 
CUX2 and BCL6 binding sites (1,471 and 6,432, respectively) were overlapped with DHS, 
and enrichment for both responsive male-biased and female-biased DHS was computed 
compared to a background set of sex independent DHS. (E) Enrichment of the male-
enriched STAT5 binding sites in each of the cGH-responsive male-biased DHS clusters 
(MI to MV) and enrichment of the female-enriched STAT5 binding sites in each of the 
cGH-responsive female-biased DHS clusters (FI to FV). (F) Enrichment of CUX2 binding 
sites in each of the responsive male-biased and female-biased DHS .(G) Enrichment 
of  BCL6 binding sites in each of the responsive male-biased and female-biased DHS. The 
enrichment of STAT5, CUX2, and BCL6 binding sites for being enriched in each of the 
DHS sets examined was calculated as described in Materials and Methods. Significant 
enrichment or depletion by the Fisher’s exact test is indicated by black or red asterisks, 
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Figure 3.4 Regulation of cGH-responsive sex-biased genes by cGH responsive sex-
biased DHS 
Sex-biased cGH responsive DHS (n = 1,884) in each of the response clusters (MI-MV and 
FI-FV) were mapped to their target genes using GREAT (see Methods) and the cGH 
responsiveness of the genes was obtained as explained in chapter 2. (A) Percentage of sex-
biased cGH responsive genes (Clusters M1-M5 and F1-F5) associated with different 
numbers of sex-biased cGH responsive DHS (Clusters MI-MV and FI-FV). (B) Male-
biased cGH-repressed DHS and female- biased cGH –induced DHS, were mapped to their 
target genes using GREAT. DHS target enrichment or depletion for male-biased cGH 
repressed and female-biased cGH induced genes was calculated compared to a background 
set of stringent sex-independent responsive genes (62). Significant enrichment or depletion 
by Fisher’s exact test is indicated by black or red asterisks, respectively (*, P  0.05; **, 
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Table 3.1 cGH responsive genes associated to cGH responsive DHS 
Percentage of cGH responsive target genes of the cGH responsive DHS in each of the 




DHS M1 M2 M3 M4 M5
Female-
biased
MI 14% 62% 19% 0% 5% 9%
MII 15% 65% 20% 0% 0% 20%
MIII 0% 67% 25% 8% 0% 8%
MIV 7% 57% 14% 14% 7% 29%
MV 0% 43% 29% 29% 0% 0%
GENES
DHS F1 F2 F3 F4 F5
Male-
biased
FI 0 0 0 0 00
FII 60% 20% 0% 0% 0% 20%
FIII 75% 25% 0% 0% 0% 0%
FIV 30% 30% 10% 25% 0% 5%
FV 16% 36% 16% 20% 12% 0%
A B
C
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Figure 3.5 Overlap of responsive DHS with sex-biased histone modifications  
(A) Heatmap for sex-biased  H3-K27ac and H3-K4me1 sites. Shown are the signal log2 
fold-change values for intact females and males treated with cGH compared to intact males 
Sex-baised H3-K27ac and H3K4me1 peaks were overlapped a 2 kb region around cGH 
responsive sex-biased DHS. (B) Enrichment for male-biased and Female-biased H3-
K4me1 sites for belonging to each of the 5 cGH responsive DHS clusters in each sex (MI-
M5 or FI-FV).  (C) Enrichment for male-biased and Female-biased H3-K27ac sites for 
belonging to each of the 5 cGH responsive DHS clusters in each sex (MI-M5 or FI-FV). 
Significant enrichment by the Fisher’s exact test is indicated by black asterisks, (*, P  0.05; 
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Figure 3.6 Enhancer associated histone marks at cGH responsive DHS  
Shown are heatmaps of normalized ChIP-seq reads for H3-K4me1 (A, B) or H3-K27ac (C, 
D)  in males (Blue), cGH treated males at 10 hours, 1 day , 4 days, 7 days or 14 days 
(purple) and in intact females. ChIP-seq signals for each of the marks are visualized in a 2 
kb region centered at the DHS summit for each of the male-biased cGH responsive DHS 
clusters (M1-MV; Panels A and C) or female-biased cGH responsive DHS clusters (FI-F5; 












































































Figure 3.7 Loss of H3-K27me3 de-represses female-biased genes  
(A) Heatmap for sex-biased H3-K27me3 sites. Shown are the signal log2 fold-change 
values for intact females and males treated with cGH compared to intact males (B) 
Localization of sex-baised H3-K27me3 regions (C) Heatmap for Log2 fold change 
expression values at each of the time-points compared to control males, for cGH responsive 
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Figure 3.8 H3K27me3 at sex-biased DHS 
(A) Enrichment for cGH responsive sex-biased DHS and stringent sex-independent DHS 
to overlap a responsive H3K27me3 site. Enrichment was calculated over a background set 
of 46,931 DHS. (B) Enrichment for male-biased and Female-biased H3-K27me3 sites for 
belonging to each of the 5 cGH responsive DHS clusters in each sex (MI-M5 or FI-FV). 
Significant enrichment by the Fisher’s exact test is indicated by black asterisks, (*, P  0.05; 
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Table S3.1 ChIP-seq and DNA-seq statistics for all the samples  
This set of tables presents the sequencing data for each of the pools of samples that 
composed the sequencing libraries. Each of the tables provides the pool ID, sequenced 
sample ID, condition, number of individual samples included in the pool, peaks identified 





Figure S3.1. STEM profiles 
STEM (Short Time-series Expression Miner) (Ernst and Bar-Joseph, 2006; Ernst et al., 
2005) was used for the analysis of the patterns of response to cGH infusion. STEM defines 
a set of model response profiles independent of the data. Each DHS was assigned to the 
pre-defined STEM profile that most closely resembled its time-dependent response. 
Colored profiles represent those that are statistically significant. Profiles 8, 39 and 44 were 










Figure S3.2  Number of cGH responsive genes 
Number of liver expressed genes (FPKM >1) that are sex-biased and or cGH responsive 
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Figure S3.3  H3-K27ac sex-biased sites in the same TAD as cGH responsive genes 
Sex-biased H3K27ac sites were discovered using MAnorm as described in methods.  M –
values for all sex-biased sites within the same TAD as a cGH responsive genes were 
obtained and graphed alongside gene expression data for (A) Cyp3a16 (B) Sult3a1 (C) 

















CHAPTER 4- Sex biased epigenetic regulation of liver gene expression by Ezh1 and 
Ezh2 
4.1 Abstract 
Liver disease and liver cancer show sex bias in their incidence and progression. Underlying 
these phenotypical differences between the sexes, are ~1000 genes expressed in a sexually 
dimorphic manner in mammalian liver. Sex-biased genes are regulated by the sex-specific 
patterns of pituitary growth hormone secretion, which act via a transcriptional network 
operating in the context of sex-biased liver chromatin states. Notably, histone H3K27me3 
is a major sex-biased repressive mark found at many highly female-biased genes in male 
mouse liver, but not at highly male-biased genes in female liver. The polycomb repressive 
complex-2 catalyzes H3K27 methylation through its homologous catalytic subunits, EZH1 
and EZH2. Here, we used an Ezh1-knockout mouse model with a hepatocyte-specific 
knockout of Ezh2 to investigate the role of H3K27me3 in repressing sex-biased genes in 
mouse liver. RNA-seq analysis revealed that liver Ezh1/Ezh2 deficiency leads to a 
significant loss of sex-specific gene expression, with many female-biased genes showing 
increased expression and male-biased genes showing reduced expression in male liver. 
Ezh1/Ezh2 deficiency had a much greater impact in male than female liver regarding the 
loss of sex-biased gene expression, loss of sites of H3K27 trimethylation, and increases in 
the active enhancer marks H3K27ac and H3-K4me1. Liver cancer and liver fibrosis-related 
genes were strongly up regulated in male, and to a lesser extent, female Ezh1/Ezh2-
deficient livers, with a subset of genes preferentially up regulated in female livers. Thus, 




maintain liver sex bias and may contribute to the observed sex-bias in liver disease 
progression. 
 
4.2 Introduction   
Liver disease shows marked sex differences. Hepatocellular carcinoma incidence and 
mortality is three times higher in males than in females (Clocchiatti et al., 2016; El-Serag, 
2012), and female mice are less susceptible to chemically induced hepatic carcinogenesis 
(Hanna et al., 2016). Additionally, males are more susceptible to non-alcoholic fatty liver 
disease, non-alcoholic steatohepatitis (NASH), and liver fibrosis than females (Ballestri et al., 
2017; Buzzetti et al., 2017; Marcos et al., 2015; Marin et al., 2016; Pramfalk et al., 2015). 
Underlying these phenotypical differences between the sexes are hundreds of genes that 
are expressed in liver in a sexually dimorphic manner. This dimorphism is largely regulated 
by the sex-specific patterns of pituitary secretion of growth hormone (GH), which is 
intermittent (pulsatile) in males and persistent (near continuous) in females. The sex-
specific effects of GH are mediated by the GH-activated transcription factor STAT5b, 
which regulates sex-specific liver gene expression in collaboration with several other GH-
responsive factors in the context of sex-biased chromatin states (Lau-Corona et al., 2017). 
Trimethylation of histone H3 at lysine 27 (H3K27me3) has been identified as a sex-biased 
chromatin mark in mouse liver, where a striking male bias in the density of H3K27me3 
marks is seen at many of the most highly female-biased genes in male liver, but not at 
male-biased genes in female liver (Sugathan and Waxman, 2013). Further, continuous 




induces the loss of hepatic H3K27me3 marks over several days in association with the 
induction of female-biased genes (Lau-Corona et al., 2017).  
 
H3K27me3, a hallmark of transcriptional silencing is deposited by the polycomb repressive 
complex-2 (PRC2), a protein group involved in several biological processes including 
differentiation, cell identity and proliferation. PRC2 has three core components, SUZ12 
(suppressor of zeste homolog), EED (embryonic ectoderm development) and the 
homologous catalytic subunits Ezh1 and Ezh2 (enhancer of zeste homolog 1 or 2). Ezh1 
and Ezh2 both contain a SET domain, which is required for methylation of lysine 27 of 
histone H3. PRC2 can also facilitate transcriptional repression by recruiting protein 
complexes that recognize H3K27me3 and induce chromatin compaction (Reddington et 
al., 2013). Ezh1 and Ezh2 have complementary and compensatory functions and share an 
overlapping set of target genes (Aranda et al., 2015; Margueron et al., 2008). Ezh1 has 
lower methyltransferase activity than Ezh2, and its expression is higher in adult tissues, 
while Ezh2 is preferentially expressed in embryonic and highly proliferative tissues 
(Margueron et al., 2008). Deletion of the SET domain of Ezh2 in embryonic mouse liver 
results in a significant reduction of liver size and hepatic progenitor cell expansion, which 
impair liver differentiation and maturation (Koike et al., 2014).  
 
Increased levels of Ezh2 and H3K27me3 are found in hepatocellular carcinoma (HCC) and 
are associated with metastasis and poor prognosis (Au et al., 2013). Ezh2 regulates the 




independent mechanisms, promoting liver carcinogenesis. Ezh2 silences several tumor 
suppressor miRNAs that are down-regulated in liver cancer (Gao et al., 2014). Further, in 
HCC, Ezh2 interacts with highly expressed oncogenic long non-coding RNAs (lncRNAs) 
to repress target genes (He et al., 2014).  
In adult mouse liver, the loss of both Ezh1 and Ezh2 induces a substantial decrease in 
H3K27me3 marks accompanied by gene dysregulation and results in a severe decrease of 
liver function, development of liver fibrosis, and impaired regeneration (Bae et al., 2015). 
Disruption of the GH-STAT5 axis in the liver also causes steatosis, liver fibrosis and 
hepatocellular carcinoma (Baik et al., 2016; Cui et al., 2007; Mueller et al., 2011). The 
mechanisms by which GH interacts with PRC2 to regulate target genes and to confer 
protection against liver disease in a sex-biased manner are not yet understood. 
 
Here, we used an Ezh1-knockout mouse model with a hepatocyte-specific knockout of 
Ezh2 to investigate the role of H3K27me3 in repressing sex-biased genes in mouse liver 
and the potential impact of this regulation on sex-biased susceptibility to liver disease. We 
found a significant sex-bias in the number of liver-expressed genes responsive to the loss 
of Ezh1/Ezh2, with a striking enrichment for effects on the expression of female-biased 
genes in male liver. Further, our findings demonstrate that the loss of H3K27me3-based 
repression preferentially increases the expression of many female-biased genes in male 
liver, but in many cases, leads to only a partial feminization of liver gene expression. 
Further, hepatic Ezh1/Ezh2 deficiency is shown to induce many presumed secondary 




identified many genes involved in liver fibrosis and liver carcinogenesis that are 
differentially regulated upon loss of Ezh1/Ezh2 in male compared to female liver and 
which may contribute to the observed sex-differences in the incidence and progression of 
liver cancer. 
 
4.3 Materials and Methods 
4.3.1 Animal treatments. Livers from 7-week-old male and female Ezh1-knockout mice 
with a hepatocyte-specific knockout of Ezh2 (DKO, Ezh1/Ezh2-double knockout) and their 
age and sex-matched littermate floxed controls were generated as described in (Bae et al., 
2015). Briefly, Ezh2fl/fl mice (Su et al., 2003) were bred with Alb-Cre transgenic mice 
(Weisend et al., 2009), and their offspring were then bred with Ezh1-knockout mice 
(Thomas Jenuwein, Research Institute of Molecular pathology, Vienna, Austria) (Ezhkova 
et al., 2011) to generate DKO mice. Livers from male and female CD1 mice 2-8 weeks of 
age were obtained as described (Conforto and Waxman, 2012). Hypohphysectomy and 
continuous GH infusion of male mice for 14 days were as described previously(Connerney 
et al., 2017; Lau-Corona et al., 2017). 
 
4.3.2 RNAseq Analysis.  Approximately 10% of each individual liver was snap frozen in 
liquid nitrogen and used for RNA extraction with TRIzol reagent (Invitrogen Life 
Technologies Inc., Carlsbad, CA) following the manufacturer’s instructions. Total liver 
RNA was isolated from 9 individual livers per treatment group (Male controls, Female 




prepared for each treatment group, with each sequencing library comprised of a pool of 
RNAs obtained from n=3 livers. Libraries were prepared using the Illumina TruSeq RNA 
library preparation kit (Illumina, cat# RS-122-2001) and 68 nt single-end sequence reads 
were obtained on an Illumina HiSeq2500 instrument at the Boston University School of 
Medicine, Section of Computational Biomedicine (Boston, MA). RNA-seq data was 
analyzed using a custom pipeline developed in our lab (Connerney et al., 2017). Briefly, 
sequence reads were aligned to mouse genome build mm9 (NCBI 37) using Tophat 
(version 2.0.13) (Trapnell et al., 2012), and FeatureCounts (Liao et al., 2014) was used to 
count sequence reads mapping to the union of the exonic regions in all isoforms of a given 
gene (collapsed exon). Differential expression analysis was conducted using the 
Bioconductor package EdgeR (Robinson et al., 2010). We identified 11,491 liver expressed 
genes at >1 FPKM (Fragments Per Kilobase length of transcript per Million mapped reads) 
in any of the four conditions. Of these 11,491 genes, 1,356 genes were significantly 
dysregulated in DKO (in either sex), as indicated by EdgeR |fold-change| > 1.5 and adjusted 
p-value (i.e., FDR, false discovery rate) < 0.05) for a comparison of DKO male vs control 
male liver, or for a comparison of DKO female vs control female liver. A set of 1,131 genes 
showing significant male-female differences in expression in livers of wild-type mice in 
the DKO background strain were identified based on FDR < 0.01 and maximum FPKM 
>1; these cutoffs empirically corresponded to a >1.2-fold sex-difference in expression 
(Supplemental Table S3). A set of 8,021 liver-expressed genes (FPKM >1) whose 
expression is stringently sex-independent was defined based on a |fold-change| for sex-




Differential expression data from male mice treated with continuous GH, 
hypophysectomized male and female mice and their strain and age matched controls were 
obtained from Supplemental Tables S2 and S3 from reference (Lau-Corona et al., 2017) 
and Supplemental Table S3 from reference (Connerney et al., 2017). A set of 113 consistent 
female-biased genes was defined as genes with a control female/control male ratio > 2-fold 
in all three independent RNA-seq datasets (Supplemental Table S5).  
 
For female-biased genes, a percent feminization value was calculated based on each gene’s 
response to each of the following: Ezh1/Ezh2 loss in male DKO liver; to pituitary hormone 
ablation, as seen in hypophysectomized male liver; and to continuous infusion of GH in 
male mice, as follows:  
% feminization = 100% [FPKM (Treated male) - FPKM (Intact male)]  
                                   [FPKM (intact female) FPKM (intact male)]. 
Heatmap generation and clustering were conducted using Morpheus 
(https://software.broadinstitute.org/morpheus/) and average linkage hierarchical clustering 
on the rows was implemented.  
 
4.3.3 qPCR analysis. Liver total RNA (1 μg) was used for reverse transcription (RT) using 
the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Fisher, Cat#43-
688-14). qPCR was performed using Power SYBR green PCR master mix and processed 
on an ABS 7900HT sequence detection system (Applied Biosystems) or the CFX384 




analyzed using the comparative Ct method with normalization to the 18S RNA content in 
each sample. Primers used for qPCR are shown in Supplemental Table S1.  
 
4.3.4 Chromatin preparation and chromatin immunoprecipitation (ChIP).  
Chromatin was extracted from frozen liver tissue from each of 6 individual mouse livers 
per group. Approximately 1 g of frozen liver was submerged in 4 ml of cross-linking buffer 
[10 mM HEPES (pH 7.6), 25 mM KCl, 0.34 M sucrose, 0.15 mM 2-mercaptoethanol, 2 
mM MgCl2, and Pierce protease inhibitor (1 tablet per 50 mL of buffer; ThermoFisher 
Scientific, cat. #A32965)] and homogenized using a glass dounce homogenizer. The liver 
homogenate was pushed thorough to a 70 micron cell strainer (Fisher Scientific. #22-363-
548) using a 3 ml syringe plunger. The full volume was transferred to a 15 ml conical tube 
containing 313 μl from a 16% formaldehyde ampule (ThermoFisher Scientific # 28906) 
and an additional 687 μl of crosslinking buffer, to reach a final concentration of 1%. The 
samples were then incubated on a rocker for 5 min at room temperature. Cross-linking was 
halted by addition of 250 μl of a 2.5 M glycine (pH 8.0) solution (final concentration, 0.1 
M), followed by incubation for 5 min at room temperature. Samples were pelleted (2,500 
g for 5 min at 4°C) and washed twice with 10 ml of PBS. Pellets were resuspended in 10 
ml of Lysis Buffer 1 [50 mM HEPES (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 
0.5% IGEPAL CA-630 (Sigma-Aldrich, cat. #I8896), 0.25% Triton X-100 (Sigma cat. 
#T8787) and Pierce protease inhibitor, as above, and incubated on a rocker for 10 min at 
4°C. Samples were centrifuged at 2,000 g at 4°C for 5 min, the supernatant was removed, 




0.5 mM EGTA, 10 mM Tris-HCl (pH 8.0) and Pierce protease inhibitor] and rocked for 5 
min at 4°C. Samples were centrifuged at 2,000 g at 4°C for 5 min, the supernatant was 
removed, and the pellet was resuspended in 2 ml of 1X radioimmunoprecipitation assay 
(RIPA) buffer [50 mM Tris-HCl (pH 8.1), 150 mM NaCl, 1% IGEPAL CA-630, 0.5% 
sodium deoxycholate] containing 0.5% SDS and Pierce protease inhibitor. Samples were 
sonicated for 20 cycles (30 s ON, 30 s OFF) using a Bioruptor Pico (Diagenode) in 15 ml 
Diagenode TPX tubes containing 0.3 ml polypropylene beads. A 15 μl aliquot of the 
sonicated chromatin was incubated at 65oC for 6 hr to reverse cross-links. RNase A 
(ThermoFisher E053, 10 mg/mL) was added to a final concentration of 0.12 mg/mL and 
samples were incubated at 37C for 30 min. Proteinase K (Bioline BIO-37084, 20 mg/mL) 
was added to a final concentration of 0.39 mg/mL and samples were incubated at 37°C for 
2h. 8 ul of the sample were electrophoresed on a 1% agarose gel to size the fragments. The 
majority of DNA fragments ranged from 100 to 300 bp. Reversed cross-linked DNA was 
quantified using a Quant-iT PicoGreen assay kit (Invitrogen). The remaining sonicated 
chromatin was snap-frozen in liquid nitrogen and stored at -80°C until further use for ChIP. 
ChIP was performed as reported previously (Shao et al., 2012) using the following ChIP-
validated antibodies: H3K27ac (Abcam cat. # ab4729, 3 μg antibody per 15 μg of sonicated 
chromatin), H3K4me1 (Abcam cat. # ab8895, 1.2 μg antibody per 15 μg of sonicated 
chromatin), H3K27me3 (Abcam cat. # ab6002, 2 μg antibody per 10 μg of sonicated 
chromatin), and normal rabbit IgG (Santa Cruz, cat. # sc-2027, 3 μg antibody per 15 μg of 
sonicated chromatin). ChIP DNA was quantified using a Quant-iT PicoGreen assay kit 




genomic regions selected as positive controls or as negative controls for each of histone 
marks based on published ChIP-seq data (Sugathan and Waxman, 2013). 
 
4.3.5 ChIP sequencing. Sequencing libraries were prepared for each of the above three 
histone marks using 20-50 ng of ChIP’d DNA. Libraries were prepared for each of 4 
individual livers (biological replicates) for each sex and each genotype (16 libraries per 
histone mark) using NEBNext Ultra II DNA Library Prep kit for Illumina (NEB, cat. # 
E7645) according to the manufacturer’s instructions. NEBNext Multiplex Oligos for 
Illumina (NEB, Set 1; cat. # E7335, NEB, Set 2; cat. # E7500) were used for multiplexing. 
The Agencourt AMPure XP system (Beckman Coulter, cat. # A63880) was used for sample 
and library purification. Sequencing on an Illumina HiSeq2500 instrument was carried out 
at the New York Genome Center (New York, NY), generating 50 nt paired-end sequence 
reads. ChIP-seq analysis was performed using a custom pipeline developed by Andy 
Rampersaud of this laboratory (Lodato, 2018). FASTQ files from individual replicates 
were concatenated and analyzed as a single sample per condition. Sequence reads were 
mapped to the genome using Bowtie 2 (version 2.3.2) (Langmead and Salzberg, 2012). For 
ChIP-seq peak visualization in the UCSC genome browser (https://genome.ucsc.edu/), 
ChIP-seq peaks were normalized using reads in peaks per million mapped sequence reads 
(RiPPM) as a scaling factor. Peak calls from all samples were concatenated into a single 
file. BEDtools merge was then used to generate a single peak list (peak union). The fraction 
of reads in the peak union list for each sample was then calculated to obtain a scaling factor. 




normalized read counts. 
 
4.3.6 Differential peak discovery. H3K27me3: Genomic regions with a significant number 
of H3K27me3 reads were identified using SICER (version 1.1, window size 400 bp and 
gap size 2400 bp) (Xu et al., 2014). diffReps (version 1.55.4) (Shen et al., 2013) was used 
to identify genomic regions where a chromatin mark showed a significant difference in 
intensity between groups that differ in sex or genotype (‘differential sites’). These analyses 
were based on pairwise comparisons of the 4 biological replicates per condition for each 
of the following comparisons: control males vs. control females; DKO males vs. control 
males; DKO females vs. control females; and DKO males vs. DKO females. Differential 
windows were discovered using the nsd broad option of diffReps using each of these four 
window sizes: 1 kb, 2 kb, 5 kb and 10 kb, where the step size was set to 1/10 of the window 
size. Default statistical testing parameters were used (Negative binomial test with a p-value 
cutoff of < 0.0001 for significant windows). Windows with significant differential 
H3K27me3 marks that were discovered with two or more of the window size settings were 
consolidated to eliminate redundancy by retaining the ID number and information for the 
largest window size setting; differential windows that were uniquely discovered by any of 
the window size settings were also retained. H3K27me3 differential sites within the 
retained windows were further filtered for downstream analyses by FDR <0.05 and |fold-
change| > 2 for the groups being compared. H3K27ac and H3K4me1: Genomic regions 
enriched for H3K27ac and H3K4me1 sequence reads (‘peak’) were discovered using 




used at the 1 kb window setting to identify differential sites. Those differential sites were 
then filtered to retain those that overlap with a MACS2-identified peak. The retained 
differential sites discovered by were further filtered for downstream analyses by diffReps 
determined FDR <0.05 and |fold-change| > 2 for the groups being compared.  
 
4.3.7 H3K27me3 peak normalization. Due to the semi-quantitative nature of ChIP-seq 
methodologies (Orlando et al., 2014), we set out to identify H3K27me3 regions that are 
largely unchanged across individuals and genotypes (static H3K27me3 sites). We used 
diffReps to identify stringent non-differential genomic windows (p-value > 0.1 and |fold-
change| < 1.2) in the comparison of control male and DKO male livers, and in the 
comparison of control female and DKO female livers. Non-differential sites identified in 
the male livers were intersected with those identified in the female livers, and 1,433 sites 
with 80% or greater reciprocal overlap across their lengths were retained. Those sites were 
then filtered by their average raw fragment counts to retain the top 35% (502 sites, >400 
average raw fragments per site); those sites were further filtered to retain the top 75% least 
variant across samples after RPM normalization (376 sites). ChIP-qPCR analysis of a 
subset of these stringent non-differential sites (see Fig. 5, below, and Supplemental Fig. 1) 
confirmed that this approach does indeed identify invariant sites. ChIP-qPCR also revealed 
moderate compression of the strong differential sites in the ChIP-seq data, as was expected. 
Next, we calculated the fraction of total sequence reads found in these 376 sites for each 
sample to obtain a scaling factor. Raw read counts were divided by the per-million scaling 




used to override the diffReps normalization and thus obtain a new set of differential sites 
for each comparison. We observed high overlap (~93%) between the differential sites 
identified using the standard diffReps parameters, described above, and those identified 
when using the stringent non-differential site peak-based normalization factors, described 
in this section. We therefore proceeded to use the standard diffReps normalization to 
identify H3K27me3 differential sites. 
 
4.3.8 Mapping differential sites to genes. DiffReps automatically annotated the H3K27me3 
differential sites (see above) and mapped them to one of the following categories, and to 
the genes associated with them: ProximalPromoter (+/- 0.25 kb of a TSS), Promoter1k (+/- 
1 kb of a TSS), Promoter3k (+/- 3 kb of a TSS), Genebody (anywhere between a gene's 
promoter and up to 1 kb downstream of the gene’s TES), Genedeserts (genomic regions 
that are depleted of genes and are at least 1 megabase long), Pericentromere (region 
between the boundary of a centromere and the closest gene, minus 10 kb of that gene's 
regulatory region), Subtelomere (defined in a manner similar to pericentromere), and 
OtherIntergenic (any region that does not belong to the above categories). H3K27me3 
differential sites annotated as ProximalPromoter, Promoter1k, Promoter3k and Genebody, 
and the genes associated to them, were used for downstream analyses. H3K27ac and 
H3K4me1 differential sites were mapped to their putative gene targets by GREAT 
(McLean et al., 2010) using the following parameters: each RefSeq gene was assigned a 
basal regulatory domain extending from 5 kb upstream to 1 kb downstream of the TSS, 




regulatory domain up to a maximum of 1,000 kb in one direction (McLean et al., 2010). 
Based on the gene-histone mark associations described above, we classified the 260 sex-
biased genes and the 586 sex-independent genes up-regulated in male DKO liver 
(Supplemental Table S6) into the 8 groups shown in Fig. 7C (below). 
 
4.3.9 Functional annotation and Pathway Analysis. Data were analyzed using the IPA 
software suite (https://www.qiagenbioinformatics.com/products/ingenuitypathway-
analysis) (QIAGEN Inc). Genes related to liver fibrosis and hepatocellular carcinoma were 
obtained searching for the terms “liver fibrosis” or “Hepatocellular carcinoma” in the 
Diseases and Functions search field. Lists were further filtered to exclude chemicals by 
retaining only terms with an associated Entrez gene ID for mouse. 217 fibrosis-related 
genes and 920 hepatocellular carcinoma-related genes are shown in Supplemental Tables 
S7 and S8.  
 
4.3.10 Statistical analysis. Enrichment for up regulation of sex-biased genes was calculated 
compared to all liver-expressed genes as shown in this example: [240 (female-biased genes 
up regulated in male DKO liver) / 606 (846 liver-expressed genes up regulated in male 
DKO liver – 240)] / [404 (female-biased genes not up regulated in male DKO liver) / 
10,847 (11,491-644) liver expressed genes not up regulated in male DKO liver] = 10.03. 
Statistical significance of all the enrichment or depletion calculations was evaluated by 
using the Fisher exact test. Graphical and statistical analyses were performed using 




errors of the mean (SEM) or standard deviation (SD) for n = 3 to 12 individual mouse livers 
per group, as specified in each figure legend. Unpaired t-test or one-way analysis of 
variance (ANOVA) with a Dunnett posttest was used to compare groups to each other, as 
noted in the figure legends.  
 
4.3.11 Accession numbers.  All raw and processed RNA-seq and ChIP-seq data for 7-week 
control and DKO mice are available under accession number GSE110934 at Gene 
Expression Omnibus (https://www.ncbi.nlm.nih.gov/gds/). RNA-seq data for CCl4-treated 
control and DKO male mouse livers, and for 8-month control and DKO male mouse livers 
(Bae et al., 2015) are available under accession number GSE53627. 
 
4.4 Results 
4.4.1 Ezh1 and Ezh2 are expressed in different patterns in pre-pubertal liver 
We determined the expression levels of Ezh1 and Ezh2 in male and female mouse livers 
from 2 to 8 weeks of age by RT-qPCR of liver RNA (Fig. 1A). Ezh2 expression peaked at 
2 weeks, when hepatocytes are still proliferating (Margueron et al., 2008) and then 
progressively declined with age in both sexes. This is consistent with the preferential 
expression of Ezh2 in highly proliferative cells and with its decline in postnatal 
developmental reported for other mouse tissues (Margueron et al., 2008). Ezh1 levels 
remained elevated over the postnatal liver developmental period examined. There was no 




4.4.2 Sex-differential responses to the combined loss of Ezh1 and Ezh2 in the liver 
To elucidate the role of Ezh1 and Ezh2 in sex-biased liver gene expression, we analyzed 
RNA from livers of Ezh1-knockout mice with a hepatocyte-specific inactivation of Ezh2 
(DKO livers) (Bae et al., 2015). Ezh1 expression was greatly reduced in both the male and 
female DKO livers, as seen by RNA-seq (Fig. 1B). Overall Ezh2 expression levels were 
unchanged, however, in the DKO livers, as determined by RT-qPCR (Fig. 1C), however, 
transcription was abolished from the exons encoding the SET domain (Fig. 1B, red box), 
which is essential for histone H3K27 methyltransferase activity (Aranda et al., 2015).  
 
4.4.3 Loss of Ezh1 and Ezh2 preferentially de-represses female-biased genes in male liver  
RNA sequencing of male and female DKO and male and female control livers identified 
11,491 liver-expressed genes, of which 1,355 genes (12%) were differentially expressed 
between DKO and control mouse liver (see Methods for details). 72% of the differentially 
expressed genes were up regulated in the absence of Ezh1 and Ezh2, and more genes 
showed significant changes in expression in DKO males (1,079 genes) than in DKO 
females (843 genes). (Supplemental Table S4). Differential expression analysis for male 
vs. female control livers identified 1,131 sex-biased liver-expressed genes, of which 38% 
(435 genes) were dysregulated in DKO livers (Fig. 2A). There was a strong enrichment for 
sex-biased genes to be dysregulated in DKO liver (ES = 9.4, p < 2.2E-16 for up regulation; 
ES = 8.9, p < 2.2E for down regulation) compared to genes that are stringently-sex 
independent and responded to DKO in either sex (413 of 8,021 such genes; Supplemental 




In a study comparing chromatin mark intensities in male vs. female mouse liver, 
H3K27me3 was identified as a major sex-biased repressive mark; it is found at many highly 
female-biased genes in male liver, but not at highly male-biased genes in female liver 
(Sugathan and Waxman, 2013). Consistent with this finding, many highly female-biased 
genes are up regulated in DKO male liver, whereas very few highly male-biased genes are 
up regulated in DKO female liver (Fig. 2B, upper left vs. upper right). Further, genes up 
regulated in DKO male liver were strongly enriched for female-biased genes (ES = 10.1, p 
< 2.2E-16) compared to all liver expressed genes. Further, 154 of the 250 up regulated 
female-biased genes were exclusively up regulated in male DKO livers (Fig. 2B, left) In 
contrast, male-biased genes were not significantly enriched for being up regulated in DKO 
female liver. Further, there was a significant enrichment for male-biased genes to be down 
regulated in DKO male liver (ES = 16.9, p < 2.2E-16), and a modest enrichment for female-
biased genes to be down-regulated in DKO female liver (ES = 2.8, p = 5.7E-07) (Fig. 2C; 
also see Supplemental Table S4). 
 
4.4.4 Classes of sex-biased genes based on their response to Ezh1/Ezh2 DKO 
The dysregulation of sex-biased genes in DKO mouse liver resulted in a significant 
decrease in sex specificity (Fig. 3A), as was also seen when comparing the overall sex ratios 
of gene expression in DKO compared to control livers (Fig. 3B). A majority of the DKO-
responsive female-biased genes (191 of 294 genes; 65%) lose sex-specificity with the loss 
of Ezh1/Ezh2, and this is primarily due to their up regulation (de-repression) in male liver. 




primarily due to their down regulation in male DKO liver, which affects 62% of these genes 
(Fig. 3C and Supplemental Table S2). Whereas the increased expression of female-biased 
genes in DKO male liver can be explained by the loss of H3K27me3-based repression, the 
loss of H3K27me3 marks is not expected to directly lead to down regulation of gene 
expression; hence, the decreased expression of male-biased genes is likely to be a secondary 
response. Indeed, 27% of the male-biased genes down-regulated in DKO male mouse liver 
are direct targets of CUX2 in female liver (Supplemental Table S2), as determined by ChIP-
seq analysis (Conforto et al., 2012). This female-specific repressor of male biased genes is 
induced 3.7-fold in male DKO liver, and likely contributes to the indirect repression of 
these male-biased genes in female DKO mouse liver.  
Many female-biased cytochromes P450 (CYPs), sulfotransferases (SULTs) and other drug 
metabolizing enzymes genes are up regulated in male DKO liver. Many of these genes are 
also significantly up regulated in DKO female liver. Interestingly, Cyp2 family members 
(Cyp2b9, Cyp2c69, Cyp2c40) are de-repressed only in male liver, and Cyp3 family 
members (Cyp3a16, Cyp3a41b) are preferentially induced in female liver, thereby 
increasing their female-bias (Supplemental Fig. S2) 
 
4.4.5 GH-responsive female-biased genes are partially feminized by DKO in male liver 
The sex-specific patterns of pituitary GH secretion regulate the expression of liver sex-
biased genes: the loss of circulating GH following hypophysectomy abolishes ~90% of 
liver sex differences, and exogenous GH given either in pulses (male GH pattern) or 




patterns of liver gene expression (Holloway et al., 2006; Wauthier et al., 2010; Wauthier 
and Waxman, 2008). GH given to intact male mice as a continuous infusion feminizes liver 
gene expression by inducing many female-biased genes and repressing male-biased genes. 
Additionally, the induction of female-biased genes has been associated with the loss of 
H3K27me3 marks in the case of several highly female-biased genes (Cux2, Cyp3a16, A1bg, 
Cyp2b9; (Lau-Corona et al., 2017) (also see Supplemental Fig. 2). To better understand the 
relationship between H3K27me3-based repression of female-biased genes and the sex-
specific patterns of GH secretion, we compared gene responses in male liver, following 
hypophysectomy(Connerney et al., 2017) or after continuous GH infusion for 14 days (Lau-
Corona et al., 2017), to the gene responses to loss of Ezh1/Ezh2, as seen in DKO male liver. 
Previous studies identified two classes of female-biased genes based on their response to 
hypophysectomy. Class I female-biased genes are those that require the female plasma GH 
pattern of near-continuous GH stimulation for expression, and consequently, their 
expression in female liver decreases following hypophysectomy. Class II female-biased 
genes are repressed in male liver by the male pituitary hormone profile, and consequently, 
their expression in male liver is induced after hypophysectomy (Connerney et al., 2017). 
Initial analysis by RT-qPCR showed that Cyp2b9, a highly female-biased class II gene, was 
significantly de-repressed in DKO male liver, while Fmo3, a class I female-biased gene, 
was not significantly induced (Fig. 4A). The distinct responses of these two genes to DKO 
suggested that Ezh1/Ezh2-catalyzed H3K27me3 marks might be responsible for the 
repression of class II female-biased genes in male liver. However, we did not find an 




liver; rather, class I genes were just as likely as class II female-biased genes to be de-
repressed (Fig. 4B, top vs. bottom).  
Loss of Ezh1 and Ezh2 in male liver up regulated 65 (58%) of the 113 consistently female-
biased genes (i.e., genes with female/male-bias > 2-fold in three independent RNA-seq 
datasets) (see Methods) and Supplemental Table S5). To further understand the GH 
dependence of these 65 DKO-responsive genes, we assessed their response to two other 
plasma GH pattern-dependent feminization models, hypophysectomy and continuous GH 
infusion. 85% of the female-biased genes up-regulated in DKO male liver were also up 
regulated in livers of hypophysectomized males and/or in livers of males infused with GH 
continuously (Fig 4C; 55/65 genes). By contrast, only 15% (34/223) of the stringent sex 
independent genes up regulated in DKO male liver respond to hypophysectomy or GH 
infusion.  
All but one of the 113 female-biased genes (Xist) were up regulated in one of more of the 
three models examined (hypophysectomy, continuous GH infusion, and Ezh1/Ezh1-DKO) 
(Fig. 4C, right). While liver gene expression was feminized in all three models, the extent 
of feminization was substantially lower upon loss of Ezh1/Ezh2 (mean feminization, 57%) 
than following hypophysectomy (mean feminization > 100%) (Fig. 4D). Substantial 
feminization (>50%) of sex-biased genes upon loss of Ezh1/Ezh2 was often seen with 
moderately sex biased genes, but was less common for highly sex-biased genes, with the 
exception of Orm3, Cyp17a1, Cyp2c40, Sult2a1 and Hao2 (Fig. 4E). It should be noted, 




and Sult2a6, were only partially feminized in all three models (Fig. 4E, bottom). This 
indicates resistance of these Sult2a genes to a change in chromatin state in male liver, 
whether in response to a change in pituitary hormone stimulation (hypophysectomy and 
GH infusion models) or due to loss of H3K27 trimethylation activity. We conclude that the 
loss of Ezh1/Ezh2 and the capacity to form H3K27me3 repressive marks in male liver is 
not sufficient to induce full expression of most female-biased genes. This indicates that 
pituitary GH represses the expression of these female-biased genes by mechanisms that are 
more complex than simply packaging the gene and its enhancers in H3K27me3 repressive 
chromatin.  
 4.4.6 Loss of H3K27me3 is preferentially associated with up regulated female-biased 
genes 
The loss of Ezh1 and Ezh2 in DKO male liver led to down regulation of H3K27me3 
immunostaining in 96% of hepatocytes at 3 months of age, without effects on non-
parenchymal cells (Bae et al., 2015). Here, we used antibodies specific to H3K27me3 in a 
ChIP-seq study to investigate the relationship between loss of H3K27me3 marks and the 
observed changes in gene expression. First, to establish the validity of our sequencing 
results in the absence of a reference epigenome, we used diffReps to identify genomic 
regions where the intensity of H3K27me3 marks was unchanged in DKO liver compared 
to control liver (static H3K27me3 sites), as well as genomic regions where H3K27me3 
marks were significantly lost (differential H3K27me3 sites) (see Methods). Analysis of 
these sites by ChIP-qPCR showed no significant change in H3K27me3 marks at the static 




seq data for the same sites (Fig. 5A, Fig. 5B and Supplemental Fig. S1). For some of the 
differential sites, sequencing did not show as extensive a loss of H3K27me3 marks in the 
DKO livers as was evident from qPCR analysis of the same ChIP’d DNA samples, 
indicating that the ChIP-seq data underestimates the loss of H3K27me3 at some sites. 
Nevertheless, we were able to identify 2,236 H3K27me3 differential sites between DKO 
male and control male livers, as well as 1,096 differential sites between DKO female and 
control female livers (diffReps FDR < 0.05, |fold-change| >2) (see Supplemental Table S6 
for ChIP-seq data). 76% of these sites showed a significant decrease in H3K27me3 mark 
intensity (Fig. 6A).  
Comparison of H3K27me3 mark intensities between control male and female liver 
identified 538 genomic regions with male-biased H3K27me3 sites and only 11 with 
female-biased sites, consistent with the strong male-bias in H3K27me3 that we described 
previously (Sugathan and Waxman, 2013). Strikingly, the sex bias in DKO livers was lost 
at all 549 of these H3K27me3 sites, while 63 other H3K27me3 sites acquired sex-bias in 
the absence of Ezh1/Ezh2 (Fig. 6B). Twice as many H3K27me3 sites were dysregulated in 
male DKO than in female DKO liver (2,236 vs 1,096; Fig. 6A), consistent with the greater 
number of genes dysregulated in male liver (Fig. 2). As expected for an Ezh1/Ezh2 
knockout, H3K27me3 marks were decreased (down regulated) at a majority (76%) of the 
sites dysregulated in DKO livers; however, we found a significant number of sites where 
H3K27me3 marks were up regulated to a similar extent as the down regulated sites were 
down regulated, as seen in both male and female DKO liver (Fig. 6C). The up regulated 




diffReps; see Methods), of which 64 genes are liver-expressed DKO-responsive genes. 30 
of these 64 genes (including Ezh1, and the GH-regulated pioneer transcription factors 
Foxa1 and Foxa2) are down regulated in the DKO livers. (Supplemental Table 6). The up 
regulation of H3K27me3 marks at these sites could be due to histone mark changes in non-
parenchymal cells, where Ezh2 is still active.  
H3K27me3 sites that are down-regulated in both DKO male and DKO female liver 
compared to control liver (male-female common sites) are enriched for female-biased 
genes (ES = 2.5, p = 5.59E-04) when compared to a background of all liver expressed 
genes. A similar enrichment for female-biased genes was seen for the sites that are only 
down regulated in DKO male liver (DKO male-unique sites) (ES = 2.3, p = 1.05E-06) and 
sites that are only down regulated in DKO female liver (ES = 1.7 p = 1.93E-02). 
Interestingly, the set of sites up-regulated only in DKO-females is also enriched for female-
biased genes (Fig. 6F).  
 
4.4.7 Gene up regulation is associated with gain of activating marks 
H3K27 can be modified by either methylation, to generate the trimethylated (repressive) 
mark, or by acetylation, to generate an activating mark, H3K27ac, which is often associated 
with active enhancers (Rada-Iglesias et al., 2011). H3K27ac is enriched in the absence of 
PRC2 and is thought to antagonize PRC2-mediated gene silencing (Aranda et al., 2015; 
Margueron and Reinberg, 2011). We performed ChIP-seq for H3K27ac and for a second 
activating mark, H3K4me1, to investigate the impact of a loss of Ezh1/Ezh2 on these 




Significant increases in H3K27ac and H3K4me1 mark intensity were seen at ~1,000-2,000 
sites, based on comparisons of male and female DKO livers to sex-matched control livers. 
Decreases in activating marks were seen at many fewer (~100-150) sites (Fig. 7A; see 
Supplemental Tables S6 for histone mark data). Thus, loss of the capacity to repress 
chromatin via H3K27 trimethylation is associated with an overall increase in activating 
histone marks. Further, the ~2-fold sex bias in the number of H3K27ac and H3K4me1 sites 
(male liver > female liver) seen in control mice was abolished in DKO mice (Fig. 7B), 
consistent with the preferential loss of H3K27me3 marks in male DKO liver. However, for 
both H3K27ac and H3K4me1, there was little overlap between the sets of sex-biased sites 
in control compared to DKO mouse liver, indicating that sex-biased sites are both gained 
and lost in Ezh1/Ezh2-deficient liver (Supplemental Fig. S3).  
H3K27ac and H3K4me1 differential sites were mapped to their putative target genes using 
GREAT (McLean et al., 2010) (see Methods). Genes up regulated in DKO compared to 
control liver (for either males or females) were classified into 8 different groups based on 
the patterns of differential histone marks associated with each gene (Fig. 7C). A similar 
distribution in histone mark patterns across the 8 groups was seen for sex-biased genes as 
for stringent-sex independent genes up regulated in DKO male livers (Fig. 7C, top vs. 
bottom). A majority (53-62%) of the up regulated genes in DKO males were not associated 
with any differential histone marks (group 1; Fig. 7C). Genes associated with an induced 
H3K27ac site, with or without other responsive marks (groups 2, 4, 6 and 7) were 
significantly more up regulated than genes associated with loss of H3K27me3 only (group 




Female-biased genes de-repressed in male DKO liver that showed both a loss of 
H3K27me3 and a gain of H3K27ac had a significantly higher sex-bias than those 
associated with the loss of H3K27me3 only (Fig. 7D, group 4 vs. group 3). Highly female-
biased genes (female/male expression ratio > 10) in group 1 (no differential marks) include 
Sult2a6, which even though it is induced in DKO male liver by 20-fold, only reaches 15% 
of the full female expression level. This group also includes Cyp2c40 and Cyp17a1, both 
of which were significantly feminized in DKO male livers (51% and 58% respectively) 
(Fig. 4E). Highly female-biased genes associated with loss of H3K27me3 and gain of both 
H3K27ac and H3K4me1 (group 2) include Cux2 (Fig. 7E), which was induced in DKO 
male liver, as noted above. Thus, highly female-biased genes require loss of H3K27me3 
and gain of H3K27ac for significant de-repression in the DKO (see genome browser 
screenshots in Supplemental Fig. S2). 
 
4.4.8 Sex-differential regulation of fibrosis and HCC related genes   
Male mice and humans are more susceptible to liver fibrosis than females (Ballestri et al., 
2017; Buzzetti et al., 2017; Marcos et al., 2015; Marin et al., 2016; Pramfalk et al., 2015) and 
several studies have shown a male predominant incidence and progression of HCC 
(Clocchiatti et al., 2016; El-Serag, 2012). Ezh1 and Ezh2 are involved in the onset and 
progression of liver fibrosis, as male DKO livers acquire nodular appearance with portal 
and periportal inflammation and collagen deposition by 8 months of age, along with a broad 
impairment of liver function (Bae et al., 2015). These changes are accompanied by strong 




fibrosis. Further, DKO male liver shows increased susceptibility to the fibrogenic and 
hepatotoxic effects of carbon tetrachloride (CCl4) (Bae et al., 2015). To determine if Ezh1 
and Ezh2 play a role in these sexually dimorphic phenotypes, we identified 217 liver 
fibrosis associated genes and 920 HCC-related genes from the Ingenuity Pathway Analysis 
(IPA) software suite. 104 of the 217 liver fibrosis genes (48%) and 425 of the 920 HCC-
related genes showed a significant change in expression (FDR < 0.05, |fold-change| >2) in 
male DKO compared to control male liver at either 7 weeks or 8 months of age, or in livers 
of control or DKO livers of male mice exposed to CCl4 using a regimen that induces 
hepatotoxicity and liver fibrosis (Bae et al., 2015) (Supplemental Tables S7 and S8). 
 
A similar number of fibrosis-related genes were induced in DKO male livers at 7 weeks of 
age as at 8 months (Table 1), even though no histopathological changes were apparent in 
the liver at 3 months of age (Bae et al., 2015). As expected, the majority of the dysregulated 
genes were up regulated with the treatments (Table 1) and there was a significant increase 
in the degree of induction (Fig. 8B) with advancing age. As previously reported for a small 
number of genes (Bae et al., 2015), livers of DKO males treated with CCl4 showed the 
greatest number of fibrosis-related genes, and the highest degree of up regulation. 
Interestingly, the number of genes and the magnitude of dysregulation was lower in DKO 
female compared to DKO male liver (Table 1 and Fig. S4). Similar results were obtained 
for the set of HCC-related genes dysregulated in DKO livers, for DKO female livers 
showed a lower percentage of up regulated genes an apparent but not statistically 




The set of 425 dysregulated HCC-related genes and the set of 104 dysregulated fibrosis-
related genes are enriched for female-biased genes and depleted for stringent sex-
independent genes compared to all liver expressed genes (Fig 8C).  Further, we identified 
32 sex-independent genes that are more highly up regulated in DKO female than DKO 
male liver, and thus acquire female-biased expression in the absence of Ezh1/Ezh2 (Fig. 
3C and Supplemental Table S9). Three of the genes that show the most significant up 
regulation are Igf2, the lncRNA gene H19, and the microRNA miR675 (Fig. 8D). Igf2 and 
H19 are imprinted genes that have been involved in HCC development (He et al., 2014; Li 
et al., 2015).  The Igf2-H19 locus has a female-biased DNase hypersensitive site and a 
female-biased H3K4me1 mark that is increased in female DKO liver (Fig 8E). Thus, while 
there is moderate loss of H3K27me3 marks in both sexes, there are female-biased 
activating marks that may explain the greater induction seen in female-liver (Fig 8E). 
 
4.5 Discussion  
Ezh1 and Ezh2 are essential for liver homeostasis and regeneration. Loss of Ezh1/Ezh2 in 
hepatocytes leads to liver fibrosis, impaired liver function and increased susceptibility to 
the hepatotoxic effects of CCl4 (Bae et al., 2015). Liver fibrosis and HCC show marked 
sexual dimorphism, and H3K27me3-based gene repression is a sex-biased regulatory 
mechanism that may contribute to these striking phenotypical differences between the sexes 
(Sugathan and Waxman, 2013). Here, we used male and female Ezh1/Ezh2 double 
knockout mice to investigate the role of Ezh1 and Ezh2 in the repression of sex-biased 




Compared to sex-independent genes, sex-biased genes were preferentially dysregulated in 
the DKO liver. Further, highly female-biased genes were de-repressed in the DKO male 
liver, while male-biased genes were not particularly affected in livers of DKO females, 
confirming that PRC2 based repression is a sex-biased regulatory mechanism in mouse 
liver. Genes involved in liver fibrosis and HCC are differentially regulated in males and 
females and may contribute to the observed differences in disease incidence and 
progression.  
Sex-biased genes were significantly more affected by the loss of Ezh1/Ezh2 than stringent 
sex-independent genes. Sex-biased genes are regulated by the sex-specific patterns of GH 
secretion. In males, GH secretion is intermittent, whereas in females, GH pulses are more 
frequent resulting in persistent stimulation of target tissues. STAT5b is the essential 
mediator of the sex-dependent transcriptional regulation by GH (Clodfelter et al., 2006; 
Holloway et al., 2007) and acts through a network of sex-biased transcription factors 
including BCL6 (Meyer et al., 2009) and CUX2 (Conforto et al., 2012) in the context of 
sex-biased chromatin states (Sugathan and Waxman, 2013). Sex differences in gene 
expression are accompanied by sex differences in chromatin accessibility and sex-biased 
binding of the GH-activated transcription factor STAT5 (Ling et al., 2010). However, the 
most striking sex-difference in the epigenetic regulatory mechanisms is H3K27me3, which 
is preferentially used to repress female-biased genes in male liver (Sugathan and Waxman, 
2013). Consistently, in this study we observed a significant enrichment for female-biased 
genes to be up regulated in DKO male liver. In contrast, male-biased genes were down 




While the up regulation of female-biased genes can be explained by their direct regulation 
by H3K27me3, the observed down regulation of male-biased genes in DKO male liver can 
be mostly explained by secondary mechanisms. Loss of H3K27me3 in male liver led to the 
transcriptional activation of Cux2 a highly-female specific transcription factor that directly 
represses a large proportion of male-biased genes (Conforto et al., 2012). TRIM24, another 
female-biased transcription factor that has been proposed to mediate the effects of CUX2 
(Laz et al., 2007), it was shown to be the main upstream regulator of the genes that were 
uniquely regulated in male liver. 
  
We found that loss of H3K27me3 repressive marks feminizes gene expression in the liver 
by de-repressing female-biased genes in male liver. The two GH-dependent models of liver 
feminization investigated here, hypophysectomy (Connerney et al., 2017)and continuous 
GH infusion (Lau-Corona et al., 2017), resulted in stronger up regulation of female-biased 
genes compared to that seen in male DKO livers, where female-biased genes were only 
partially feminized. Thus, while PRC2-based repression is essential for the repression of 
many female-biased genes in male liver, removal of the repressive mark alone is, by itself, 
not sufficient to fully activate expression of the female-biased genes. Individual female-
biased genes showed large differences in their responsiveness to the loss of Ezh1/Ezh2, 
with genes such as Hao2 and Cyp17a1 showing clear loss of H3K27me3 associated with a 
> 50% feminization in DKO male liver. In contrast, Fmo3 and Sult2a6 are barely feminized 
by the loss of H3K27me3 (Supplemental Fig. S2).  




Corona et al., 2017) and a subset of them are also de-repressed by hypohphysectomy 
(Connerney et al., 2017). Here, significant de-repression of many GH-regulated female-
biased genes was achieved by loss of Ezh1/Ezh2 in male liver, even though stimulation by 
the normal (pulsatile) male plasma GH pattern is presumably still ongoing. Moreover, de-
repression of female-biased gene expression was associated with increases in active 
enhancer marks, including H3K4me1, as well as H3K27ac, which is enriched in the absence 
of PRC2 (Pasini et al., 2010), prevents PRC2 binding and antagonizes its repressive actions 
(Aranda et al., 2015) and cannot be acetylated until Ezh1/Ezh2-catalyzed K27 methylation 
is reversed. Thus, the GH-independent activation of female-biased genes is a result of direct 
de-repression caused by the loss of H3K27me3 marks and the subsequent gain in H3K27ac 
as well as other activating marks. In fact, gain of H3K27ac was associated with stronger 
induction of gene expression (Fig. 7C). Thus, the establishment and maintenance of liver 
sex-bias by GH requires a complex interaction between epigenetic marks and other sex-
biased regulatory mechanisms.  
The strong enrichment of H3K27me3 marks at female-biased genes in male liver shown in 
previous studies (Sugathan and Waxman, 2013), and confirmed here, suggests that PRC2-
based repression is an important mechanisms to enforce sex-biased liver gene expression. 
Further, this repressive mechanism is plasma GH pattern-regulated, insofar as continuous 
GH infusion of male mice induces loss of this mark at female-biased genes (Lau-Corona et 
al., 2017). Here, we showed that a high fraction of female-biased genes (37%) are de-
repressed in DKO males suggesting that Ezh1/Ezh2 mediate (either directly or indirectly) 




that Ezh1/Ezh2 show no sex-bias in their expression in young adult mouse liver. The 
mechanisms by which PRC2 is recruited to its target genes generally, and in this case, how 
sex-dependent plasma GH patterns regulates interacts with the PRC2 is poorly understood. 
Several long non-coding RNAs (lncRNAs) are physically associated with PRC2 (Aranda 
et al., 2015) and may impact the site-specificity of PRC’s actions. Several hundred liver-
expressed lncRNAs show sex-biased expression in mouse liver, many of which are nuclear 
enriched and regulated by growth hormone (Melia et al., 2016). Further studies are required 
to determine what roles male-biased lncRNAs that interact with PRC2 may play in the 
recruitment of PRC2 to repress female-biased genes in male liver.    
Some of the most highly female-biased sulfotransferase genes (Sult2a2, Sult2a5, Sult2a6) 
failed to be significantly feminized by any of the three models studied. The continuous GH 
model and the hypophysectomy model, abolish the intrinsic male pattern of GH secretion 
in adult male mice. For these two models, partial feminization may be due to irreversible 
imprinting by GH in the neonatal period as it has been suggested by recent studies (Das et 
al., 2017). Among these genes Sult2a6 is associated with loss of H3K27me3 at its gene 
body however only reaches 15% of the female level of expression in the male DKO 
(Supplemental Fig. S2). This suggests that other mechanisms are at play. Further studies 
are required to elucidate the GH dependent epigenetic mechanisms that establish these 
irreversible differences in male liver, such as DNA methylation (Reizel et al., 2015). 
DKO male mice develop liver fibrosis at 8 months of age, and at 3 months of age, when 




to the hepatotoxic effects of CCl4 when compared to wild type controls (Bae et al., 2015). 
We observed, however, that livers of male, and to lesser extent female DKO mice, show 
significant up regulation of genes associated with liver fibrosis and HCC. The number of 
fibrosis/HCC related genes and the degree of up regulation in male liver increased with age 
and with CCl4 treatment (Fig. 8), and this up regulation correlates with the severity of the 
liver phenotype (Bae et al., 2015). DKO females showed the lowest number of 
fibrosis/HCC-related up regulated genes, which is consistent with the slower disease 
progression widely described for female livers (Yokoyama et al., 2005). Similar to what 
was observed for the full set of DKO up-regulated genes, 40% of the fibrosis and/or HCC-
related genes up regulated in 7-week-old DKO male liver, have associated decreases in 
H3K27me3 or increase in activating histone marks (Supplemental Table S6)  
Female-biased genes dominate the set of HCC-related genes that were up regulated in DKO 
male liver (Figure 8). This is not surprising, as the full set of genes that are up regulated in 
DKO male liver is also enriched for female-based genes. However, it raises the question of 
why the induction of liver fibrosis seen in DKO male liver (Bae et al., 2015) is associated 
with activation of female-biased genes, when the elevated expression of those genes in 
wild-type female compared to wild-type male liver does not confer an increase in liver 
fibrosis and liver disease. The answer may relate to our observation that, among the up 
regulated female-biased genes are genes that may specifically confer the protection against 
HCC that is seen in wild-type females. For example, Hao2, which is down regulated in 
hepatocellular carcinoma and whose levels are inversely correlated with metastasis and 




(and other protective female-biased genes) are induced in DKO male liver, the increase in 
expression is, apparently, not sufficient to counteract the severe liver injury generated by 
the loss of Ezh1/Ezh2. Moreover, other female-biased genes that have been recognized as 
tumor suppressors in HCC such as Trim24 (Herquel et al., 2011a; Jiang et al., 2015) are 
not up-regulated in the male DKO. Further studies are required to determine the extent to 
which the higher expression of these liver disease-protective genes in females contributes 
the observed sex-differences in liver fibrosis and liver disease. 
Estrogen has been implicated as the major hormonal regulator of the sex-bias in liver 
disease. Estrogen treatment reduces the levels of liver damage markers, promotes 
regeneration and decreases the proliferation of hepatic stellate cells and collagen deposition 
(Yokoyama et al., 2005). During hepatocarcinogenesis, estrogen receptor and the 
transcription factors FOXA1 and FOXA2 share target genes. Foxa1/Foxa2-deficient 
female mice are more susceptible to chemically induced carcinogenesis, thus, they are 
essential for sexual dimorphism in HCC (Li et al., 2012). Here, Foxa1 and Foxa2 were 
down regulated in DKO females.  
Sex-independent HCC related genes that were preferentially up regulated in female DKO 
liver include Igf2, H19 and miR675. Igf2 and H19 are both imprinted genes (Pope et al., 
2017) and are adjacent in the genome. Aberrant imprinting and epigenetic abnormalities in 
Igf2-H19 have been observed in HCC (He et al., 2014). H19 is highly expressed in 
proliferative tissues, including liver regeneration after injury (Pope et al., 2017). H19 




vitro and in vivo (Li et al., 2015). These observations may suggest an increased 
susceptibility to HCC in the DKO females (Yokoyama et al., 2005). Further studies are 
needed to determine the phenotype of the DKO female mice regarding their response to 
liver injury and to determine the impact of GH treatment on disease onset or progression.  
As expected, the loss of H3K27me3 results in the up regulation of the vast majority of the 
responsive genes, however, we observed a significant number of genes that were down 
regulated in the absence of Ezh1 and Ezh2, in both male and female liver. The down 
regulation of some of those genes was associated with up regulation of proximal 
H3K27me3 marks (Fig. 6D). While, H3K27me3 is generally regarded as a repressive mark, 
H3K27me3 enrichment at the TSS is associated with bivalent genes, and further, 
H3K27me3 enrichment at promoters is associated with active transcription (Young et al., 
2011). In this study, the partial loss of H3K27me3 at regulated genes could represent signal 
from non-parenchymal cells where Ezh1/Ezh2 expression was not affected (Bae et al., 
2015). Further, loss of Ezh1/2 leads to increased cell proliferation, residual H3K27me3 
could also be explained by the presence of immature hepatocytes, where the alb-cre 
transgene is not yet active (Weisend et al., 2009) 
In conclusion, Ezh1/Ezh2-dependent, H3K27me3-based repression is essential to establish 
and maintain GH-regulated sex differences in liver gene expression. Loss of Ezh1 and Ezh2 
in mouse hepatocytes preferentially de-represses the expression of many female-biased 
genes in male liver in association with the loss of H3K27me3 marks and the acquisition of 




fibrosis-related genes between males and females contributing to the observed differences 





Figure 4.1. Ezh1 and Ezh2 expression in wild-type pre-pubertal and adult liver and 
in DKO mouse liver.   
(A) Relative expression levels of Ezh1 and Ezh2 determined by RT-qPCR in male and 
female mouse livers at 2, 3, 4 and 8 weeks of age. Data shown mean ± SEM for n=3 (Ezh1) 
or n=6 (Ezh2) individual livers per group. Primers used are shown in Supplemental Table 
S1. Significance values by Student’s t-test are indicated in each figure, as follows: * P < 
0.05; ** P < 0.01 and *** P < 0.001. (B) UCSC genome browser screenshots of RNA-seq 
BigWig tracks evidencing the absence in 7 week male and female DKO livers of Ezh1 and 
Ezh1 sequence reads from several exons, including those that code for the SET domain 
(exons 16-19, marked with a red box). In the case of Ezh1, but not Ezh2, Ezh gene 
disruption leads to a significant decrease in overall normalized sequence reads (FPKM 
expression values, shown in C), based on mean ± SEM for n=3 individual livers per group. 
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Figure 4.2. Loss of Ezh1 and Ezh2 preferentially de-represses female biased genes in 
male liver.  
 (A) Percentage of all RefSeq genes that are liver-expressed (FPKM >1) and either sex-
biased (male/female FDR < 0.01; n=1,131 genes) (Table S2) or stringently sex-
independent (male/female |fold-change| < 1.2 and FDR > 0.1; n=8,021 genes) (Table S3) 
whose expression in DKO liver is significantly changed compared to control liver (|fold-
change| >1.5 and FDR <0.05). The number of sex-biased genes that are up or down 
regulated in DKO liver and their enrichment compared to DKO-responsive, stringently-
sex independent genes are shown above each bar (enrichment scores (ES), significance 
values). (B) Graph of log2 expression ratios for DKO/control liver compared to the log2 
sex-ratio for 1,131 sex-biased genes in male (blue) and female (red) mouse liver. (C) 
Overlap of DKO-responsive sex-biased genes identified in male vs. female liver, shown 
separately for genes that are up regulated (left) and genes down regulated (right) in the 
DKO livers. Five genes responded to the loss of Ezh1/Ezh2 in the opposite direction in 
male vs. female liver and were excluded from the Venn diagrams. (D) Overlap of stringent 
sex-independent genes that were DKO responsive in male vs. female liver. Enrichment 
scores compared to a background set of 11,491 liver-expressed genes (FPKM >1) were as 
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ES = 8.9,  p < 2.2E-16
ES = 9.4, p < 2.2E-16
* 4 Female biased genes up-regulated in MDKO and down-regulated in FDKO




















ES = 10.1, p < 2.2E-16
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Figure 4.3. Classification of sex biased genes by their response to the DKO.  
(A) Heatmap for the set of 440 DKO-responsive sex-biased genes (Supplemental Table 
S4), based on the log2 fold-change values for each of the four indicated comparisons. (B) 
Male/female expression ratios in control and in DKO livers, for all 146 DKO-responsive 
male-biased (top) and 294 female-biased genes (bottom).  (Supplemental Table S4). 
Significance by t-test are indicated in each panel. (C) Number of DKO-responsive sex-
biased genes that lose, maintain, or gain sex specificity in DKO mouse liver. In addition, 2 
genes show a reversal from female to male bias in DKO liver. Sex bias is either: M, male; 
















































































Figure 4.4. Loss of Ezh1 and Ezh2 partially feminizes the expression of GH-
responsive genes.    
(A) Expression of two female-biased genes, Fmo3 and Cyp2b9, in total liver RNA isolated 
from control and DKO male and female mice. The data shown are mean +/- SD values 
determined by RT-qPCR for each of 9-12 individual mice per group. The mean expression 
value for the control female group was set to 1. Significance values by ANOVA are shown: 
*, p< 0.05; ***, p< 0.001. Primers used for RT-qPCR analysis are shown in Supplemental 
Table S1.  (B) Proportion of female-biased genes (n= 127; female/male expression ratio > 
2-fold) and proportion of the subset comprised of 73 female-biased genes that are up-
regulated in DKO male liver and are pituitary-hormone dependent, that respond to 
hypophysectomy (Hypox) and are either class I female-biased genes (genes down-
regulated in female liver after Hypox), or are class II female-biased genes (genes up 
regulated in male liver after Hypox), or that do not respond to Hypox (NR, not responsive). 
(C) Overlap between female-biased genes (n= 113, male/female expression ratio > 2-fold 
in the control mouse livers from the three models shown (i.e., DKO, Hypox, continuous 
GH models), that are induced in male liver after DKO, hypophysectomy (Hypox) or 
continuous GH infusion for 14 days (cGH). Overlaps are also shown for the set of 
stringently sex-independent genes, where a much greater fraction of the genes that 
responding to DKO do not also respond to Hypox or cGH treatment. Also see data for the 
113 genes in Supplemental Table S5. (D) Boxplot showing the distribution of feminization 
values for 31 female-biased genes induced in male liver after all three of the indicated 




(green) each box. Statistical significance by ANOVA (*, p < 0.05). (E) Graph, in the form 
of a MA plot, showing log2 male/female ratio vs. gene expression level, in log2 FPKM 
units, for 113 sex-biased genes (EdgeR FDR< 0.01, FPKM >1, and fold-change > 2 in all 
three mouse models. Genes are colored, as marked in the box, if they show > 50% 
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Figure 4.5. Normalization of H3K27me3 ChIP-seq.  
Reads per million (RPM) normalized read counts and ChIP PCR validation of (A) static 
sites and (B) differential sites identified by DiffReps for each of the groups and the input 
control, as described in Methods. Read counts were obtained for the genomic location 
corresponding to the qPCR amplicon plus 100 bp, to approximate the 200 bp average insert 
size. qPCR data shown corresponds to % input for n= 4 individual ChIP DNA samples per 
group, mean +/- SEM, with significance values determined by ANOVA with Tukey’s 
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Figure 4.6. H3K27me3 ChIP-seq.  
(A) Number of H3K27me3 sites that were up regulated and were down regulated in DKO 
male and in DKO female liver when compared to control mice of the same sex. (B) Number 
of sex-biased H3K27me3 sites found in control and in DKO male and female liver 
chromatin. Sex-bias was lost at all 549 H3K27me3 sites in DKO liver. The 29 male-biased 
and 34 female-biased H3K27me3 sites that acquire sex bias in DKO liver (right) are 
associated with 24 genes, of which only 5 are responsive to Ezh1/Ezh2 loss and only one 
is sex-biased (data not shown). The number of H3K27me3 sites in each group is shown 
above each column (C) Log2 of DKO/control K27me3 signal fold-change at those sites 
where H3K27me3 marks decrease (Down) or are increased (Up) in male and female DKO 
liver. (D) H3K27me3 sites that are up regulated and down regulated in DKO male and 
DKO female liver compared to the sex-matched control livers; Venn diagrams show the 
overlap in these sites for the indicated male-female comparisons (see Supplemental Table 
S6 for listing of these sites). (E) Shown on the left are heatmaps for H3K27me3 sites that 
are differential only in DKO male compared to control male (DKOM unique) (first column 
in the heatmap) and RNA-seq expression ratios for their associated genes (next three 
columns). Right heatmap: H3K27me3 sites that are differential only in DKO female vs. 
control female comparison (DKOF unique) and their associated genes. Middle heatmap: 
H3K27me3 differential sites common to DKO males and DKO females and their 
associated genes. Gene associations for each H3K27me3 site were based on the diffReps 
tool’s output for those sites located in the gene body or promoter region. Values in the first 




and control liver, and the values for each of the remaining 3 columns represent the log2 
fold-change of the gene expression values between the indicated conditions, determined by 
RNA-seq. Shown above each heatmap is the number and percentage of sites associated 
with genes. (F) Shown are the enrichment scores and p values for female-biased genes to 







B  H3-K27me3 sex-biased sites Figure 6
H3K27me3 down regulated sites 
(DiffReps, FDR <0.05, FC >2) 
MDKO/M
FDKO/F
H3K27me3 up regulated sites




































































































Response to Ezh1/Ezh2 loss
E



















Male DKO Female DKO
A C 







































11 29       34
F
Enrichment for up-regulation of F 
biased genes

























Figure 4.7. De-repression of gene expression and responsive histone marks.  
(A) Number of sites that show a significant decrease (Down) or a significant increase (Up) 
in each chromatin mark in DKO male and DKO female liver compared to sex-matched 
control liver. (B) Number of male-biased sites (Male) and number of female-biased sites 
(Female) for H3K27ac and H3K4me1 in control liver, and in DKO liver. (Supplemental 
Table S6). (C) Upper Proportion of the 846 genes up-regulated in DKO male liver that 
show histone mark changes (i.e., genes which show down regulation of H3K27me3 signal 
at their gene-body or promoter region, or are associated with an induced H3K27ac or 
H3K4me1 mark, as determined by GREAT (see Methods)). Lower results shown only for 
the 260 sex-biased genes up regulated in DKO male liver. (D) Upper Boxplots showing 
the distribution of log2 fold-change values of DKO-male/control male for the 846 genes in 
each of the groups based on their association with responsive histone marks. Lower 
Boxplots showing the distribution of log2 sex-ratio for the 244 female-biased genes in each 
of the groups based on their association with responsive histone marks. Significance values 
by ANOVA are indicated in each figure as follows: *P, 0.05; **P, 0.01; ***P, 0.001. The 
symbol † indicates that statistical significance was reached by t-test and not by ANOVA. 
(E) UCSC genome browser screenshot of the genomic region surrounding Cux2, a highly 
female-biased gene, induced 3.7-fold in the DKO male liver that is associated with loss of 
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Figure 4.8 Sex-biased dysregulation of liver fibrosis and HCC related genes.  
(A) Heatmaps showing the log2 expression ratios for 104 responsive fibrosis-related genes 
and for 425 responsive HCC-related genes obtained from IPA as explained in Methods. 
The comparisons shown are control males vs. control females, DKO male vs. control male, 
DKO female vs. control female, and DKO male vs. DKO female liver.  (B) Boxplots 
showing the distribution of log2 expression changes for 9 fibrosis-related (green) and 52 
HCC-related genes (purple) that are up-regulated in 7-week and 8-month DKO male liver. 
Values shown for 7-week DKO males, 8-month DKO males, males treated with CCl4 and 
DKO males treated with CCl4 compared to their age-matched controls, as described in 
Methods. (C) Enrichment for female-biased genes or stringent sex-independent genes for 
being in the set of dysregulated fibrosis-related or HCC related genes compared to all liver 
expressed genes. (D) Expression of Igf2, H19 and miR675 determined by RNA-seq 
(FPKM) in 7-week male and female control livers and in livers of male and female DKO 
mice. Data shown are mean expression levels based on n=4 individual livers per group. 
Significance values are based on FDR values determined by EdgeR: ** P<0.01, and *** P 
< 0.001. (E) UCSC genome browser screenshot of the Igf2-H19 gene locus. Shown are 
normalized read tracks for H3K27ac, H3K4me1 and H3K27me3 ChIP-seq data. Red bars 
represent differential sites identified by diffReps for histone marks and for sex-biased 












Table 4.1. Number of fibrosis-related or HCC-related genes induced or repressed in 
each of the indicated treatments  
	 	
Liver Fibrosis (217) HCC (920)
Induced Repressed Induced Repressed
DKOM/Male (7 weeks) 22 1 96 10
DKOF/Female (7 weeks) 10 1 62 17
DKOM/Male (8 months) 24 2 110 6
CCl4 treated Make/Male 46 11 189 79
DKOM +CCL4/Male 63 10 245 68
Table 1.
Table 1. Numbe  of fibrosis-related or HCC-related genes 




Figure S4.1. Normalization of H3-K27me3 ChIP-seq 
Reads per million (RPM) normalized read counts and ChIP PCR validation of static sites 
for each of the groups and the input control. Read counts were obtained for the genomic 
location corresponding to the qPCR amplicon plus 100 bp to approximate the 200bp 
average insert size. The qPCR data correspond to % input for n= 4 individuals per group, 
MEAN +/- SEM, significance values determined by ANOVA with Tukey’s multiple 

























































































Fig S1. Normalization of H3-K27me3 ChIP-seq
Reads per million (RPM) normalized read counts and ChIP PCR 
validation of static sites for each of the groups and the input 
control. Read counts were obtained for the genomic location 
corresponding to the qPCR amplicon plus 100 bp to 
approximate the 200bp average insert size. The qPCR data 
corresponds to % input for n= 4 individuals per group, MEAN 
+/- SEM, significance values determined by ANOVA with 
Tukey’s multiple comparisons test (***< P 0.001).




Figure S4.2. Responsive female-biased genes   
Shown are UCSC screenshots of normalized RNA-seq or ChIPseq reads for the following 
DKO responsive female-biased genes (A) A1bg (B) Cyp3a16 (C) Hao2 (D) Fmo3 (E) 
















Figure S4.3 Overlap of sex-biased H3-K27ac and H3-K4me1 sites in controls and 
DKO mice   
Shown are the overlaps between male and female-biased sites identified in control males 
compared to control females and the male or female-biased site set identified in DKO males 
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Fig. S4.4. Induction of fibrosis related and HCC-related genes in MDKO and FDKO.  
Boxplots showing the distribution of log2 expression ratios for DKO over control, for 
fibrosis-related and HCC related genes in Male liver and female liver. 
 
  














APPENDIX 1 – List of supplemental tables for Chapter 2 
Supplemental Tables are available upon request by email to djw@bu.edu or in PMID 
28694329 
  
Table S1 - Differential expression analysis for 983 Liver Sex biased genes (FPKM >1, 
EdgeR Adjusted p<0.01) based on PolyA+ RNA-seq Exon collapsed counts.  
Table S2 – Characterization of 113 Male-biased genes (FPKM >1, EdgeR p<0.01, FC >2) 
based on their response to continuous GH infusion and their transcriptional and epigenetic 
regulation.  
Table S3 - Characterization of 142 Female-biased genes (FPKM >1, EdgeR p<0.01, FC 
>2) based on their response to continuous GH infusion and their transcriptional and 
epigenetic regulation.  
Table S4 – Differential expression analysis for 62 Stringent sex-independent genes (FPKM 
>1, EdgeR p>0.1, FC <1.2) that are responsive to continuous GH (EdgeR p<0.05, FC >2).  
Table S5 – Transcription factor binding sites and DNase Hypersensitive sites (DHS) 
associated to 7,225 Stringent sex-independent genes (FPKM >1, EdgeR p>0.1, FC <1.2).  
Table S6 - Primer sequences used for qPCR analysis. 
Table S7 – KEGG Pathway analysis. 
Table S8 - Differential expression analysis for 226 sex-biased genes with sufficient 




APPENDIX 2 – List of supplemental tables for Chapter 4 
Supplemental Tables are available upon request by email to djw@bu.edu 
 
 
Table S1 – qPCR primers used for analysis of the indicated mouse mRNAs.  
Table S2 –Data for 1,131 liver expressed genes (maximum FPKM >1) that showed a 
significant sex-bias in expression (EdgeR adjusted p-value < 0.01) in wild-type (control) 
mouse liver. shown are the differential expression values obtained by EdgeR analysis 
(Robinson MD et al, Bioinformatics, 2010) for the following pairwise comparisons: 
Males/Females (Columns C-G); DKO-males / males (Columns H-M); DKO-females 
/females (Columns N-S) and DKO-males/DKO-females (Columns T-X)  
Table S3 - 8,021 liver-expressed genes that show stringently sex-independent expression 
(FPKM >1, EdgeR adjusted p-value >0.1, |Fold-Change| < 1.2).  Shown are the differential 
expression results obtained using EdgeR (Robinson MD et.al. Bioinformatics, 2010) for 
the following comparisons: Male/Female (i.e., wild-type) liver (columns C-G); DKO-
males / males (columns H-L); DKO-female /female (columns N-Q), and DKO-male /DKO-
female (columns R-V). |Fold-Change| and adjusted p-values are based on EdgeR-
normalized read counts 
Table S4 – Responses to sex biased genes to loss of Ezh1/Ezh2 in male and female DKO 
liver. Analyses are based on the 1,131 sex-biased genes shown in Table S2 with the impact 
of DKO on gene expressed evaluated at |fold-change| > 1.5 and FDR < 0.05 
Table S5 – Shown is the set of 113 consistently female-biased genes (female/male |fold-
change| > 2-fold) with the RNA-seq differential expression data based on EdgeR analysis 




hypophysectomized male/control male from (Connerney et al. Endocrinology 2017, 
PMID: 28323953); and [male mice treated with for 14 days with continuous GH 
(cGH)]/male (Lau-Corona et al, MCB 2017 PMID: 28694329). 
Table S6 – ChIP-seq data for H3-K27me3, H3-K27ac and H3-K4me1  
Table S7 – Expression data for a set of 217 genes involved in liver fibrosis. Shown are the 
EdgeR differential expression results in mouse liver for the following comparisons: 
Males/Females; DKO-males/males (7 week); DKO-females/females (7 weeks); DKO-
males/males (8 months); males treated with CCl4/control males; and DKO-males treated 
with CCl4/control males 
Table S8 -  Expression data for a set of 920 genes involved in hepatocellular carcinoma 
(HCC). Shown are the EdgeR differential expression results in mouse liver for the 
following comparisons: Males/Females; DKO-males/males (7 week); DKO-
females/females (7 weeks); DKO-males/males (8 months); males treated with 
CCl4/control males; and DKO-males treated with CCl4/control males. 425 genes that 
responded in DKO male liver or in livers of males treated with CCl4 are highlighted in 
orange. Raw data for 8-month old male mice and from CCl4-reated mice were obtained 
from GEO, accession # GSE53627 and reported in Bae et al, FASEB J 2015; PMID: 
25477280.  
Table S9-  82 genes that gain sex-bias in DKO mouse liver.  Shown are the differential 
expression results obtained using EdgeR (Robinson MD et.al. Bioinformatics, 2010) for 




H-L); DKO-females /females (Columns M-Q); and DKO-males/DKO-females (Columns 
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